Patricia Coyle

Curriculum Vitae State University of New York at Stony Brook Health Sciences Center

Name:

Patricia K. Coyle

Birthplace:

New York City

Mailing Address:

HSC T12, Room 20 Stony Brook, NY 11794-8121

Home Telephone:

(631) 473-8932

Work Telephone:

(631) 444-8188

Higher Education (Including Internship, Residency & other formal professional training)

From

To

Degree and Date

Institution, Location & Field

9/1966

6/1970

B.S. 1970

Fordham University, NY Honors Program, Summa Cum Laude in Cursu Honorum

7/1970

6/1974

M.D. 1974

Johns Hopkins, MD Medicine, AOA

7/1974

6/1975

Internship

Cornell, NY Hospital Medicine

7/1975

6/1977

Residency

Johns Hopkins, MD Neurology

7/1977

6/1978

Chief Resident

Johns Hopkins, MD Neurology

7/1978

6/1980

Research Fellow

Johns Hopkins, MD Neuroimmunology and Neurovirology

1

Certification & Licensure (ECFMG, FLEX, National & Professional Boards & Licenses)

Date

Agency

January 1980

American Board of Psychiatry & Neurology (ABPN)

2004

Recertification, ABPN

July 1980

New York State Medical License #124559

Appointments (Academic Appointments)

Date

Title

Status*

Institution & Location

7/80 – 6/88

Ass’t. Prof.

S

SUNY – Stony Brook

7/88 – 3/93

Assoc. Prof.

T

SUNY – Stony Brook

3/93 – present

Professor

T

SUNY – Stony Brook

10/88 – 4/89

Acting Chair

SUNY – Stony Brook

10/91 – 6/92

Acting Chair

SUNY – Stony Brook

3/03 – 9/12

Acting Chair

SUNY – Stony Brook

10/12 – present

Vice Chair (Clinical Affairs)

SUNY – Stony Brook

*Status: Voluntary (V), Salaried (S), Tenured (T)

Other Appointments Date

Title

Status

Institution & Location

7/80 – present

Attending Neurologist

S

University Medical Center, Stony Brook

7/80 – 1995

Attending Neurologist

V

Northport VAMC

8/87 – 1993

Consultant

V

Central Islip Psychiatric Center

2

Professional Practice & Services Date

Activity

Location

Institution Affiliation(s)

7/1980 – present

Attending Neurologist

Stony Brook Univ. Hospital

SUNY – Stony Brook

7/1980 – 1995

Staff Neurologist

Northport VAMC

SUNY – Stony Brook

Professional & Scientific Societies Date

Organization

2015 -

Member, Scientific Advisory Panel, Southampton Hospital Resource Center

1977 – present

American Academy of Neurology (AAN)

1990 – 1994

Chair, Infectious Disease Task Force, Self-Assessment Steering Committee

1980 – 2005

American Association for the Advancement of Science

1980 – 1990

American Federation for Clinical Research

1980 – 2005

American Society of Microbiology

1982 – 1986

Medical and Scientific Advisory Board, ARDA (Nassau/Suffolk County Chapter)

1980 – 2000

New York Academy of Science

1987 – 1991 1992 – present

Medical Board, National Multiple Sclerosis (MS) Society

1988 – 2004

Clinical Advisory Committee (CAC)

1988 – 2001

Long Island MS Society Chair (CAC)

1988 – 1994

Association for Research in Vision and Ophthalmology

1989 – 1992

Society for Experimental Neuropathology

1992 – 1994

Association of Medical Laboratory Immunologists

1991 – 2003

AAN Graduate Education Subcommittee (GES)

1997 – 2003

Chair, GES

1992 – 1997

AAN Annual Meeting Subcommittee 3

1993 – 1997

AAN Scientific Issues Committee

1994 – 1997

AAN Public and Professional Information Committee (Liaison member)

1997 – 2003

AAN Education Committee

1999

AAN Reviewer, Infectious Disease Abstracts

1992 – present

Elected Member, American Neurological Association (ANA)

1998 – 1999

Member, ANA Education Committee

1996 – 1997

Member, ANA Nominating Committee

2001 – 2003

Councilor, ANA; member, ANA Scientific Program Committee

1995 – 1998

Infectious Disease Society of America

1997 – 1999

National MS Society

2000 – 2002

Professional Education Committee

1997 – 2003

National MS Society Advisory Committee for the Compendium of MS Information

1999 – 2003

NARCOMS, Management Team, MS Registry

1997 – present

Member, AAN MS section

2000 – 2002

Chair, MS section

2000 – 2001

Member, Scientific Committee, Cost modeling in MS

2001 – 2008

Member, Advisory Board, NARCOMS Project, Consortium of MS Centers (CMSC)

2001 – 2008

Member, Board of Directors, American Academy of Immunotherapy

2001 – 2002

Development-Vice Chair, Consortium of MS Centers

2001 – 2012

Editor-in-Chief, Neura

2003 – present

Member, NYSMSC Executive Committee

2007

DSMB, Member, Betaseron Pregnancy Registry

2007

Co-Chair, Committee on Maintenance of Certification

2007

Member, Part 1 Neurology C Examination Committee

2008

Chair, DSMB Committee, Forte Trial 4

2008

Steering Committee, REGARD Trial

2008

Steering Committee, ORACLE Trial

2008

Vice President, American Board of Psychiatry & Neurology

2008

Chair, Neurology Council

Academic & Professional Honors Date

Honor

2016

New York Times Top Doctors 2016

2016

Chair, Novartis, New Developments and Emerging Treatment Options for the Treatment of Multiple Sclerosis Advisory Board Meeting, Fort Lauderdale, FL, May 21, 2016.

2016

Chair, Sanofi Genzyme Aubagio Real World Advisory Board, “Teriflunomide Patient-Reported Outcomes: Clinical and Real-World Experience,” Chicago, IL, May 14, 2016.

2016

Invited Speaker, Genzyme Multiple Sclerosis Roundtable 2016: Preserving Brain Function, “Aubagio Impact on Brain Atrophy and Disability,” “Aubagio: Real World Experience,” “Clinical Cases,” Buenos Aires, Argentina, May 6-7, 2016.

2016

Advisor, Genentech Regional Advisory Board East Meeting, New York, NY, April 9, 2016.

2016

Chair, Sanofi Genzyme MS Advisory Board, “Aubagio Long-term Efficacy: Disability and MRI Global Advisory Board,” Amsterdam, Netherlands, April 2, 2016.

2016

Chair, EMD Serono MRI Forward MS Experts Advisory Board Meeting, Dallas, TX, March 19, 2016.

2016

Invited Faculty & Speaker, 2016 AUBAGIO Academy of Knowledge, Berlin, Germany, March 11-12, 2016

2016

Chair, Genzyme Global Strategic Advisory Board Meeting, Cambridge, MA, March 1-2, 2016

2016

Super Doctors New York 2016

2015

Chair, Catamount Medical Education, “ForuMS: A Virtual Journal Club for MS Clinicians,” October 18, 2015.

5

2015

Chair, Genzyme Women in MS Editorial Board Meeting, Chicago, IL, September 26, 2015.

2015

Best Doctors in America

2015

Invited Speaker, Genzyme Speaker Series, “Navigating the MS Management Challenge – A Clinician’s Perspective Australia,” September 1-6, 2015.

2015

Chair, MCM Education Video Roundtable CME activity, “Improving Women’s Health Outcomes in MS: A Multidisciplinary Approach,” New York, NY, July 1, 2015.

2015

Consultant, Biogen’s Tecfidera Global Medical Advisory Board Meeting, Berlin, Germany, June 24, 2015.

2015

Chair, CMSC Symposia, “Biomarkers in MS: The Role of CSF,” Indianapolis, IN, May 28, 2015.

2015

Chair, Medical Learning Institute, Inc. CMSC Symposium, “Understanding the Evolution of MS Care: Optimizing Therapeutic Decision Making,” Indianapolis, IN, May 27, 2015.

2015

Chair, CMSC Clinical Courses, “What Neurologists Need to Know About Infections: Part I and II,” Indianapolis, IN, May 27, 2015.

2015

Invited Faculty, The France Foundation, “Strategies to Improve the Care of MS in Women,” Chicago, IL, January 14, 2015.

2014

Consultant, Genzyme Global Strategic Advisory Board, Cambridge, MA, October 20-21, 2014.

2014

Invited Faculty, Medscape Education, CME-accredited Video Roundtable Discussion, “Clinical Decision Making in MS, Part 2: When to Change Therapy,” Boston, MA, September 11, 2014.

2014

Chair, International Journal of MS Care, “Progressive Multifocal Leukoencephalopathy (PML) and Other Infectious Complications in the Care of Multiple Sclerosis,” May 2014; 16:1-34.

2014

Chair, Novartis Post-AAN Advisory Board Meeting, Philadelphia, PA, May 3, 2014.

2014

Chair, Genzyme Global Strategic Advisory Board Meeting, Cambridge, MA January 27-28, 2014.

2014

Best Doctors in America

2013

America’s Top Doctors

2013

Top Doctors: New York Metro Area 6

2013

Chair, MS Experts Consensus Summit, “No Evidence of Disease Activity as a Treatment Target in MS,” Las Vegas, NV, December 12-14, 2013.

2013

Chair, CME Roundtable and Consensus Panel, “Community Neurology and Case Managements; Building Synergies to Enhance Patient-centered Care,” Philadelphia, PA, Nov 15, 2013.

2011

US News/Castle Connolly Top 1% of Neurologists

2011

Long Island Newsday Top Doctors

2011

Co-Chair Editorial Board Meeting, Improving Diagnosis, Management and Treatments of NDO Through Integrated Care, Oct 13, 2011 Jersey City, NJ (Brown University CME).

2008

Long Island’s Top Doctors

2006

Elected to executive committee, ABPN

2006

Co-organizer, & co-chair, meeting on Chronic Lyme Disease Syndromes: New a Venues for Investigation, Cold Spring Harbor Laboratory, NY, October 15-18, 2006.

2004 – 2006

New York Magazine Best Doctors

2004

Chair, “Symposium on Maximizing Long-Term Outcomes in MS”, New York, NY, December 6, 2004.

2003

Chair, Multiple Sclerosis Regional Advisory Meeting, Las Vegas, NE, October 10-12, 2003.

2003

Co-chair, CME program, University of South Florida college of Medicine, Tampa, FL, May 24-25, 2003.

2002

Co-chair, University of South Florida, “Fifth Annual Review of MS”, Orlando, FL, May 25-26, 2002.

2001 – present

Americas Top Doctors

2001

Chair, Satellite symposium at the 15th annual meeting of the CMSC: the cost of delaying therapy.

2001

Organizing committee, CMSC consensus conference on diagnosis of MS, Fort Worth, TX, November 30- December 2, 2001.

2001

Co-Chair, Faculty Update, Worsening MS: New paradigms of care, Palm Beach, FL, November 16-17, 2001.

2001

Co-chair, Regional Advisory Meeting on MS, Orlando, FL, November 8-11, 2001. 7

2001

Co-Chair, CMSC conference on role of MRI in MS Vancouver, BC, Canada, Nov 2-4, 2001.

2001

Consultant, Glaxo Wellcome, Oct 8, 2001.

2001

Chair, MS Regional Advisory Meeting, Key Biscayne, FL, October 5-7, 2001.

2001

Consultant, MS meeting, Dublin, Ireland, Sept 9-11, 2001. Symposium, March 26-29, 1995.

2001

Consultant, UBS Warburg, London, UK, Sept 3-4, 2001.

2001

Chair, Southwest MS Regional Advisory Meeting, Newport Beach, CA, August 3-5, 2001.

2001

Course director, weekend meeting, “Gender Issues in MS”, Las Vegas, NV, July 14-15, 2001.

2000 – 2008

Director, American Board of Psychiatry & Neurology

2000 – 2008

New York Metro Areas Top Doctors

2000 – 2002

New York Magazine Best Doctors

2000

Director, regional courses on “Treatment of MS: update 2000”, New York, NY, November 11, 2000

2000

Co-chair, conference on MS: clinical issues & decisions, Miami, FL, November 3-5, 2000.

2000

Chair, Symposium “secondary progressive MS emerging issues in clinical practice”, Boston, MA, October 14, 2000.

2000

Chair, Northeast and North Central regional advisory forum on MS, Southampton Princess Bermuda, August 18-20, 2000.

2000

Chair, “Women’s issues in MS” symposium Santa Fe, NM, July 29-30, 2000.

2000

Co-chair, conference on MS: Clinical Issues & Decisions, Cancun, Mexico, March 3-5, 2000.

1999 – present

Member, Neurology Vignette Committee, American Board of Psychiatry and Neurology

1999 – 2003

Chair, Grant Review Committee, National MS Society

1999 – 2000

Invited Participant, Review Committee of the Institute of Medicine, Division of Neuroscience and Behavioral Health. “MS: Current Status and Strategies for the Future”. 8

1999

Co-Chair, Session on evidence for an infections trigger in MS, in an international MS workshop “Demonstrating Infectious Cause: Viral and Bacterial Infections in MS and Related Disorders”, Brighton, England, August 23-25, 1999.

1999

Co-Chair, Brighton meeting on role of infectious agents in MS

1999

Co-Chair, Multiple Sclerosis: Clinical Issues and Decisions, Vancouver, British Columbia May 21-23, 1999.

1999

Chair, Symposium on the Spectrum of Multiple Sclerosis: A Team Approach, Kansas City Marriott Downtown, Kansas City, Missouri, May 13, 1999.

1999

Co-Chair, Conference on “Multiple sclerosis: Clinical Issues & Decisions”, Charleston, SC, February 5-7, 1999.

1998 – present

Consultant, Merck Medco, MS

1998 – 1999

Associate Director, Clinical Research Center, Stony Brook University Hospital Medical Center

1998

Co-Chair Weekend Meeting on “Multiple Sclerosis: Clinical Issues & Decisions”, Washington, DC, September 11-13, 1998. Chair, An Educational Program Development Workshop, “New Directions in the Management of MS”, Maui, HI, February 5-9, 1998. Expert Consultant, Teva Neurosciences; Bayer, EMD Serono Pharmaceuticals

1998 1997 – 2010

1997 – 2000

Director, Clinical Neuro-immunology Course, Annual meeting of AAN

1997 – 1998

Member, Scientific Peer Review Committee A, National MS Society

1997

Co-Chair, Conference on “MS Clinical Issues and Decisions”, Dallas, TX, November 21-23, 1997.

1997

Chair, Symposium on “Management of MS in the Era of Immunotherapy”, New York, NY, October 7, 1997.

1997

Session Chair, “Persisting (Refractory) Infection”, 10th Annual International Scientific Conference on Lyme Disease and other Tick-Borne Disorders, NIH Clinical Center, Bethesda, MD, April 28-30, 1997

1997

Co-Chair, Clinical Roundtable: Immunotherapy for Relapsing-Remitting MS

1997

Editor, Inflammatory Diseases Section, Current Opinion in Neurology

1996 – 1997

Program Committee, Lyme Disease Foundation 10th Annual International Conference Washington DC, April 28-30 1997 9

1996

1996 Facilitator, Fatigue Management Workshop, 1996 Annual Conference of Consortium of MS Centers, September 27, 1996, Atlanta, GA

1996 – 2010

Neurology Advisory Board, Bayer Pharmaceuticals

1996 – 1998

Chair, Merck Medco, MS Advisory Panel

1997 – 2000

Senior Examiner, American Board of Psychiatry and Neurology

1995 – 2000

Invited Member, IDSA Panel to Develop Guidelines on Lyme Disease

1995

Chair, Immunology Session, Lyme Disease: Molecular and Immunologic aspects of Detection and Vaccine Developments, Banbury Center - Cold Spring Harbor Symposium, Match 26-29, 1995.

1995

Consultant, SmithKline Beecham Pharmaceuticals, Lyme Vaccines Program

1995

Invited Participant, NASA Workshop on EVA Technology Applied to MS, Sunnyvale, California, January 29-31, 1995.

1994 – 1999

Consultant, NIH, Chronic Lyme Disease

1994 – 1998

Member, Peripheral and Central Nervous Systems Drugs Advisory Panel for the FDA Chair, Neuroborreliosis Session, Lyme Disease: 1994 State of the Art, Stamford, CT

1994

1993

Elected as Fellow, ANA

1993

Chair, Immunology Session, Banbury Center Conference on Molecular and Immunologic Aspects of Lyme disease

1992 – 1997

Examiner, American Board of Psychiatry and Neurology

1992 – 1996

Director, Infectious Disease Course, Annual Meeting of the AAN

1992

Consultant, Abbott Laboratories, Diagnostic Division), on “Diagnostic and Prognostic Assays in Neurology”

1992

Chair, Pathogenesis I Scientific Session, 5th International Conference on Lyme Borreliosis, Arlington, VA

1992

Certificate of Appreciation, AAN

1992

Elected to active membership, AAN

1991

Chair, Neurology Session, The Molecular Immunobiology of Lyme Disease, Banbury Center-Cold Spring Harbor Symposium 10

1991

Program Selection Committee, Vth Intl. Conference on Lyme Borreliosis, Arlington, VA

1990 – present

Medical Director, MS Comprehensive Care Center, University Hospital

1990

Discussant, Neuro-ophthalmology Session, AAN, April 1990

1989

Co-Chair, Session on Neuro-immunology and MS III, AAN 41st Annual Meeting, April1989

1974

Pre-doctoral Fellow, National MS Society

1974

Alpha Omega Alpha, Johns Hopkins Medical School

1971

Goldberger Fellow, Council on Foods & Nutrition of AMA

1970

Phi Beta Kappa, Fordham University

Editorial Boards 2015 - 2016

Drugs Springer

1993 – 2000

Continuum American Academy of Neurology

2006 – 2012

NEURA Editor

2010 – present

Frontiers in Multiple Sclerosis and Neuroimmunology Editor The Neurologist Williams and Wilkins

1993 – 1996 1993 – 2001

Journal of Spirochetal and Tick Borne Diseases Lyme Disease Foundation

1995 – 2000

Neurological Infections and Epidemiology W.B. Saunders Company Ltd.

1997 – 1998

Neurobase Arbor Publishing Company

11

Research Support: Grants, Contracts Project

Role in Project

Dates

CBAF312A2304 (Novartis)

Principal Investigator

9/15 -

WA21093/Ocrelizumab RRMS (Genentech/Roche)

Principal Investigator

9/15 -

WA25046/Ocrelizumab PPMS (Genentech/Roche)

Principal Investigator

9/15 -

WA21493/ACT4422G/ Ocrelizumab RRMS (Genentech/Roche)

Principal Investigator

9/15 -

FTY720D2312 (Novartis)

Principal Investigator

11/13 -

Hyperbaric Oxygen Therapy for Multiple Sclerosis Relapse

Principal Investigator

8/13 -

Opexa 2012-00

Principal Investigator

8/13 –

AC-058B201 (Actelion)

Principal Investigator

1/10 –

NeuroNEXT (NINDS)

Site Principal Investigator Levin (PI)

Phase II Pain Research in MS Trial (Avanir)

Principal Investigator

Other Information A multicenter, randomized, double-blind, parallelgroup, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy and Safety of Ocrelizumab in Comparison To Interferon Beta-1A(Rebif) in Patients with Relapsing Multiple Sclerosis A Phase III, multicenter, randomized, parallelgroup, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis A Phase II, multicenter, Randomized, ParallelGroup, Assessor and Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy, as measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients with Relapsing Remitting MS Compare 2 doses of fingolimod to Copaxone and to evaluate the efficacy of fingolimod for treatment of MS Steroid treatment w/adjunct hyperbaric oxygen therapy vs. steroid treatment (1:1) Multi-center, randomized, double-blind, placebocontrolled, 2-arm, 2-year, parallel-group study of Tcelna compared with placebo in subjects with gradual increasing disability with or without superimposed clinical relapses in the preceding two years Dose finding study of ACT-128800, an oral S1P1 receptor agonist, in relapsing MS. The goal is to evaluate a novel oral agent in relapsing MS. Compare 2 doses of fingolimod to Copaxone and to evaluate the efficacy of fingolimod for treatment of MS. Clinical trials infrastructure grant.

12

Previous Grant Support Dates

Project

2014-2015

CFTY720D2306E (Novartis): Phase III trial of FTY720 open label in primary progressive MS.

2013 - 2014

FTY720D2405: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod (Novartis)

2009 - 2014

CFTY720D2306: Phase III trial of FTY720 vs. placebo in Primary Progressive MS (Novartis) Research Grant, Leeds Foundation. This grant supports novel research approaches to study MS.

2004 – 2010

CAMPATH Study: Protocol CAMMS223 Open-label three-arm study comparing low and high dose CAMPATH (MABCAMPATH) and high-dose Rebif in patients with early, active relapsingremitting multiple sclerosis (Ilex Pharmaceuticals, LP)

2004 – 2008

PreCISe Study: Protocol GA-9010 Study to evaluate the effect of early glatiramer acetate treatment in delaying the conversion to clinically definite multiple sclerosis of subjects presenting with a clinically isolated syndrome (Teva Neuroscience LLC)

2004 – 2007

Study comparing the combined use of interferonβ-1a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis: Protocol NIH/NINDS R U 01 NS45719-01A1 (Mount Sinai School of Medicine).

2004 – 2008

Achieve Study: Protocol GA-9013 A multicenter, randomized, single blind, parallel group study to compare the efficacy, tolerability and safety, of copaxone to that of high dose interferon (Betaseron or Rebif) in the treatment of relapsing multiple sclerosis patients. (Teva Neuroscience LLC)

2004 – 2007

Protocol 24735 Phase IV Study: If Rebif 44 mcg administered three times per week SC compared with Copaxone 20 mg administered daily SC in treatment of relapsing remitting multiple sclerosis (Serono)

2004 – 2007

Protocol 306440 International multicenter, phase III study patients with relapsing remitting multiple sclerosis comparing over treatment period of 104 weeks (Berlex Laboratories INC)

2003 – 2007

“Gender issues in MS” (Teva Neuroscience)

2003 – 2006

Neurocrine biosciences: a randomized double blind placebo controlled study to evaluate the safety tolerability and efficacy of NBI5788 in patients with relapsing remitting multiple sclerosis (Pharmaceutical Research Associates INC)

2003 – 2006

Extended IL-7 assay protocol: For detection of proliferative and cytokine response profiles, and cross-reactivates of confirmed antigen-reactive cells for the NBI5788 clinical trial (University of California at San Francisco)

2003 – 2005

ABOVE Study: Protocol 307245 A multi-center research trial sponsored by Berlex Laboratories Inc. to establish the safety, and effectiveness of the standard dose of 250 micrograms of Betaseron® taken every other day compared to the standard dose of 30 micrograms of Avonex® taken once per week in patients with relapsing remitting multiple sclerosis (RRMS). (Berlex Laboratories INC)

13

2003 – 2005

An open label study evaluating the ability of multiple sclerosis on chronic Rebif 44 mcg TIW treatment to mount an immunological response to influenza vaccine (Serono INC)

2002 – 2004

Effects of different dose regimens of IGIV-chromatography 91GIV-C, 10% treatment of relapsing remitting multiple sclerosis (PRA International incorporated)

2002 – 2008

Pre-Beyond Study: Protocol 307320 Safety/Tolerability of Betaseron 500 mg, subcutaneously every other day and Betaseron 250 mg every other day for patients with relapsing remitting multiple sclerosis. (Berlex Laboratories INC)

2002 – 2004

Study of Natalizumab in combination with Glatiramer Acetate in subjects with relapsing remitting multiple sclerosis.

2002 – 2003

Rebiject Trial: A randomized, Multi-center, parallel group, open label study comparing the tolerability of Rebif injection with and without the use of rebiject mini in relapsing remitting multiple sclerosis.

2001 – 2003

Serono/Renew Study Prospective open label tolerability and safety monitoring study of Novatrone in a selected cohort of multiple sclerosis (Serono/Immunex Corporation)

2000 – 2004

PROMISE Trial: A multi-national, multi-center double-blind, placebo controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate for injection in primary progressive multiple sclerosis patients, Protocol (Teva Marion Partners)

2000 – 2004

EVIDENCE Trial 21125: An open label randomized multicenter comparative study of Rebif 44 mcg administered 3 times per week by subcutaneous injection, (Serono)

2000 – 2003

CORAL Trial: Teva Marion Partners

2000 – 2003

Quantitation of blood-brain barrier permeability in MS lesion development, NMSS3168A1/1 (Co-PI)

2000 – 2002

Blood Brain Barrier Permeability and the menstrual cycle, USB/BNL 2000 seed grant program

2000 – 2001

Protocol No. GA/7023 Oral glatiramer acetate in relapsing remitting multiple sclerosis, (Teva Marion partners)

1999 – 2003

A multi-national, multi-center, double-blind, placebo controlled study to evaluate the efficacy, tolerability & safety of glatiramer acetate for injection in primary progressive multiple sclerosis patients, (Teva Marion partners)

1999 – 2001

ATM-027: Astrazeneca in patients with multiple sclerosis.

1997 – 2002

“Neurologic Aspects of Lyme Disease in North America” NINDS P1NS34092A (Overall PI for PPG)

1997 – 1998

Phase 2 Study of Hu23F2G in Acute Exacerbations of Multiple Sclerosis, SCIREX (Co-PI)

1996 – 2004

New York Consortium, research to establish present database of MS patients in NY State.

1996 – 2000

“Chronic Fatigue in Lyme Disease” NIAID (RO1 AI 31561) (Co-PI)

1996 – 2000

Phase III, Double-Masked, Placebo-controlled Study to Evaluate the Safety and Efficacy Of Two Doses of Betaseron in Patients with Secondary-Progressive MS, Berlex (PI)

14

1996 – 1997

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Roquinimex (Linomide) in Relapsing-Remitting and Secondary Progressive MS, Pharmacia Upjohn (PI)

1996 – 1997

Phase I/II Trial of Safety and Immunogenicity of TCR peptide vaccines in patients with MS, Connectives (PI)

1996 – 1997

Phase I/II Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of 3-Every Other Day Intravenous Doses of Placebo or AG284 in Patients with Secondary Chronic Progressive Multiple Sclerosis, Anergen (PI)

1993

“Clinical and Immunological Effects of Cooling in MS,” MS Assn. of America

1990 – 1996

“Immune Complex Analysis in Lyme Neuroborreliosis” NIAMSD (RO1AR40470)

1987 – 1992

National MS Society, “A Study of IgA in MS”

1985 – 1988

MERIT Review, VA

1983 – 1988

Teacher-Investigator Development Award NINCDS

1982 – 1985

MERIT Review, VA

1981 – 1982

Biomedical Research Support Grant, USPHS

1981 – 1982

Small Grants Program, NIMH

1981 – 1983

Research Grant, KROC Foundation

1981 – 1987

Research Grant, National MS Society

1981 – 1982

RAGS Grant, VA Courses Directed

Date

Institution/Organization

Course

Title

Enrollment

1985 – 1988

SUNY at Stony Brook

Neuroscience Course for second year medical students

Director

90 plus

1992 – 1996

AAN

“Infections of the Nervous System”

100 plus

1997 – 2000

AAN

“Clinical Neuroimmunology”

100 plus

1997 – 2000

AAN

“Neurologic Infections”

30 – 60

2001

AAN

“Gender Issues in MS”

350 plus

Neuroscience systems course

100 plus

2004 2013 – present

SUNY at Stony Brook

Mini Fellowship Sponsored by Genzyme 15

Director

16 plus

Teaching Activities Date

Level

1992

Role Supervised research for college student, Maria Montalbano

Undergraduate Summer 1993

Research, Kara Bertolone

Summer 1993

Neuroscience fellowship for medical student, Angelo Milazzo Jr. Graduate

12/03 – 12/04

Gender based issues in multiple sclerosis, Abhishek Dwivedi

1994

Sponsor, MHSSRAP Summer Program for Minority Students High School

Summer 1995

Sponsor, Westinghouse Science Program for High School Students Dissertations Supervised

Date

Candidate

1995

David J. Peters

Title Induction of Cytotoxicity in Cell Cultures by B. burgdorferi

Institution Program in Molecular Neural and Cellular Biology (Pathology Track)

University Service (Standing University committees, major ad hoc committees)

Date

Activity

1982 – 1992

Department of Neurology, Grand Rounds Committee

1982 – 1992

Department of Neurology, Grand Rounds Committee

1982 – 1990

Member, MD-PhD Committee

1983 – 1989

Member, Resource Allocation and Academic Planning Committee

1986 – 1989

Chairperson, Resource Allocation an Academic Planning Committee

1985 – 1986

Member, Systems Steering Committee

1985 – present

Member, Infection Control Committee Lecturer in Undergraduate Biology; Microbiology; Physicians' Assistants; Neurosciences Courses

1987 – 1988

Member, ENT Search Committee

1988

Member, Clinical Sciences Dept. Subcommittee of the Self-Study Task Force 16

1988 – 1989

Member, Search Committee for Neurology Chair Nassau County Medical Center

1989 – 1990

Member, Radiology Chair Search Committee

1991 – 1992

Acting Chair, member of: 1. CCCA, 2.CPMP, 3. Medical Board, 4. Chair Committees

1991 – 1992

Department of Neurology Residency Committee

1991 – 1992

Graduate Medical Education Committee

1992 – 1996

Member, Appointments-Promotion-Tenure (APT) Committee

1992 – present

Department of Neurology Credentials Committee

1992 1992 – 1995

Personnel Committee, CPMP board Member, Joint Arts and Sciences/HSC Committee for APT

1992 – 1993

Member, Task Force on Research, Scholarship, and Creative Activity

1995 – 1996

Member, Search Committee for Chair of Medicine, SUNY Stony Brook

1990 – present 1994 – 1996

Director, MS Comprehensive Care Center, Stony Brook University Medical Center Member, Search Committee for Chair of Psychiatry, SUNY-Stony Brook

1994 – 1998

Faculty Senator, School of Medicine

1996 – present

Member, Finance Committee

1997

Chair, Finance Committee

2003 – present

Acting Chair, member of: CPMP board, managed care committee, medical board, SOM Chairs

2014 – present

Member, Neurosciences Clinical Operations Committee

Papers Presented at National Meetings 1.

“Circulating immune complexes in progressive rubella Panencephalitis contain anti-rubella IgG”. 32nd Annual Meeting, AAN, New Orleans, 1980.

2.

“CSF Fc (IgG) receptor bearing lymphocytes are decreased and immune complexes appear in CSF during MS exacerbations”. 32nd Annual Meeting, AAN, New Orleans 1980.

3.

“Evidence for Ongoing Systemic Virus production in MS: Circulating immune complexes contain antibodies to multiple agents”. 108th Annual Meeting, ANA, New Orleans, 1983. 17

4.

“CSF Immune Complexes in MS: Evidence for intrathecal virus reactivation?” 36th Annual Meeting, AAN; Dallas, 1985.

5.

“Tear Analysis in MS”. 37th Annual Meeting, AAN; Dallas, 1985.

6.

“Oligoclonal Bands in Tears”. 38th Annual Meeting, AAN, New Orleans, 1986.

7.

“Analysis of Immune Complexes in Multiple Sclerosis”. Workshop on cellular and humoral components of CSF in MS, Hengelhoef, Limburg, Belgium, 1986.

8.

“Tear Analysis in Optic Neuritis”. 39th Annual Meeting, AAN, Chicago, 1989.

9.

“Cell Subpopulations in the External Mucosal fluids of MS patients”, 40th Annual Meeting, AAN, Cincinnati 1988.

10.

“Activated Lymphocytes in MS Tears”, 41st Annual Meeting, AAN, Chicago, 1989.

11. “Chronic Meningitis”, 41st Annual Meeting, AAN of Neurology, Chicago, 1989. 12. “Lyme Disease”. 42nd Annual Meeting AAN, Miami Beach, 1990. 13. “Chronic Meningitis”. 43rd Annual Meeting, AAN, Boston, 1991. 14. “CSF Analysis in Infectious Diseases”. 44th Annual Meeting, AAN, San Diego, 1992. 15. “Pharmacology of CNS Infections”. 44th Annual Meeting, AAN, San Diego, 1992. 16. “Detection of Borrelia Burgdorferi antigen in cerebrospinal fluid”. 44th Annual Meeting, AAN, San Diego, 1992. 17. “Serial Immune Changes in MS patients under treatment for fatigue”. 44th Annual Meeting, AAN, San Diego, 1992. 18. “Infectious Diseases of the Central and Peripheral Nervous Systems”, 5th Annual Meeting, American Medical Laboratory Immunologists, Alexandria, VA August 14, 1992. 19. “Cytokine Correlates of Fatigue in MS”, 45th Annual Meeting, AAN, New York, 1993. 20. “Lyme Disease", 45th Annual Meeting, AAN, New York, 1993. 21. “Chronic Fatigue in Neurologic Disorders”, 45th Annual Meeting, AAN, New York, 1993. 22. “Neuroborreliosis: diagnosis and differential diagnoses” and The Role of CSF Research tests in Neuroborreliosis", Lyme Disease: 1994 State of the Art Conference, Stamford, CT April 1994. 23. Invited Plenary Lecture, Lyme disease: Diagnosis and treatment of the Post Lyme Syndrome; 119th Annual Meeting of the ANA, San Francisco, CA October 1994. 24. “New Tools in the Diagnosis of Neurologic Lyme Disease”. VIII Annual International Scientific Conference on Lyme Borreliosis and other Spirochetal and Tick-Borne Diseases, Vancouver, British Columbia, April 1995.

18

25. “CSF Markers of Early Neurologic Lyme Disease”, Banbury Center - Cold Spring Harbor Conference on Lyme Disease, April 25, 1995. 26. IX Annual Scientific Conference on Lyme Borreliosis, “Neurologic Complications of Late and Chronic Lyme Disease”, The Copley Plaza Hotel, Boston, Mass, April 18-21, 1996. 27. “Lyme disease vs. Chronic Fatigue Syndrome”, American Psychiatry Assn. 149th Annual Mtg., New York, May 9, 1996. 28.

“MS Update”, AAPA 24th Annual Physicians Assistant Conference, New York Hilton, New York, NY, May 25-30, 1996.

29. Invited Speaker 13th International Convocation in Immunology, “Borrelia burgdorferi”, Immunological and Molecular Diagnosis of Infectious Disease. The Ernest Wiletsky Center for Immunology, Buffalo, NY, June 2-5, 1996. 30. “A CSF Analysis in Neurologic Lyme Disease”, VII International Congress on Lyme Borreliosis Conference, The Fairmont Hotel, San Francisco, California, June 16-21, 1996. 31. Invited Speaker, “Rapid Diagnosis of CNS Infections”, Symposium on Neurologic Therapeutics, 121st Annual Meeting, ANA, Miami, FL October 16, 1996. 32. Invited Speaker, “Diagnosis and Treatment of Neurologic Lyme Disease” 10th Annual International Scientific Conference on Lyme Disease and other Tick Borne Disorders, NIH Clinical Center, Bethesda, MD, April 28-30, 1997. 33. Invited Speaker, “Spirochetal Infections”, World Federation of Neurology, Buenos Aires, Argentina, Sept 13-19, 1997. 34. Invited Speaker, ACTRIMS “Hormonal Effects on the Immune System”, Montreal, Canada, October 18, 1998. 35. Invited Speaker, “Lyme Disease” and “MS Update”, at 26th Annual Meeting Southern Clinical Neurological Society, Disease, Curacao, NA January 20, 1999. 36. Invited Speaker, Congressional Briefing “Status Report on Women’s Health and Autoimmune Diseases”, Washington, D.C., March 18, 1999. 37. Invited Speaker, 12th International Conference on Lyme Disease and Other Spirochetal and Tick-Borne Disorders, New York, NY April 9-10, 1999. 38. Invited Speaker, “MS update”, Annual Meeting of the Florida Society of Neurology, Vera Beach, Florida July 9, 1999. 39. Invited Lecturer, “MRI and MS”, “Clinical Neuroimmunology”, Current Review of Multiple Sclerosis, Orland, FL, July 10, 1999. 40. Invited Speaker, “Neurologic Lyme disease”, 14th international scientific conference on Lyme disease & other tick-borne disorders, Farmington, CT, April 21-23, 2001. 41. Invited Speaker, “Neurology and Pregnancy”, AAN Fall Conference, Las Vegas, NV, Oct 2427, 2013. 19

Bibliography Organized As Follows: 1. Papers in referred journals 2. Reviews, symposia, book chapters 3. *Abstracts

Papers in Referred Journals: 1.

McKhann GM, Coyle PK, Benjamin JA. Nutrition and brain development. Res Publ Assn Res Nerv Ment Dis 51:10-22, 1973.

2.

Herndon RM, Rean-Descalzi L, Griffen DE, Coyle PK. Age dependence of viral expression. Electron microscopic and immunoperoxidase studies of Measles virus replication in mice. Laboratory Investigation 33:544-553, 1975.

3.

Niedermeyer E, Coyle PK, Preziosi TS. Hypersomnia with sudden sleep attacks on the basis of vertebrobasilar artery insufficiency. Waking and Sleeping 3: 361-364, 1979.

4.

Coyle PK, Brooks BR, Hirsch RL, et al. Cerebrospinal fluid lymphocyte subpopulations and immune complexes in active multiple sclerosis. Lancet II (8188): 229-232, 1980.

5.

Coyle PK, Wolinsky JS. Characterization of immune complexes in progressive rubella panencephalitis. Ann Neurol 9: 557-562, 1981.

6.

Coyle PK, Wolinsky JS, Buimovici-Klein E, et al. Rubella-specific circulating immune complexes following congenital infection and vaccination. Inf Imm 36: 498-503, 1982.

7.

Bergey GK, Coyle PK, Krumholz A, et al. Herpes simplex encephalitis with occipital localization. Arch Neurol 39: 312-213, 1982.

8.

Sterman AB, Coyle PK. Subacute toxin delirium following nitrous oxide abuse. Arch Neurol 40: 446-447, 1983.

9.

Coyle PK, Johnson C. Optimal detection of oligoclonal bands in CSF by silver stain. Neurology 33: 1510-1512,1983.

10. Keeler EK, Coyle PK. Contrast enhancement in NMR imaging by selection of radiofrequency pulse sequence and time: examples in demyelinating disease. Physiol Chem Phys 15: 235-239, 1983. 11. Coyle PK, Banks N, Schutzer SE. A micro-ELISA raji cell assay to detect immune complexes. J Immunol Methods 74: 191-197, 1984. 12. Coyle PK, Procyk-Dougherty Z. MS immune complexes: an analysis of component antigens and antibodies. Ann Neurol 16: 660-667, 1984. 13. Coyle PK. CSF immune complexes in multiple sclerosis. Neurology 35:429-432, 1985. 14. Coyle PK, Schutzer SE, Sterman AB, Peress N, Miller F. Humoral abnormalities in idiopathic chronic polyneuropathy. NY State J Med 85: 248-250, 1985. 20

15. Sterman AB, Coyle PK, Panasci DJ, Grimson R. Disseminated abnormalities of cardiovascular autonomic functions in multiple sclerosis. Neurology 35:1665-1668, 1985. 16. Rabins PV, Brooks BR, O'Donnell P, Pearlson GD, Moberg P, Jubelt B, Coyle PK, Dalos N, Folstein MF. Structural brain correlates of emotional disorder in MS. Brain 109: 585-597, 1986. 17. Coyle PK, Sibony PA. Tear analysis in MS. Neurology 36: 547-550, 1986. 18. Coyle PK, Sterman AB. Focal neurologic symptoms in panic attacks. Amer J Psychiatry 143: 648-649, 1986. 19. Coyle PK, Sibony PA. Tear immunoglobulins measured by ELISA. Invest Ophthalmol Vis Sci 27: 622-625, 1986. 20. Coyle PK, Sibony PA, Johnson C. Increased monomeric IgA levels in tears from multiple sclerosis patients. Ann Neurology 21: 211-214, 1987. 21. Coyle PK, Sibony PA, Johnson C. Oligoclonal IgG in tears. Neurology 37: 853-856, 1987. 22. Coyle PK, Sibony PA. Viral specificity of multiple sclerosis tear immunoglobulins. J Neuroimmunology 14: 197-203, 1987. 23. Coyle PK. Detection and isolation of immune complexes in multiple sclerosis cerebrospinal fluid. J Neuroimmunology 15: 97-107, 1987. 24. Halperin JJ, Little BW, Coyle PK, et al. Lyme disease -cause of a treatable peripheral neuropathy. Neurology 37: 1700-1706, 1987. 25. Gordon MF, Coyle PK, Golub B. Eales’ Disease presenting as Stroke in the young adult. Ann Neurol24: 264-266, 1988. 26. Coyle PK, Sibony PA. Viral antibodies in normal tears. Invest Ophthalmol Vis Sci 29: 15521558, 1988. 27. Coyle PK. Molecular analysis of IgA in multiple sclerosis. J Neuroimmunology 22: 83-92, 1989. 28. Coyle PK, Bulbank M. Immune-reactive cells in MS mucosal secretions. Neurology 39: 378-380, 1989. 29. Coyle PK, Sibony PA. Electrophoresis combined with immunologic identification of human tear proteins. Invest Ophthalmol Vis Sci. 30: 1872-1878, 1989. 30. Coyle PK. Borrelia burgdorferi antibodies in MS patients. Neurology 39: 760-761, 1989. 31. Gordon MF, Allen M and Coyle PK. Drug-induced meningitis. Neurology 40:163-164, 1990. 32. Schutzer SE, Coyle PK, Belman AL, et al. Sequestration of antibody to B. burgdorferi in seronegative Lyme disease. Lancet 1:312-315, 1990.

21

33. Coyle PK, Schutzer SE, Belman AL, et al. CSF immune complexes in patients exposed to B. burgdorferi: detection of Borrelia specific and nonspecific complexes. Ann Neurol 28:739744, 1990. 34. Mehta PD, Cook SD, Troiano RA, Coyle PK. Increased free light chains in the urine from patients with MS. Neurology 41:540-544, 1991. 35. Coyle PK. Viral infections of the developing nervous system. Semin Neurosci 36, 157-163, 1991. 36. Krupp LB, Masar D, Schwartz J, Coyle PK, et al, Cognitive functioning in late Lyme Borreliosis. Arch Neurol. 48:1125-1129, 1991. 37. Mehta PD, Kuczycki J, Mehta SP, Sobezyk W, Coyle PK, et al. Increased levels of β2 microglobulin, soluble interleukin-2 receptor, and soluble CD8 in patients with subacute sclerosing panencepahlitis. Clinical Immunol Immunpathol 65:53-59, 1992. 38. Coyle PK, Schutzer SE, Belman AL, Krupp LB, Deng Z. Cerebrospinal fluid immunologic parameters in neurologic Lyme disease. Current Communications in Cell and Molecular Biology 6:31-43, 1992. 39. Schutzer SE, Coyle PK, Brunner M. Identification of Specific Borrelia burgdorferi components in circulating antigen antibody complexes. Current communications in Cell and Molecular Biology 6:135-148, 1992. 40. Belman AL, Coyle PK, Roque C, Cantos E. MRI findings in children infected with B. burgdorferi. Ped Neurol 8:428-431, 1992. 41. Krupp LB, Jandorf L, Coyle PK, Mendelson WB. Sleep disturbance in chronic fatigue syndrome. J Psychosom Res 37:325-331. 1993. 42. Coyle PK, Deng Z, Belman AL et al. Detection of Borrelia burgdorferi antigens in cerebrospinal fluid. Neurology 43:1093-1097, 1993. 43. Coyle PK, Krupp LB, Doscher C. Significance of reactive Lyme Serology in MS. Ann Neurol 34:745-747, 1993. 44. Belman AL, Iyer M, Coyle PK, Dattwyler RJ. Neurologic manifestations in children with North American Lyme Borreliosis. Neurology 43:2609-2614, 1993. 45. Peper CM, Krupp LB, Friedberg F, Doscher C, Coyle PK. A comparison of neuropsychiatric characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. J Neuropsychiatry & Clinical Neurosciences 5:200-205, 1993. 46. Coyle PK, Krupp LB, Doscher C, Amin K. Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic. Clin Infect Dis 18:S24-S27, 1994. 47. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proceedings of the National Academy of Sciences of the United States of America 91:8368-8372, 1994. 22

48. Schutzer SE, Coyle PK, Brunner M, Luft BJ, Dunn JJ. Early and specific antibody response to OspA in Lyme disease. J Clin Invest 94:454-457, 1994. 49. Krupp LB, Sliwinski M, Masur D, Friedberg F, Coyle PK. Cognitive functioning in chronic fatigue syndrome and multiple sclerosis. Arch Neurol 51:705-710, 1994. 50. Coyle PK, Schutzer SE, Deng Z, Krupp LB et al. Detection of Borrelia burgdorferi specific antigen in antibody-negative CSF in Neurologic Lyme disease. Neurology 45:2010-2015, 1995. 51. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 45:19561961, 1995. 52. Coyle PK. Editorial: Neurologic Lyme disease: is there a true animal model? Ann Neurol. 38:560-562, 1995. 53. Lawrence C, Lipton RB, Lowy FD, Coyle PK.: Seronegative chronic relapsing neuroborreliosis. Europ Neurology 135: 113-117, 1995. 54. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 53:185-188, 1996. 55. Coyle PK, Krupp LB, Doscher C, Deng Z, Milazzo A. Clinical and Immunological Effects of Cooling in MS. J Neurol Rehab 10:9-15, 1996. 56. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB.: Cooling and multiple sclerosis: cognitive and sensory effects. J Neurol Rehab 10:17-22, 1996. 57. Hendler T, Squires NK, Moore JK, Coyle PK. Auditory evoked potentials in multiple sclerosis: correlation with magnetic resonance imaging. J. Basic & Clini Physiol & Pharmacol 7:245-278, 1996. 58. Coyle PK. The neuroimmunology of Multiple sclerosis. Advances in Neuroimmunology 6:143-154, 1996. 59. Coyle PK. Borrelia burgdorferi infection: clinical diagnostic techniques. Immunol Invest 26:117-128, 1997. 60. Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, et al. A multicenter, randomized, double-blind placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48:312-314, 1997. 61. Visudtibhan A, Mehta PD, Kulczycki J, Coyle PK, Thormar H. Intrathecal production of measles-specific IgA in subacute sclerosing panencephalitis. Acta Neurol Scand 96:97-100, 1997. 62. Coyle PK. Advances and pitfalls in the diagnosis of Lyme disease. FEMS Immun Med Microb 19:103-109. 1997.

23

63. Schutzer SE, Coyle PK, Krupp LB, Deng Z, Belman AL, Dattwyler R, Luft B. Simultaneous expression of Borrelia OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease. J Clin Invest 100:763-767, 1997. 64. Schutzer SE, Luan J, Coyle PK. Detection of Lyme disease after OspA vaccine. N Engl J Med 337:794-795, 1997. 65. Belman AL, Reynolds L, Preston T, Postels D, Grimson R, Coyle PK. Cerebrospinal fluid findings in children with Lyme disease-associated facial nerve palsy. Arch Ped Adol Med 151:1224-1228, 1997. 66. Gaudino EA, Coyle PK, Krupp LB. Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences. Arch Neurol 54:1372-1376, 1997. 67. Mehta PD, Kulczycki J, Mehta SP, Coyle PK, Wisniewski HM. Increased Levels of Cerebrospinal Fluid Interleukin 1-β and soluble intercellular Adhesion Molecule in Subacute Sclerosing Panencephalitis. J Infect Dis 175:689-692, 1997. 68. Smouha EE, Coyle PK, Shukri S. Facial Nerve Palsy in Lyme Disease: Evaluation of Clinical Diagnostic Criteria. AM J Otol 18:257-261, 1997. 69. Coyle PK. Hormonal effects on the immune system. Multiple Sclerosis. 4:509-510, 1998. 70. Ettinger AB, Weisbrot DM, Krupp LB, Coyle PK, Jandorf L, Devinsky O. Fatigue and depression in epilepsy. J Epilepsy 11:105-109, 1998. 71. Ettinger AB, Coyle PK, Jandorf L, Cabahug CJ, Oster ZH, Atkins HL, Weisbrot DM, Devinsky O. Postictal SPECT in epileptic versus nonepileptic seizures. J Epilepsy 11: 67-73, 1998. 72. Mehta PD, Cook SD, Coyle PK, Troiano RA, Constantinescu CS, Rostami AM. Free light chains in multiple sclerosis urine. Multiple Sclerosis 4:254-256, 1998. 73. Sood SK, Belman AL, Coyle PK, Preston T, Grimson R, Postels D, Reynolds L. Facial palsy in Lyme disease. Arch Ped & Adol Med 152:928-929, 1998. 74. Coyle PK. Glucocorticoids in central nervous system bacterial infection. Arch Neurol 56:796-801, 1999. 75. Schutzer SE, Coyle PK, Reid P, Holland B. Borrelia burgdorferi-specific immune complexes in acute Lyme disease. JAMA 282: 1942-1946, 1999. 76. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, et al. A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium. Multiple Sclerosis 5:369-376, 1999. 77. Coyle PK. Glucocorticoid therapy shows promise in CNS bacterial infections. Modern Medicine 67:44-45 1999. 78. Krupp LB, Elkins L, Coyle PK, Pollina D, Masur DM. Post Lyme syndrome: contrasts with recovered Lyme patients on cognitive and symptom measures. J. Spirochetal and tickborne disease 6:112-116, 1999.

24

79. Coyle PK. Viruses and infectious agents in the development of multiple sclerosis. MSQR winter, 1999. 80. Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P-B, Stewart T, Nelson S, Fischbein N, Coyle PK, Forhman E, Jacobs L, Holcenberg J, Lee M, Mocci S. A phase I trial of solubilized DR2: MBP84-102 (AG284) in multiple sclerosis. Neurology 54(7): 1414-1420, 2000. 81. Coyle PK. Chronic meningitis. Current Treatment Options in Neurology 2(4): 375-387, 2000. 82. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Psrsing DH, Fish D and Luft BJ. Guidelines from the infectious diseases society of America. Clinical infectious disease 31(Suppl 1): S1-14, 2000. 83. Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs, LD, Krupp LB, Miller AE, Wende KE, Brownscheidle CM, et al. Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 55(12): 1901-1903, 2000. 84. Schutzer SE, Holland B, Reid P, Coyle PK. Serologic testing for Lyme disease. JAMA 284(6): 695-6, 2000. 85. Schutzer SE, Coyle PK, Chen D. The role of the allergist in Lyme disease. Allergy & Asthma Proc 22(1): 29-31, 2001. 86. Vlay SC, Vlay LC, Coyle PK. Combined cardiomyopathy and skeletal myopathy: a variant with atrial fibrillation and ventricular tachycardia. PACE 24 (part I): 1389-1397, 2001. 87. Pan JW, Krupp LB, Elkins CE, Coyle PK. Cognitive dysfunction lateralizes with NAA in Multiple Sclerosis. Applied Neuropsychology 8(3): 155-160, 2001. 88. Coyle PK, Rizvi S. A Global perspective on Multiple Sclerosis. Medscape.com CME 7-132001. 89. Coyle PK, Hartung H-P. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose and frequency dependent effects on clinical response. Multiple Sclerosis 8:(1): 2-9, 2002. 90. Pan JW, Coyle PK, Bashir K, Whitaker JN, and Krupp LB. Metabolic differences between multiple sclerosis subtypes measured by quantitative MR spectroscopy. Multiple Sclerosis 8:(3): 200-6, 2002. 91. Coyle PK. Gender-related differences in autoimmune disease: why hormones matter. Advances in immunotherapy 9(1):13-21, 2002. 92. Coyle PK. The evidence for a dose-response relationship to Interferon therapy in MS. Neurology reviews, supplement 4-9, 2002. 93. Coyle PK, Schutzer SE. Neurologic aspects of Lyme disease. The Medical Clinics Of North America, 86(2): 261-284, 2002. 94. Coyle PK. Lyme disease. Curr Neurol Neurosci Rep. 2(6):479-487, 2002. 25

95. Rutschmann OT, et. al and the Immunization Panel of the Multiple sclerosis Council for Clinical Practice Guidelines (Coyle PK, et. al). Immunization and MS. Neurology 59: 18371843, 2002. 96. Zajkowska J, Hermanowska-Szpakowica T, Coyle PK, et. al. Comparative study of early Lyme disease: erythema migrans in New York State and Northeastern Poland. Med Sci Monit, 3: CR37-43, 2002. 97. Coyle PK. Multiple Sclerosis: a guide to disease-modifying therapies. CNS News, special edition, 4: 102-106, 2002. 98. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinshenker B. Randomized, comparative study of interferon ß-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 59: 1496-1506, 2002. 99. Corboy JR, Boudreau E, Morgenlander JC, Rudnicki S, Coyle PK. Neurology residency training at the millennium. Neurology 58: 1454-1460, 2002. 100. Kalish RS, Wood JA, Golde W, Bernard R, Davis LE, Grimson RC, Coyle PK, Luft BJ. Human T Lymphocyte Response to Borrelia burgdorferi Infection: No Correlation between Human Leukocyte Function Antigen Type 1 Peptide Response and Clinical Status. JID 187(1):102108, 2003. 101. Mehta PD, Patrick BA. Pirttila T, Coyle PK, Aisen PS. Detection of apolipoprotein E phenotype from unconcentrated cerebrospinal fluid. J. Clinical Laboratory Analysis, 17: 18-21, 2003. 102. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, Dattwyler R, Chandler B. Study and treatment of post Lyme disease (STOP-LD). Neurology 60: 1923-1930, 2003. 103. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J; New York State Multiple Sclerosis Consortium. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis 9: 293298, 2003. 104. Lepen C, Coyle PK, Vollmer T, Blumharadt L, Lilliu H, Beresniak A. Long-term cost effectiveness of interferon β-1a in the treatment of relapsing-remitting multiple sclerosis. Clin Drug Invest 23: 571-581, 2003. 105. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2003; 61: 602-611. 106. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of MS: Report of the TTA Subcommittee of the AAN. Neurology, November 2003; 61: 1332-1338.

26

107. Wielopolski L, Ramirez LM, Coyle PK, Wang ZM, Heymsfield SB, Zimman J. Some aspects of measure Potassium in the Human Brain. Acta Diabetol 2003; 40:s73-s75. 108. Fikrig E, Coyle PK, Schutzer SE, Chen Manchuan, Deng Z, Flavell RA. Preferential presence of decorin-binding protein B (BBA25) and BBA50 antibodies in cerebrospinal fluid during neurologic Lyme disease. Journal of Clinical Microbiology, March 2004; 42:1243-1246. 109. Coyle PK. Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, Lynn J, Weinstock-Guttman B, Pardo L (Women Neurologists MS Initiative (WNMSI)). MS Gender Issues: Clinical Practices of Women Neurologists. MS 2004;10:582-588. 110. Scherl WF, Krupp LB, Christodoulou C, Morgan TM, Hyman L, Chandler B, Coyle PK & MacAllister WS. Normative data for the Selective Reminding Test: a random digit dialing sample. Psychological Reports. Psychol Rep 2004; 95:593-603. 111. Adair JC, Rudnickisa, Boudreau E, Weiner W, Coyle PK, Corbdy. Rasing all shps: strategies to the quality of future (submitted). 112. Miller A, Coyle PK. Clinical features of MS. Continuum 2004; 10: 38-73. 113. Coyle PK. MS clinical variants and differential diagnosis. Continuum 2004; 10: 102-119. 114. Rooney WD, Coyle PK. Recent advances in the neuroimaging of multiple sclerosis. Curr Neurol Neurosci Rep 2005; 5: 217-224. 115. Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in Optic Neuritis. J NeuroOphthalmol 2005; 25: 71-82. 116. Mehta PD, Patrick BA, Dalton AJ, Patel B, Mehta SP, Pirttila T, Coyle PK. Increased serum neopterin levels in adults with Down syndrome. J. Neuroimmunol 2005; 164:129-33. 117. Panitch H, Goodin D, Francis G, Chang P, Coyle PK, et al. Benefits of high-dose, highfrequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J. Neurological Sciences 2005; 239: 67-74. 118. Simon JH, Li D, Traboulsee A, Coyle PK, et al. Standardized MR imaging protocol for MS: Consortium of MS centers consensus guidelines. AJNR 2006; 27:455-461. 119. Cook S, Wolinsky JS, Coyle PK, et al. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a task force of the national multiple sclerosis society. Retrieved on 7/29/2006 at Stony Brook, NY. At: http://www.nationalmssociety.org/pdf/forpros/Exp_ChangTherapy.pdf. 120. Coyle PK. Clinical relevance of neutralizing antibodies to the treatment of multiple sclerosis. 121. Adair JC, Rudnicki SA, Boudreau E, Weiner WJ, Coyle PK, Corboy JR. Survey of training programs' means for promoting neurology and attracting trainees. Neurology 2006; 67(6):936-939.

27

122. Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Coyle PK. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006; 63:1388-1393. 123. Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, et al. Glatiramer Acetate in Primary Progressive Multiple Sclerosis: Results of a Multinational, Multicenter, Double-Blind, Placebo-Controlled Trial. Ann Neurol 2007; 61:14-24. 124. Stern D, Bainbridge JL, Coyle PK, Conner CS. Treatment optimization strategies for multiple sclerosis. CMC Clinical monograph 2007, 1-24. 125. Coyle PK. Evidence-based medicine and clinical trials. Neurology. 68(24 Suppl 4):S3-7, June 2007. 126. Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology. 71: S3-S7, 2008. 127. Hurwitz BJ, Jeffery DR, Arnason BG, Bigley GK, Coyle PK, et al. Safety and tolerability of interferon beta-1b 500ug and 250ug every other day in patients with relapsing-remitting multiple sclerosis. Clin Ther 30:1102-1112, 2008 128. Mikol DD, Barkhof F, Chang, P., Coyle PK, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open label trial. Lancet Neurol 2008;7:903-914. 129. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol March 2008;255 Suppl 1:44-50. 130. Faulkner LR, Tivnan PW, Johnston MV, Aminoff MJ, Coyle PK, et al. Invited Article: The ABPN maintenance of certification program for neurologists: past, present and future. Neurology Aug 2008;71:599-604. 131. Coyle PK, B Arnason, B Hurwitz and F Lublin. Optimizing Outcome in Multiple Sclerosis- A Consensus Initiative Mult Scler 2009;15(2):suppl S5-S35. 132. Coyle PK. Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol 2009;12(4):273-82. 133. Jobin C, Larochelle C, Parpal H, Coyle PK, Duquette P. Gender issues in multiple sclerosis: an update. Womens Health (Lond Engl) 2010; 6:797-820, 2010. 134. Coyle PK. The role of natalizumab in the treatment of multiple sclerosis. Am J Manag Care 2010;16:S174-170. 135. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, Hixson KK, Lipton MS, Camp DG, Coyle PK, Smith RD, Bergquist J. Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010;5(6):e10980. 136. Coyle PK, Dissecting the immune component of neurologic disorders: a grand challenge for the 21st century. Neurol 2011;2:37.

28

137. Uitdehaag BMJ, Barkhof F, Coyle PK, et al. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opinion 2011;8:1529-1537. 138. Coyle PK. Pediatric multiple sclerosis: just like their elders? Arch Neurol 2011 68:419-421. 139. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH. Distinct cerebrospinal fluid proteomes differentiate post-treatment Lyme disease from chronic fatigue syndrome. PLoS One 2011;6(2):e17287. 140. Coyle PK, Burks J. Levels of Evidence Required to Determine the Benefit of Treating CCSVI to Alleviate Symptoms of MS. A neurology perspective. Endovascular Today 2012; July:41-50. 141. Dilmanian FA, Jenkins AL 3rd, Olschowka JA, Zhong Z, Park JY, Desnoyers NR, Sobotka S, Fois GR, Messina CR, Morales M, Hurley SD, Trojanczyk L, Ahmad S, Shahrabi N, Coyle PK, Meek AG, O'Banion MK. X-ray microbeam irradiation of the contusion-injured rat spinal cord temporarily improves hind-limb function. Radiat Re 2013;179(1):76-88. 142. Foley JF, Balabanov R, Coyle PK, et al. Updated best practice recommendations for selection and management of patients with multiple sclerosis receiving natalizumab (submitted). 143. Coyle PK. Switching Therapies in Multiple Sclerosis. CNS Drugs April 2013; 27(4):239-247. 144. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Xie F, Berquist J, Vécsei L, Zadori D, Camp DG, Holland BK, Smith RD, Coyle PK. Gray Matter is Targeted in First-Attack Multiple Sclerosis. Plos One 2013; 10.1371/journal.pone.0066117. 145. Coyle PK. Current Evaluation of Alemtuzumab in Multiple Sclerosis. Expert Opin Biol Ther 2014;14(1):127-135. 146. Leist TP, Comi G, Cree B, Coyle PK, Freedman MS, Hartung HP, Vermersch P, CassetSemanaz F, Scaramozza M, The effect of oral cladribine on time to conversion to clinically definite MS in patients with a first demyelinating event. Lancet Neurol 2014;13(3):257-67. 147. Coyle PK. Multiple Sclerosis in Pregnancy. Continuum 2014;20(1):42-59. 148. Coyle PK, Cohen BA, Leist T, et al. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol 2014; 14:49. 149. Coyle PK, Sinclair SM, Scheuerle AE, et al. Final Results from the Betaseron (interferon β1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancyrelated adverse events. BMJ Open 2014;4(5):e004536. 150. Chinea Martinez AR, Correale J, Coyle PK, et al. Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses. Adv Ther 2014; 31:1072-1081. 151. Coyle PK, Multiple sclerosis and pregnancy prescriptions. Expert Opin Drug Saf 2014; 13(12):1565-8.

29

152. Cohen BA, Coyle PK, Leist T, Oleen-Burkeyd MA, Schwartze M, Zwibelf H. Therapy Optimization in Multiple Sclerosis: A Cohort Study of Therapy Adherence and Risk of Relapse. Mult Scler and Relat Disord 2015; 4:75–82. 153. Coyle, PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 2016; DOI: 10.1177/1756285616631897. 154. Coyle PK. Approach to Symptom Management and Lifestyle Modifications in Multiple Sclerosis. Continuum 2016; 22(3):815-836. 155. Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK. Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication (TSQM) fit for purpose? MSJ [accepted] 156. Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, et al. Factors Associated with Benign Multiple Sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurology [accepted]

Reviews, Symposia, Book Chapters 1.

Wolinsky J and Coyle PK. Progressive rubella panencephalitis. In: Search for Cause of Multiple Sclerosis and Other Chronic Diseases of CNS. (A Boese, ed.), Verlag Chemie, Weinheim p. 26, 1980.

2.

Coyle PK. Congenital Viral Infection. In current therapy. In: Neurologic Disease Vol. 2. (RT Johnson, ed.) BC Decker Inc., Philadelphia, p.120-124, 1987.

3.

Coyle PK. Analysis of immune complexes in multiple sclerosis. In: Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis. (A Lowenthal, and J Raus, eds.). Plenum Press, NY, p.129-137, 1987.

4.

Mehta PD, Coyle PK. Diagnostic usefulness of CSF IgG in MS and OND. CIMNDC 10: p.95110, 1990.

5.

Coyle PK, Dattwyler R. Spirochetal infections of the Central Nervous System. Infect Dis Clin N Amer 4:731-746, 1990.

6.

Mehta PD, Isaacs CE, Coyle PK. Immunoglobulins G subclasses in human colostrum and milk. In: Immunology of Milk and the Neonate (Mestecky J, et al, eds). Plenum Press, NY, p.223-226, 1991.

7.

Coyle PK, Schutzer SE. Decision making in medicine: neurologic presentations in Lyme disease. Hospital Practice (Office Edition) 26:55-70, 1991.

8.

Coyle PK. Book review: “Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases”. Rowland LP (ed.) Raven Press, NY. Quarterly Rev. Biol. 67(1): 77-78, 1992.

9.

Coyle PK. Neurologic Lyme disease. Seminars Neurology 12:200-208,1992.

10. Coyle PK. Congenital Viral Infections. In: Prognosis of Neurological Disorders. (Evans RW, Baskin DS, Yatsu FM, eds.) Oxford University Press, NY, p.135-148, 1992. 30

11. Coyle PK. Antigen detection and cerebrospinal fluid studies. In: Lyme disease. (Coyle PK, ed.) Mosby - Year Book, St. Louis, p.136-145, 1993. 12. Coyle PK. Vaccine development. In: Lyme disease. (Coyle PK, ed.) Mosby - Year Book, St. Louis, p.172-175, 1993. 13. Coyle PK. Lyme Disease. In: Current Therapy of Neurologic Disease. 4th ed. (Johnson RT, Griffin JW, eds.) Mosby-Year Book, St. Louis, p.128-132, 1993. 14. Coyle PK. Neurological complications of Lyme disease. Rheum Dis Clin N Am. 19:9931009, 1993. 15. Coyle PK, Bell WE, Davis LE, Hanley DF, McArthur JC. The neurologist and infectious disease. Continnum 1993. 16. Coyle PK. Chronic Meningitis. In: Current Diagnosis in Neurology. (Feldmann E, ed.) Mosby, St. Louis, p.101-106, 1994. 17. Coyle PK. Lyme Disease. In: Current Diagnosis in Neurology. Feldmann E, ed.) Mosby, St Louis, p.110-114, 1994. 18. Coyle PK, Roque C. Central Nervous System Infections. In: Functional Neuroimaging. (Kelley RE, ed.) Futura, Armonk p.275-315, 1994. 19. Coyle PK, Luft BJ. Management of Lyme disease. Curr Opinion Infect Dis. 8:444-450, 1995. 20. Krupp LB, Coyle PK, Sliwinski M. Fatigue in the Elderly. In: Practical Neurology of the Elderly. (Mark M, Sage J, eds.) Marcel Decker, New York, p.377-398, 1996. 21. Coyle PK. Lyme disease. In: CNS Infectious Diseases and Therapy. (Roos KL, ed.) New York, Marcel Decker, p.213-236, 1997. 22. Coyle PK. Inflammatory diseases overview. Curr Opinion Neurol. 10:245-246, 1997. 23. Gerber O, Roque C, Coyle PK. Vasculitis owing to infection. Neurol Clin N Am. 15:903-925, 1997. 24. Smiroldo J, Coyle PK. Advances in the treatment of multiple sclerosis. IM 19:30-37, 1998. 25. Coyle PK, Kaufman M. Lyme neuropathy. In: Immunological and infectious diseases of the Peripheral Nerves. (Kelly JJ, Latov N, Wokke JHJ, eds.) Cambridge, New York, p.308-318 1998. 26. Coyle PK. Multiple Sclerosis. In: Neurologic Disease in Women. (Kaplan PW, ed.) Demos Vermande, New York, p.251-264. 1998. 27. Coyle PK. Bacterial infections. In: Textbook of Neurology. Bogousslavsky J, Fisher M. ed). Butterworth-Heinemann, Boston, p.573-588, 1998. 28. Coyle PK. Multiple Sclerosis. In: Prognosis in Neurology. Gilchrist JM, ed). ButterworthHeinemann, Boston, p.239-243. 1998. 29. Coyle PK. Chronic and recurrent meningitis. In: Prognosis in Neurology. (Gilchrist JM, ed.) Butterworth-Heinemann, Boston, 1998. 31

30. Coyle PK. Congenital Rubella. In: Neurobase. 3rd ed. (Gilman S, Goldstein GW, Waxman SG, eds.) CA, San Diego, Arbor Publishing Company, 1999. 31. Coyle PK. Congenital Cytomegalovirus. In: Neurobase. 3rd ed. (Gilman S, Goldste GW, Waxman SG, eds.) CA, San Diego, Arbor Publishing Company, 1999. 32. Coyle PK. Leptospirosis. In: Neurobase. 3rd ed. (Gilman S, Goldstein GW, Waxman SG, eds.) CA, San Diego, Arbor Publishing Company, 1999. 33. Coyle PK. Body fluid markers for disease course and activity. In: Multiple Sclerosis Therapeutics. (Rudick RA, Goodkin DE, ed.) Martin Dunitz Ltd, UK, p.129-141, 1999. 34. Schutzer SE, Coyle PK. Natural models of neuroimmunologic disease. In: Neuropsychiatric Aspects of HIV infection. (Grade MM, ed.) Rutgers Press, NJ (in press). 35. Coyle PK, Goodman JL, Krupp LB, Logigian EL, Reik L. Lyme disease. Continuum 5(4); 1999. 36. Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin FD, Paty DW, Rice GP, WeinstockGuttman B. Multiple sclerosis. Continuum 5(5); 1999. 37. Coyle PK. Overview of acute and chronic meningitis. Neurol Clin. 17(4): 691-710, 1999. 38. Bernal O, Coyle PK. Two patients with headache and systemic symptoms. In: Advanced therapy of headache. (Rapoport AM, Sheftell FD, and Purdy RA, ed.) BC Decker Inc. Lewiston, NY. p.251-261, 1999. 39. Nasr JT, Andriola MR, Coyle PK. ADEM: Literature review and case report of acute psychosis presentation. Ped Neurol 22:8-18, 2000. 40. Coyle PK. Chronic Meningitis. In: Prognosis of Neurological Disorders. (Evans RW, Baskin DS, Yatsu FM eds). Oxford University Press, Inc., NY, p.224-236, 2000. 41. Coyle PK. Neurological aspects of Lyme disease. In: Infectious diseases of the Nervous system. (Davis LE, Kennedy PGE eds). Butterworth-Heinemann, Woburn, MA, p.43-81, 2000. 42. Coyle PK. Postinfectious encephalomyelitis. In: Infectious diseases of the Nervous system. (Davis LE, Kennedy PGE eds). Butterworth-Heinemann, Woburn, MA, p.83-108, 2000. 43. Coyle PK. Diagnosis and classification of inflammatory demyelinating disorders. In: Multiple Sclerosis. Diagnosis, medical management, and rehabilitation. (Burks JS, Johnson KP eds). Demos Medical Publishing, Inc., New York, NY, p.81-96, 2000. 44. Coyle PK. Women’s issues. In: Multiple Sclerosis. diagnosis, medical management, and rehabilitation. (Burks JS, Johnson KP eds). Demos Medical Publishing, Inc., New York, NY, p.505-514, 2000. 45. Coyle PK. Multiple Sclerosis. In: Textbook of the Autoimmune Disease. (Lahita RG, Chiorazzi N, Reeves WH eds). Lippincott Williams & Wilkins, Philadelphia, PA, p.595-609, 2000. 46. Coyle PK. Viral meningitis and encephalitis. In: Conn’s Current Therapy. (Rakel RE and Bope ET, eds). W.B. Saunders Co. 53rd edition, p.951-956, 2001. 32

47. Coyle PK. The Immunopathology of MS. International J. MS Care, 3: 4-5, 2001. 48. Goodkin DE, Coyle PK, et, al. A phase I trial of solubilized DR2: MBP(84-102) (AG284) in multiple sclerosis. In: Multiple Sclerosis: tissue destruction and repair. (Kappos L, Johnson K, Kesselring J, Radu EW, eds). Martin Dunitz Ltd, London, United Kingdom, P.337-338, 2001. 49. Coyle PK, Halper J. Meeting the challenge of progressive MS. Demos Medical Publishing, Inc., New York, 2001. 50. Coyle, PK. Multiple Sclerosis Current Status and Strategies for the Future. Institute of Medicine, National Academy Press, p.1-438, 2001. 51. Coyle PK. Neurologic Lyme Disease. In: Current therapy in neurologic disease. (Johnson RT, Griffin JW and McArthur JC, eds). Mosby 6th edition, St Louis, MO, P.159-164, 2002. 52. Coyle PK. Lyme Disease. Current Neurology and Neuroscience reports 2: 479-487, 2002. 53. Burks JS, Arnason BG, Coyle PK, Ford CC, Noronha A, Rammohan KW. Issues and practices in multiple sclerosis. Neurorehabil Neural Repair. 16: 307-320, 2002. 54. Coyle PK. Lyme Disease. In: Disease of the nervous system. (Asbury AK, McKhann GM, McDonald WI, Goadsby PJ, McArthur JC, eds). 3rd edition Cambridge University Press, Cambridge, UK, P.1754-1765, 2002. 55. Miller AE, Lublin FD, Coyle PK. In: Multiple Sclerosis in Clinical Practice (Miller AE, Lublin FD, Coyle PK, eds). MD Martin Dunitz Taylor & Francis Group plc, UK, 2003. 56. Coyle PK. Chronic Meningitis. In: Saunders Manual of Neurologic Practice. (Evans RW, ed). The Curtis Center Philadelphia, PA, P.704-710, 2003. 57. Coyle PK, Mustafa A, Saleh FG. Lyme Disease. In: EMERGING NEUROLOGICAL INFECTIONS: Epidemiology, Pathogenesis and Interventions. (Power and Johnson, ed). Publisher: Marcel Dekker/Taylor & Francis Books, Inc. 207-238, 2004. 58. Coyle PK. Controlling neurodegeneration and slowing progression of disability with glatiramer acetate: the evidence. Drugs in focus. 21-32, 2004. 59. Coyle PK, Havrdova E, Barone D etal. Along the winding road: decision-making process in the treatment of multiple sclerosis. Tow case studies: an interactive workshop. Drugs in focus. 23-45, 2004. 60. Coyle PK. Gender issues. Neurol Clin 23: 39-60, 2005. 61. Coyle PK, Mustafa A. Multiple sclerosis. In: NEUROLOGICAL Disease in women. (Kaplan, ed). Publisher: Demos, New York. p.265-282, 2006. 62. Coyle PK. Multiple sclerosis biomarkers. In: Handbook of Multiple Sclerosis (4th edition). (Cook, ed). Publisher: Taylor & Francis Group, LLC, Atlanta, GA. p.223-242, 2006. 63. Coyle PK, Halper J. Living with Progressive Multiple Sclerosis: Overcoming the challenges. 2nd Ed Demos Press 2008; 1-141. 33

64. Coyle PK. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. Multiple Sclerosis Monitor Volume 2, Number 3 Summer 2008. 65. Coyle, PK. Lyme Disease, In International Neurology: A Clinical Approach. Lisak Truong, Carroll, Bhidayasiri (eds). Blackwell Publishing, 2009;269-273. 66. Coyle PK. Introduction to Neuroimmunology In: Clinical Neuroimmunology Multiple Sclerosis and Related Disorders. (Rizvi, SA, Coyle PK, ed.), Springer Science+Business Media, LLC, p.1-14, 2011. 67. Coyle PK. MS: Pathology and Immunology, In: Clinical Neuroimmunology Multiple Sclerosis and Related Disorders. (Rizvi, SA, Coyle PK, ed.), Springer Science+Business Media, LLC, p.43-69, 2011. 68. Coyle PK. Acute Disseminated Encephalomyelitis, In: Clinical Neuroimmunology Multiple Sclerosis and Related Disorders. (Rizvi, SA, Coyle PK, ed.), Springer Science+Business Media, LLC, p.203-217, 2011. 69. Coyle PK. Chapter 27 Central Nervous System Vasculitis Due To Infection, In: The Vasculitides, Volume 2: Nervous System Vasculitis and Treatment. (Younger, ed). Nova Science Publishers, p. 127-150, 2014. 70. Coyle PK. Lyme Disease In: International Neurology: A Clinical Approach. (Lisak, Truong, William, Carroll, Bhidayasiri (eds). Blackwell Publishing, p.256-259, 2015. Abstracts & Posters 1.

Hirsh Hirsch RL, Brooks BR, Jubelt B, Coyle PK, Seay A and Johnson RT. Human lymphocyte blastogenic responses to influenza virus: Effect of immunization with disrupted influenza virus vaccine. Abstract American Federation for Clinical Research, May 1979.

2.

Coyle PK, Wolinsky JS, et al. Circulating immune complexes in progressive rubella panencephalitis contain anti-rubella IgG. Neurology 30:427,1980.

3.

Coyle PK, Brooks BR, Hirsch R, et al. CSF Fc (IgG) receptor bearing lymphocytes are decreased and immune complexes appear in CSF during multiple sclerosis exacerbations. Neurology 30:447,1980.

4.

Brooks BR, Hirsch R, Jubelt B, Coyle PK, et al. Effect of steroids in appearance of antigen reactive peripheral blood mononuclear cells following influenza virus immunization in multiple sclerosis patients. Neurology 30:448,1980.

5.

Tandon D, Griffin J, Drachman D, Price D, and Coyle PK. Studies in humoral mechanism of inflammatory demyelinating neuropathies. Neurology 30:362,1980.

6.

Brooks BR, Coyle PK, Hirsch RL, et al. Cerebrospinal fluid mononuclear phagocytes and IgG-binding mononuclear cells in multiple sclerosis. Effect of steroid treatment. Ann Neurol 8(1):114, 1980.

7.

Bullock K, Coyle PK. The effects of myasthenia gravis sera in the autonomic nervous system innervation of the thymus gland of mice. (Poster presented at The Myasthenia Gravis meeting, NY Academy of Science, Dec. 1981. 34

8.

Heinicke HU, Coyle PK, Hamburger M. Reticuloendothelial System (RES) Fc receptor function in MS. Neurology 31:146,1981.

9.

Coyle PK, Schutzer SE, Krim M. Interferon modulation of immunoglobulin production in normal controls and patients with multiple sclerosis. Clin Res 30(2):345A,1982.

10. Schutzer SE, Coyle PK, Cunningham-Rundles C. IgA deficiency and immune complex formation in multiple sclerosis. Clin Res 30(2):357A,1982. 11. Coyle PK, Schutzer SE, Sterman AB, et al. Anti-nerve antibodies and circulating immune complexes in cold agglutinin positive chronic inflammatory polyradiculoneuropathy. Ann Neurol 12(1) 102, 1982. 12. Coyle PK, Banks N, Schutzer SE. Adaptation of the Raji celI immune complex test to a micro-ELISA assay. Clin Res 32(2): 341 A, 1983. 13. Coyle PK, Procyk-Dougherty Z. Evidence for ongoing systemic virus production in MS: circulating immune complexes contain antibodies to multiple agents. Ann Neurol 14: 108, 1983. 14. Coyle PK, Procyk-Dougherty Z, Mellman R, Schutzer SE. Interferon enhances con A proliferation by MS cell subpopulations. Neurology 34(351):114, 1984. 15. Coyle PK. CSF immune complexes in MS: evidence for intrathecal virus reactivation? Neurology 34(351):168, 1984. 16. Hassett R M, Coyle PK, Zalneraitis EL, Peress N. Postvaccinal encephalitis following autoinoculation with polyvalent animal vaccine. Neurology 34 (351):168,1984. 17. Sterman AB, Coyle PK. Anxiety attacks present as focal neurologic disturbances: A new clinical association. Neurology 34 (351): 173, 1984. 18. Sterman AB, Coyle PK, Panasci D, Grimson R. Disseminated cardiovascular autonomic abnormalities in MS. Neurology 35 (4S1): 314, 1984. 19. Coyle PK, Sibony PA. Tear analysis in multiple sclerosis. Neurology 36 (4S1): 315, 1986. 20. Coyle PK, Sibony PA, Johnson C. Oligoclonal bands in tears. Neurology 36 (4S1):315, 1986. 21. Walcott P, Sibony PA, Coyle PK, et al. Protein and immunoglobulin release from lacrimal gland fragments. ARVO-1986. 22. Halperin JJ, Coyle PK, Dattwyler R. Lyme Disease-A spirochete associated, treatable polyneuropathy. AFCR-1986. 23. Coyle PK, Sibony PA. Tear analysis in optic neuritis. Neurology 37 (351): 228,1987. 24. Coyle PK, Scholnick H. Immunoglobulin changes in external secretions of MS patients. J Neuroimmunology 16(1):38, 1987. 25. Coyle PK. Molecular analysis of IgA in MS. Ann Neurol 22 (1): 154, 1987. 26. Coyle PK. Antigenic specificity and electrophoretic pattern of polymeric and monomeric IgA in MS. Neurology 38 (S1): 197, 1988. 35

27. Coyle PK. Cell subpopulations in the external mucosal fluids of MS patients. Neurology 38 (S1): 250, 1988. 28. Coyle PK, Sibony AA. Viral antibodies in normal tears. Invest Ophthalmol Vis Sci 29: 41, 1988. 29. Sibony PA, Coyle PK. Electrophoresis of normal tears. Invest Ophthalmol Vis Sci 29: 97, 1988. 30. Coyle PK, Schutzer SE. Cerebrospinal fluid immune complexes in Lyme Disease. Ann Neurol 24: 142, 1988. 31. Mehta PD, Cook SD, Troiano R, Coyle PK. Increase free light chains in the urine of patients with MS. Neurology 39 (3S1): 384, 1989. 32. Schutzer SE, Coyle PK. CSF markers in neurologic Lyme disease. Clinical Research 37(2):439A, 1989. 33. Coyle PK, Johnson C. Activated lymphocytes in MS tears. Neurology 39 (3S1): 174, 1989. 34. Coyle PK, Krupp LB, Belman AL. Immune correlates of cognitive impairment in Lyme disease. Neurology 40 (S1): 332, 1990. 35. Mehta PD, Troiano R, Coyle PK. Free light chains in serial urines from patients with MS. Neurology 40 (S1): 333, 1990. 36. Schutzer SE, Coyle PK, Belman AL et al. Sequestered antibody to B. burgdorferi in immune complexes in seronegative Lyme disease. Clinical Research 38(2): 306A, 1990. 37. Coyle PK, Schutzer SR, Belman AL, et al. B. burgdorferi specific and nonspecific CSF immune complexes in neurologic Lyme disease. Clinical Research 38(2): 366A, 1990. 38. Coyle PK, Krupp LB. B.burgdorferi infection in the chronic fatigue syndrome. Ann Neurol 28(2): 243-244, 1990. 39. Coyle PK. Intrathecal formation of IgM immune complexes in MS. Ann Neurol 28(2): 244, 1990. 40. Coyle PK. Oligoclonal bands in tears vs. CSF of early MS patients. Neurology 41(S1): 148, 1991. 41. Belman AL, Coyle PK, Nachman S, Roque C. Brain MRI abnormalities in children infected by B.burgdorferi. Neurology 41(S1): 180, 1991. 42. Coyle PK, Krupp LB, Mohr K, Doscher C, Mehta PD. Immune activation Markers in Neurologic Patients with Symptomatic Chronic Fatigue. Ann Neurol 30(2): 306,1991. 43. Krupp LB, Coyle PK, Langenbach L et al. Assessment of depression in multiple sclerosis patients with severe fatigue. Ann Neurol 30(2): 277, 1991. 44. Belman AL, Coyle PK. Borrelia burgdorferi-specific immune complexes in children with neurological involvement associated with Lyme disease. Ann Neurol 30(3):506, 1991. 36

45. Coyle PK, Deng Z, Belman AL et al. Detection of Borrelia burgdorferi antigens in CSF. Neurology 42(S3): 371, 1992. 46. Mohr K, Coyle PK, Krupp LB et al. Serial immune changes in MS patients under treatment for fatigue. Neurology 42(s3): 384, 1992. 47. Belman AL, Pyer M, Coyle PK. Neurologic involvement in children with North American Lyme disease. Neurology 42(S3): 385, 1992. 48. Doscher C, Krupp LB, Coyle PK, et al. Post-infectious neurobehavioral syndromes associated with Lyme disease. Neurology 42(S3):293, 1992. 49. Belman AL, Iyer M, Roque C, Coyle PK. Brain MR abnormalities in children with North American Lyme disease. (Vth International Conference on Lyme Borreliosis, 1992). 50. Belman AL, Iyer M, Coyle PK. Neurologic manifestations in children with North American Lyme disease. (Vth International Conference on Lyme Borreliosis, 1992). 51. Coyle PK, Belman AL, Krupp LB. B. burgdorferi specific immune complexes in CSF (Vth International Conference on Lyme Borreliosis, 1992). 52. Coyle PK, Deng Z, Krupp LB, et al. B.burgdorferi-triggered CSF anti-idiotypes (Vth International Conference on Lyme Borrreliosis, 1992). 53. Coyle PK, Krupp LB, Doscher C. Significance of reactive Lyme serology in multiple sclerosis. Ann Neurol 32: 258,1992. 54. Coyle PK, Deng Z, Krupp LB, Belman AL, Benach JL, Luft BJ. B. burgdorferi antigen in cerebrospinal fluid from neurologic Lyme disease patients in the absence of anti-B. burgdorferi antibodies. Ann Neurol 32: 262,1992. 55. Coyle PK, Krupp LB, Doscher C, Amin K. Borrelia burgdorferi reactivity in chronic fatigue patients from a Lyme -endemic region. International CFS/ME Research Conference, October 1992. 56. Krupp LB, Sliwinski MJ, Doscher C, Jandorf L, Burns BS, Coyle PK. Fatigue, mood, and cognitive function in chronic fatigue syndrome and multiple sclerosis. International CFS/ME Research Conference, October 1992. 57. Bertolone K, Coyle PK, Krupp LB et al. Cytokine correlates of fatigue in MS. Neurology 43: A356, 1993. 58. Coyle PK, Dattwyler RJ, Krupp LB et al. CSF findings in North American Lyme disease. Neurology 43: A218-A219, 1993. 59. Krupp LB, Coyle PK, Doscher C, et al. A comparison of Amantadine, Pemoline and Placebo in the treatment of MS fatigue. Neurology 43: A281, 1993. 60. Coyle PK, Krupp LB, Doscher C. Postinfectious chronic fatigue in Lyme disease. Ann Neurol 34: 318 1993.

37

61. Reynolds L, Belman AL, Deng Z, Coyle PK. Detection of Borrelia Burgdorferi antigen in cerebrospinal fluid from pediatric patients evaluated for neurologic Lyme disease. Neurology 44:A169 1994. 62. Coyle PK, Krupp LB, Doscher C, Belman AL, Mehta PD. IgG subclass disturbance in treated Lyme patients with persistent neurologic symptoms. Neurology 44:A185-186 1994. 63. Doscher C, Coyle PK, Krupp LB, Belman AL, Mehta PD. Cytokine levels in treated Lyme patients with persistent fatigue and encephalopathy. Neurology 44: A186 1994. 64. Boortz-Marx RL, Coyle PK, Peterson K. Detection of CSF Borrelia burgdorferi antibody and antigen in a seronegative patient with ascending polyradiculopathy and myelopathy. Neurology 44: A186 1994. 65. Gaudino E, Coyle PK, Doscher C, Krupp LB. Neuropsychiatric profile of Post-Lyme Syndrome. Neurology 44: A376 1994. 66. Gaudino EA, Geisler MG, Preston T, Coyle PK, Masur DM, Krupp LB. Neuropsychiatric differences between chronic Lyme disease and chronic fatigue syndrome. Neurology 45: A166 1995. 67. Krupp LB, Gaudino MG, Squires NK, Kaufman P, Coyle PK. Neurophysiologic abnormalities in Lyme disease. Neurology 45:A166 1995. 68. Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, La Rocca N, Lopez S. A multi-Center, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 45: A436 1995. 69. Krupp LB, Coyle PK, Gaudino EA, Geisler MW, Doscher C. Post- Lyme syndrome: clinical findings. Ann Neurol 38: 284 1995. 70. Coyle PK, Krupp LB, Doscher C, Deng Z, Milazzo A. Clinical and immunological effects of cooling in multiple sclerosis. Ann Neurol. 38:312 1995. 71. Geisler MW, Gaudino EA, Squires NK, Coyle PK, Krupp LB. Cooling and Multiple Sclerosis: An auditory-evoked potential and neuropsychological analysis. Ann Neurol 38: 346 1995. 72. Coyle PK, Dattwyler RJ, Krupp LB, Belman AL, Luft BJ. North American Lyme meningitis. Ann Neurol 38: 349 1995. 73. Belman AL, Reynolds L, Coyle PK. Cerebrospinal fluid findings in children with Lyme disease-related facial nerve palsy. Ann Neurol 38:513 1995. 74. Coyle PK, Belman A, Krupp LB, Dattwyler, Luft BJ. Cerebrospinal fluid culture positive for North American Lyme meningitis. Ann Neurol 40:494 1996. 75. Coyle PK, Schutzer SE, Krupp LB, Belman AL, Deng Z. Antigen specificity of cerebrospinal fluid immune complexes in neurologic Lyme disease. Neurology 48: A224 1997. 76. Krupp LB, Gaudino E, Coyle PK: Psychiatric status and cognitive functioning in Lyme disease. Ann Neurol 42:394-395 1997. 38

77. Pollina DA, Squires NK, Coyle PK, Krupp LB: Cognitive-specific deficits in chronic Lyme disease. Ann Neurol 42:394 1997. 78. Coyle PK, Krupp LB. Postinfectious encephalomyelitis/ multiple sclerosis versus Lyme disease. Ann Neurol 42:467 1997. 79. Pollina DA, Lawson TA, Smiroldo J, Coyle PK, Krupp LB. “Voice matching” can quantify dysarthritic speech in multiple sclerosis. Ann Neurol 42:466 1997. 80. Krupp LB, Soefer MH, Pollina DA, Smiroldo J, Coyle PK. Fatigue measures for clinical trials in multiple sclerosis. Neurology (supplement 4)50: A126 1998. 81. Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB, Miller AE, Wende K, and the New York State Multiple Sclerosis Consortium. Quantitative measures are more sensiio worsening neurological function in a prospective multiple sclerosis study. Ann Neurol 44:483 1998. 82. Coyle PK, Deng Z, Luft B, Dattwyler R, Yang X. Heterogeneous response to outer surface protein in early Lyme disease. Ann Neurol 44:489 1998. 83. Krupp LB, Elkins LE, Scott SR, Smiroldo J, Coyle PK. Donepezil for the treatment of memory impairments in Multiple Sclerosis. Neurology (supplement 2) 52:A137 1999. 84. Elkins LE, Krupp LB, Coyle PK. Comparison of the neuropsychiatric profiles in early and late Lyme disease. Neurology (supplement 2) 52:A153 1999. 85. Belman AL, Parvez S, Milazzo M, Coyle PK. Disseminated Lyme disease in children. Ann Neurol 46:458 1999. 86. Pan W, Krupp LB, Elkins L, Coyle PK, Reilly S, Scheffer S, Smiroldo J. Cognitive performance and magnetic resonance spectroscopy: correlates in multiple sclerosis. Ann Neurol 46:475 1999. 87. Coyle PK, Rizvi S, Melville PM. Symptomatic early Lyme disease in adults. Ann Neurol 46:488 1999. 88. Coyle PK, Mehta PD. Amyloid-β peptide levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 46:489 1999. 89. Coyle PK, Rizvi S, Bernal O. Neurologic involvement in early Lyme disease. Neurology (supplement 3) 54(7): A157-A158 2000. 90. Rizvi S, Robertson S, Krupp LB, Coyle PK. To assess the benefits of brief bed rest on postdural puncture headache (PDPH). Neurology (supplement 3) 54:A423 2000. 91. Yangala R, Mousli HM, Zarif M, Rizvi S, Coyle PK. Neurologic Lyme disease presenting as incomplete transverse myelitis: clinical and MRI findings. Neurology (supplement 3) 56:A479 2001. 92. Beitinjaneh F, Rizvi S, Coyle PK, Krupp LB. Diagnostic accuracy of serologic testing for Lyme disease. Neurology (supplement 3) 56:A479 2001.

39

93. Coyle PK. Results of comparative efficacy trial using two formulations of interferon betal1 in RRMS. J Neurological Sciences (supplement 1) 187: S436. 94. Coyle PK, Rizvi S, Taylor M, Johnson M, Deng Z. Acute Lyme disease in North America: Neurologic aspects. Neurology (supplement 3) 58:A262 2002. 95. Coyle PK. Consensus guidelines for standardized MRI scanning in MS. Neurology (supplement 3) 58:A210 2002. 96. Rooney WD, Coyle PK, Li X, Taylor M, Telang FW, Springer CS. Cerebral MRI T1 histograms efficiently summarize total disease burden in MS brain. Neurology (supplement 1) 60:A299 2003. 97. Corboy JR, Boudreau I, Weiner WJ, Coyle PK. The Neurology residency in 2002: results from a resident survey. Neurology (supplement 1) 60:A13 2003. 98. Adair JC, Richerson GB, Corboy J, Rudnicki S, Coyle PK. Directing the neurology residency: a sustainable career choice. Neurology (supplement 1) 60:A14 2003. 99. Coyle PK, Johnson K, Pardo L, Stark Y. Pregnancy outcomes in patients with Multiple Sclerosis treated with Glatiramer Acetate (Copaxone®). Neurology (supplement 1)60:A60 2003. 100. Rooney WD, Coyle PK, Li X, Dwivedi A, Taylor M, Telang FW, Springer CS. Sex differences of brain H2O T1 values in controls and MS subjects: the role of estradiol. Proc Intel Soc Mag Reson Med 2003; 11:123. 101. Rooney WD, Yankeelov TE, Coyle PK, Telang FW, Springer CS. Quantitative measurement of contrast reagent blood-brain barrier permeability in Multiple Sclerosis. Proc Intel Soc Mag Reson Med 2003; 11:276. 102. Rooney WD, Li X, Telang FW, Springer CS, Coyle PK, Caparelli E, Ernst T, Chang L. Age and sex: effects on brain properties assessed by H2O T1 histograms. Proc Intel Soc Mag Reson Med 2003; 11:1087. 103. Rooney WD, Yankeelov TE, Coyle PK, Telang FW, Springer CS. Regional blood volumes and Intravascular water lifetimes in human brain. Proc Intel Soc Mag Reson Med 2003; 11:2188. 104. Tekwe CD, Coyle PK, et al. Familial multiple sclerosis in the New York State multiple sclerosis consortium. Neurology (supplement 2) 66:A227 2006. 105. Zivadinov R, Coyle PK, et al. Evolution of benign multiple sclerosis in the New York State multiple sclerosis consortium according to different classification criteria. Neurology (supplement 2) 66:A380 2006. 106. Fox E, Al-Sabbagh A, Bennett R, Coyle PK, et al. Ongoing evaluation of the safety and tolerability of Novantrone® (mitoxantrone) worsening multiple sclerosis: the RENEW study. ECTRIMS 2006; [P759]. 107. Zivadinov R, Weinstock-Guttman B, Cookfair DL, Krupp L, Schwid S, Miller AE, Lava N, Coyle PK, et al. Evolution of benign multiple sclerosis in the New York State multiple sclerosis Consortium according to different classification criteria. ECTRIMS 2006; [P468]. 40

108. Mikolf D, Barkhof F, Coyle PK, et al. Baseline demographics of a randomized study comparing interferon beta-1a with glatiramer acetate in treating relapsing-remitting multiple sclerosis, using McDonald criteria for inclusion: the REGARD study. ECTRIMS 2006; [P729]. 109. Coyle PK, “Immunogenicity, Tolerability and Patient Disposition In a Randomized, Assessor-Blinded, Multicenter Study of Interferon Beta-1a and Glatiramer Acetate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from REGARD Study” Presented at the American Academy of Neurology 60th Annual Meeting, April 12 to April 19, 2008 Chicago, IL. 110. Coyle PK, Edwards KR, Khatri BO, et al. Teri-PRO: Study Design and US Patients’ Baseline Characteristics. Presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting, September 1013, 2014, Boston, MA. [P.078] 111. Coyle PK, Fang J, Hassan A, et al. No evident disease activity at 24 weeks in patients with relapsing MS treated with interferon β-1a SC vs. interferon β-1a IM in the EVIDENCE study. Presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting, September 10-13, 2014, Boston, MA. [P102] 112. Coyle PK, Fang J, Hassan A, et al. No evident disease activity in relapsing MS patients treated with interferon β-1a SC vs. interferon β-1a IM: subgroup analyses of the EVIDENCE study. Presented at the 2014 Joint ACTRIMS-ECTRIMS Meeting, September 10-13, 2014, Boston, MA. [P104] 113. Coyle PK, LaGanke C, Khatri B, et al. Treatment Satisfaction With Teriflunomide: Preliminary Results at Week 4 From the US Cohort of the Teri-PRO Phase 4 Study. Presented at the 27th Annual International Meeting of the Academy of Managed Care Pharmacy, April 7-10, 2015, San Diego, CA. 114. Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Coyle PK. How Satisfied With Their Treatment Are Patients With MS? Psychometric Evaluation of the Treatment Satisfaction Questionnaire for Medication (TSQM). Presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), April 18-25, 2015, Washington, DC. 115. Coyle PK, Fang J, Hassan A, et al. No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC tiw vs. Interferon Beta-1a IM qw in the EVIDENCE study. Presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), April 18-25, 2015, Washington, DC. [P7.220] 116. Coyle PK, LaGanke C, Khatri, B, et al. Baseline Characteristics of Patients Enrolled in the Teri-PRO Phase 4 Study in the United States vs. Canada, Europe, and Latin America. Presented at the Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), May 27-30, 2015, Indianapolis, IN. [QL02] 117. Reder AT, Freedman MS, Dangond F, Fang J, Coyle PK. Predictive Value of MRI Measures in Patients with Relapsing Multiple Sclerosis Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of EVIDENCE Data. Presented at the Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), May 27-30, 2015, Indianapolis, IN. [DX68] 118. Gold R, Coyle PK, LaGanke C, et al. Treatment Satisfaction With Teriflunomide: Preliminary Results at Week 4 for Patients From Canada, Europe and Latin America Enrolled in the 41

Teri-PRO Phase 4 Study. Presented at the 1st Congress of the European Academy of Neurology (EAN), June 20–23, 2015, Berlin, Germany. [F4121] 119. Coyle PK, LaGanke C, Khatri B, et al. Improvements in Patient-Reported Outcomes With Teriflunomide: Week 24 Interim Results From the US Cohort of the Teri-PRO Phase 4 Study. Presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 7-10, 2015, Barcelona, Spain. [P562] 120. Coyle PK, Freedman MS, Dangond F, et al. Predictive value of early MRI measures for longterm disease activity in patients with relapsing-remitting multiple sclerosis receiving IFNβ1a SC tiw or IFNβ-1a IM qw: post hoc analyses of the EVIDENCE study. Presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 7-10, 2015, Barcelona, Spain. [P1142] 121. Meca-Lallana JE, Edwards KR, Coyle PK, et al. Treatment Satisfaction With Teriflunomide: Preliminary Results at Week 4 for Patients Enrolled in the Teri-PRO Study in Europe, Canada, and Latin America. Presented at the LXVII Reunión Annual de la Sociedad Española de Neurología (SEN), November 17-21, 2015, Valencia, Spain. 122. Coyle PK, Shang S, You X, et al. In patients with RRMS, SC peginterferon beta-1a every 2 weeks demonstrated comparable clinical efficacy to SC interferon beta-1a TIW using a matching-adjusted method. European Academy of Neurology (EAN), May 28-31, 2016 Copenhagen, Denmark. 123. Freedman MS, Leist T, Comi G, Cree BAC, Coyle PK et al. Efficacy of Cladribine Tablets in ORACLE Study Patients Who Retrospectively Met 2010 McDonald Multiple Sclerosis (MS) Criteria at Baseline. American Academy of Neurology (AAN), April 15-22, 2016, Vancouver, British Columbia. [P035] 124. Coyle PK, Freedman MS, Comi G, et al. Effect of early versus delayed subcutaneous interferon (scIFN) β-1a to achieve no evidence of disease activity (NEDA) in patients with clinically isolated syndrome (CIS): a post-hoc analysis of REFLEXION. American Academy of Neurology (AAN), April 15-22, 2016, Vancouver, British Columbia. [P111] 125. Reder AT, Freedman MS, Fang J, Dangond F, Coyle PK. Predictive Value of Early MRI Measures for Long-Term Disease Activity in Patients with Relapsing–Remitting Multiple Sclerosis Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of the EVIDENCE Study. American Academy of Neurology (AAN), April 15-22, 2016, Vancouver, British Columbia. [P189] 126. Reder AT, Freedman MS, Fang J, Dangond F, Coyle PK. MRI Frequency and No Evidence of Disease Activity Status Among Patients with RRMS Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of EVIDENCE. American Academy of Neurology (AAN), April 1522, 2016. Vancouver, Britich Columbia. [P190] 127. Coyle PK, LaGanke C, Khatri B, et al. Improvements in Patient-Reported Outcomes (PROs) with Teriflunomide: Results from the US Cohort of the Teri-PRO Phase 4 Study. Consortium of Multiple Sclerosis Centers (CMSC), June 1-4, 2016, National Harbor, MD. [PO019]

42

128. Kavak KS, Teter BE, Vaughn CB, Edwards KR, Coyle PK, et al. Intrauterine Devices May be Associated with a Later MS Disease Onset. Consortium of MS Centers (CMSC), June 1-4, 2016. National Harbor, Maryland. [EG05] 129. Vaughn CB, Kavak KS, Teter BE, Coyle PK, et al. Pregnancy Decision-Making in Women with Multiple Sclerosis. Consortium of MS Centers (CMSC), June 1-4, 2016. National Harbor, Maryland. [QL04]

Service as a Reviewer 1.

The Journal of Infectious Diseases (1993)

2.

Science

3.

Neurology (1997)

4.

Journal Neuroimmunology (1997)

5.

Annals of Neurology

6.

Investigative Ophthalmology and Visual Science

7.

Infection and Immunity

8.

Southern Medical Journal

9.

New England Journal Medicine (1995, 1998)

10. Journal of Clinical Investigation (1995) 11. NINCDS Special Review Committee for ALS Site Visit, June 1986. 12. NINDS Special Review Committee for Proteolipid Protein Program Project Grant, Washington University, St. Louis, May 3-4, 1989. 13. Examiner, American Board of Psychiatry and Neurology, Boston, November 12-14, 1989; New York, November 15-17,1992; Boston November 6-8, 1994; Washington DC April 2325, 1995; New Orleans November 16-18, 1997; Chicago March 9-31, 1998. 14. VA Merit Review Committee, Consultant: 1989, 1990 15. NIH Special Review Committee, Cooperative Program Projects for Chronic Fatigue Syndrome, Bethesda, MD July 18-19, 1991. 16. National Institutes of Health Reviewers Reserve (NRR), July 1992 - June 1996. 17. National Center for Research Resources, GCRC grant review for the Brigham and Women's Hospital Boston, MA, Dec 6- 7,1993. 18. NIH Special Review “Animal Models for Chronic Lyme Disease”, Bethesda, MD, June 9-10, 1994. 43

19. Archives Neurology (2010, 2011). 20. MS Journal (2010, 2011). 21. CNS Drugs (2013, 2014, 2015, 2016). 22. Journal of the Neurological Sciences (2013, 2014). 23. JAMA Neurology (2013, 2015). 24. Neurology Reviews (August 2014). 25. Drugs and Therapy Perspectives (May 2015). 26. Advances in Therapy (June 2015). 27. Therapeutics and Clinical Risk Management (July 2015, Dec 2015) 28. Multiple Sclerosis and Related Disorders (2015, May 2016) 29. Obstetrics & Gynecology (2015) 30. Expert Opinion on Drug Safety (March 2016) 31. Patient Preference and Adherence (March 2016) 32. Canadian Journal of Infectious Diseases and Medical Microbiology (April 2016) 33. Neurology and Therapy (April 2016)

Invited Lectures/Symposia 1.

Fairleigh Dickinson University - National MS Society, MS Research Day.

2.

Suffolk County Chapter, National MS Society.

3.

Suffolk County Bureau of Public Health Nurses Symposium on Neurological Diseases

4.

Nassau County Medical Center, Neurology Grand Rounds

5.

Annual Medical Update for Physicians' Assistants, Washington, D.C.

6.

University of Maryland, Dept. of Neurology Grand Rounds.

7.

Workshop on Cellular and Humoral Components of CSF in Multiple Sclerosis; Hengelhoef, Belgium, March 1986.

8.

Symposium on Myasthenia Gravis: Current Concepts, Stony Brook, N.Y., May 1986.

9.

U.M.D.N.J. - New Jersey Medical School, “Immunology Today. A Course for the Practicing Physician”, Invited lecture on “Neuroimmunology: New perspectives, October 30, 1987. 44

10. Invited lecture, Institute for Basic Research in Developmental Disabilities and Mental Retardation, Staten Island, December 1987. 11. North Shore University Hospital, Neurology Grand Rounds, “MS Update”, January l988. 12. Invited Lecture, Brookhaven National Laboratory, “MS”, January l988. 13. Neurology Grand Rounds, Central Islip, Psychiatric Center, “Tardive Dyskinesia”, April l988. 14. Neurology Grand Rounds, Central Islip Psychiatric Center, “Lyme Disease and Organic Brain Syndrome”, July l988. 15. Invited Lecture, Workshop on “Diagnostic and Therapeutic Trials in MS: A New Look”, Jekyll Island, GA, November l988. 16. North Shore MS Club, “Mucosal immunity - common viruses, implications for MS”, November l988. 17. Neurology Grand Rounds, Central Islip Psychiatric Center, “Motor Neuron Disease”, February 15, l989. 18. Neuropsychiatry Conf., “Chronic Meningitis, April 6, 1989. 19. Invited lecture, Infectious Disease Course, American Academy of Neurology, “Chronic Meningitis”, April 18, 1989. 20. Neuroscience Course, “Spinal Cord Syndromes”, NYCOM, April 25, 1989. 21. Neuroscience course, “Olfaction”, NYCOM, June 8, 1989. 22. Neuroscience course, “Gustatory function”, NYCOM, June 9, 1989. 23. Neuroscience course, “Clinical Correlations II”, NYCOM, June 13, 1989. 24. Neuroscience course, “Dementia”, NYCOM, June 15, 1989. 25. Neurology Grand Rounds, Central Islip Psychiatric Center, “Dementia”, June 21, 1989. 26. Rheumatology Rounds, VAMC-Northport, CNS Vasculitis, December 1989. 27. Invited Seminar, Department of Microbiology and Molecular Genetics, UMDNJ, “Immune Complexes in Lyme Disease”, December 11, 1989. 28. Neurology Grand Rounds, Central Islip Psychiatric Center, “Chorea”, April 18, 1990. 29. North Shore MS Club, North Shore University Hospital, “Therapy of MS”, Sept. 12, 1990. 30. “Neurologic Lyme Disease”, Institute for Basic Research in Developmental Disability, Staten Island, October 24, 1990. 31. “On Long Island”, Telicare Television Show, “Multiple Sclerosis”, November 2, 1990. 32. Invited Lecture, “Immune Complex Analysis in Lyme Neuroborreliosis”, First Annual Lyme Disease Research Meeting, NIH, Bethesda, MD, November 25-28, 1990. 45

33. Neurology Grand Rounds, “Neurocysticercosis”, Stony Brook, NY, December 4, 1990. 34. Invited lecture, Chronic Fatigue Society, “The role of infections in fatigue”, Port Jefferson, NY, December 6, 1990. 35. Southside Hospital MS Group, “Therapy in MS”, Bay Shore, NY, January 28, 1991. 36. Invited Lecture, “Lyme Disease”, NIH Workshop on the Definition and Medical Outcome Assessment of CFS in Research; Bethesda, MD, March 18-19, 1991. 37. Neuroscience Course, “Spinal Cord Modalities and Lesions”, NYCOM, Old Westbury, NY, March 26, 1991. 38. Neurology Grand Rounds, “Chronic Meningitis”, Stony Brook, NY, April 2, 1991. 39. Invited lecturer, "Immune complex analysis in Borrelia burgdorferi infection"; Banbury Center Conference on the Molecular Immunobiology of Lyme Diseases, Cold Spring Harbor, NY, April 7-10, 1991. 40. Invited Lecture, “MS”, Current Issues in Primary Care Conference, NYS Society of Physicians' Assistants, East Elmhurst, NY, April 13, 1991. 41. Neuroscience Course, “Oculomotor Control”, NYCOM, Old Westbury, NY, April 17, 1991. 42. Neuroscience Course, “Brainstem Lesions”, NYCOM, Old Westbury, NY, April 18, 1991. 43. Shirley MS Group, “MS”, Shirley, NY, May 2, 1991. 44. Neuroscience Course, “Visual System Abnormalities”, NYCOM, Old Westbury, NY, May 7, 1991. 45. Neuroscience Course, “Vascular Syndromes” NYCOM, Old Westbury, NY, May 14, 1991. 46. Invited Lecture, Dean's Colloquium, “Neurologic Lyme Disease”, UMDNJ, Newark, NJ, May 16, 1991. 47. Neuroscience Course, “Higher Cortical Functions”, NYCOM, Old Westbury, NY, May 23, 1991. 48. Stony Brook MS Support Group, “What's New in MS Research?”, East Setauket, NY, June 27, 1991. 49. Invited Lecture, “Neurologic Lyme Disease”, 2nd Annual Meeting of Lyme Disease Pathogenesis RFA Grantees, Hamilton, MT, September 12-14, 1991. 50. Neurology Grand Rounds, “Pharmacotherapy of MS”, Stony Brook, NY, October 8, 1991. 51. Invited Lecture, Long Island MS Society Annual Conference, “Current Research in MS”, Huntington, NY, Oct 23, 1991. 52. Family Medicine Continuing Education Course, “Viral Infections in the CNS” Brookhaven Memorial Hospital, Patchogue, NY, January 3, 1992.

46

53. Neurology Grand Rounds, Brown University Medical School, “Neuroimmunology of MS”, Providence, RI, March 4, 1992. 54. Neurology Grand Rounds, Univ. of Maryland Med. School, “Neurologic Lyme Disease”, Baltimore, MD, March 18, 1992. 55. Invited Lecture, 18th Annual Family Medicine Update, “Tremor”, Stony Brook, NY, March 29, 1992. 56. Invited Speaker, Animals in Research Workshop, American Medical Association and American Academy of Neurology, “Impact of the animal rights movement on the practice of Neurology”, San Diego, CA, May 5, 1992. 57. Neurology Ground Rounds, “Clinical Neuropharmacology”, Stony Brook, NY, April 7, 1992. 58. Long Island MS Society Caregivers' Workshop, “Understanding the Disease Process of MS”, Stony Brook, NY, May 12, 1992. 59. Invited Lecture, Symposium on Current Topics in Lyme Disease, “CSF abnormalities in neurologic Lyme disease”, East Brunswick, NJ, May 14, 1992. 60. Invited lecture, “Acute and Persistent Infections of the Nervous System”, Institute for Basic Research Developmental Disabilities, Staten Island, New York, May 20, 1992. 61. Invited Speaker, First Annual NIAID Chronic Fatigue Syndrome Cooperative Research Centers Meeting, "Detection of B. burgdorferi infection", NIH, Bethesda, MD, June 24, 1992. 62. Neurologic Grand Rounds, “CSF in Neurologic Infections”, Stony Brook, NY, August 7, 1992. 63. Fifth Annual Meeting American Medical Laboratory Immunologists, "Infectious Diseases of the Central and Peripheral Nervous Systems, Alexandria, VA, August 14, 1992. 64. Invited lecture, “Infectious and Immunologic Aspects of CFS”, Symposium on Chronic Fatigue Syndrome, Suffolk Academy of Medicine, Hauppauge, NY, September 9, 1992. 65. Invited Lecture, “Neurologic Lyme disease”, Lyme Disease Update, Southampton Hosp., Southampton, NY, Sept 21, 1992. 66. Neurology Grand Rounds, “Chronic Meningitis”, Nassau County Medical Center, East Meadow, NY, October 2, 1992. 67. Invited Speaker, “The CNS exam”, Department of Emergency Medicine, Stony Brook, NY, October 9, 1992. 68. Neurology Grand Rounds “Neurologic Lyme Disease”, Albert Einstein College of Medicine, Bronx, NY, Nov 18, 1992. 69. Medical Rounds, “Chronic Fatigue Syndrome and Mainstream Medicine”, Mid Island Hosp., Bethpage, NY, March 2, 1993. 70. MS patient support group, “Multiple Sclerosis”, Coram, NY, March 11, 1993. 47

71. Invited Speaker, Molecular and Immunologic Aspects of Lyme Disease, "Evidence for early and persistent infection of the CNS/in neurologic Lyme disease, Banbury Center Conference, Cold Spring Harbor, NY, March 28-31, 1993. 72. Invited Speaker, Cold Spring Harbor Meeting on Lyme Disease, “Neurologic Lyme disease”, Cold Spring Harbor, NY. March 28, 1993. 73. Invited Speaker, 6th Annual Lyme Disease Scientific Conference, “Evidence for Early CNS Invasion by B. Burgdorferi”, Atlantic City, NJ, May 5-6, 1993. 74. Invited Speaker, MetPath Educational Seminar, “Lyme Disease”, Tarrytown, NY, May 12, 1993; Garden City, NY, May 13, 1993. 75. Invited Speaker, Clinical Education Conference, National MS Society Long Island Chapter, “MS: Update” Smithtown, NY, May 15, 1993. 76. Invited Speaker, Institute for Basic Research in Developmental Disabilities, “Lyme Disease: CNS complications”, Staten Island, NY, June 9, 1993. 77. Invited Speaker, 23rd Annual Family Medicine Update 1993, “Tremor” Stony Brook, NY, June 1993. 78. Invited Speaker, NIMH Workshop on Viral Basis of CNS Disease “CSF Studies in Lyme Disease”, Chevy Chase, MD, July 20-21,1993. 79. Invited Speaker, Neurology Grand Rounds at Winthrop Hosp., “Neurologic Lyme Disease”, Mineola, NY, Oct 7, 1993. 80. Invited Speaker, NIH Workshop on Clinical Management of Chronic Fatigue Syndrome, “Post Lyme Disease Fatigue”, Bethesda, MD, November 18-19, 1993. 81. Invited Speaker, NIH Workshop on Chronic Lyme Disease, “Evaluation of the Patient with Chronic Lyme Disease”. Bethesda, MD, Jan 31, 1994. 82. Neurology Grand Rounds, “Cytomegalovirus”, Stony Brook, NY, February 18, 1994. 83. Neurology Grand Rounds, “Leptospirosis”, Stony Brook, NY, March 4, 1994. 84. Neurology Grand Rounds, “Viral Encephalomyelitis” Mid Island Hospital, Bethpage, NY, May 10, 1994. 85. Invited Speaker, 24th Annual Family Medicine Update 1994, “Chronic Fatigue”, June 1994. 86. Invited Lecture, Symposium on MS Update, “Betaseron”, Stony Brook, NY, June 25, 1994. 87. Neurology Grand Rounds, “New Directions in the Management of MS”, Nassau County Med. Center, Plainview, NY, Oct 14, 1994. 88. Neurology Grand Rounds, “New Directions in the Management of MS” NYU Medical Center, NYC, October 21, 1994. 89. Neurology Grand Rounds, “Neuroimmunology of MS” Long Island Jewish Medical Center, Queens, NY, November 23, 1994. 48

90. Invited Lecture, SEED program, “Lyme Disease”, SUNY, Old Westbury, NY, November 29, 1994. 91. Neurology Grand Rounds, “CNS Infections in Cancer”, Stony Brook, NY, February 10, 1995. 92. Invited Speaker, Neurology Grand Rounds, “Neurologic Lyme Disease”, SUNY at Downstate Medical Center, Brooklyn, NY, May 17, 1995. 93. Invited Speaker, 25th Annual Family Medicine Update 1995, “Neurologic Aspects of Lyme Disease”, Stony Brook, NY, June 4, 1995. 94. Invited Speaker, Grand Rounds, “Multiple Sclerosis” Kimball Medical Center, NJ, June 13, 1995. 95. Invited Speaker, Neurology Grand Rounds, “New Directions in the Management of Multiple Sclerosis” Beth Israel Medical Center, NYC, September 8, 1995. 96. Invited Speaker, Neurology Grand Rounds, “New Directions in the Management of Multiple Sclerosis” VA Medical Center, Coatesville, PA September 20, 1995. 97. Invited Speaker, “Lyme Disease”, Bethel Baptist Church, East Setauket, NY, August 13, 1995. 98. Invited Speaker, “Multiple Sclerosis: Diagnosis, Classification, Prognosis” Pacific Regional Meeting on “MS: Clinical Issues and Decisions” Newport Beach, CA, August 18-20, 1995. 99. Invited Speaker, “Optimizing Immunotherapy: The Challenge of Side Effect and Compliance”, Northeastern Regional Meeting at “MS: Clinical Issues and Decisions”, Washington DC, September 22-24, 1995. 100. Invited Speaker, Central South Carolina Meeting on MS, “New Directions in the Management of MS”, Greenville, SC, September 25, 1995. 101. Invited Speaker, Quarterly Meeting of the Eastern Long Island Hospital Medical Staff, “Chronic Neuropsychiatric Aspects of Lyme Disease”, Greenport, NY, Sept 26, 1995. 102. Invited Speaker, “MS: New Therapeutic Advances, Annual Meeting National MS Society, Long Island Chapter, Hauppauge, NY, October 30, 1995. 103. Invited Speaker, “Betaseron Update”, Topical Issues in Multiple Sclerosis, Stony Brook, NY, November 4, 1995. 104. Invited Speaker, “Neurologic Aspects of Lyme Disease”, Tulane Primate Ctr., Covington, LA, November 10, 1995. 105. Invited Speaker, Metro West Medical Center, “New Directions in the Management of Multiple Sclerosis”, Framingham, MA, December 5, 1995. 106. Invited Lecture, Connecticut Neurological Society, “Neurological Issues of Lyme Disease”, Trumbull, CT, December 11, 1995. 107. Invited Speaker, “Eastern Regional Conference in MS: Clinical Issues and Decisions”, St. Petersburg, FL, February 3-4, 1996. 49

108. Invited Speaker, “Western Regional Conference on MS: Clinical Issues and Decisions”, Rancho Mirage, CA, February 17-18, 1996. 109. Invited Speaker, “Neuropsychological Problems in Lyme Disease”, Southampton Hosp., Southampton, NY, April 5, 1996. 110. Invited Speaker, Neurology Grand Rounds, “Multiple Sclerosis”, University of North Carolina, Chapel Hill, NC, April 10, 1996. 111. Participant, Presentation Skills Development Workshop, “Clinical Significance of Neutralizing Antibodies”, Dallas, TX. April 17-18, 1996. 112. Invited Speaker, Neurology Grand Rounds “New Directions in the Management of MS”, Rhode Island Hospital, Providence, RI, May 1, 1996. 113. Invited Speaker, First National Telemedicine Neurology Symposium, Neurology Update for the Practitioner: “Neurologic Manifestations of Lyme Disease”, Garden City Hotel, Garden City, NYC, May 4, 1996. 114. Invited Panelist, National MS Societies Ninth Annual Teleconference, “Progress and Promise in MS Research”, NYC, May 4, 1996. 115. Invited Speaker, Healthy Women 2000 Conference on Autoimmune Diseases, “Treatment of MS”, Washington DC, June 11, 1996. 116. Invited Speaker, Dinner Seminar on MS, Berkeley, CA June 18, 1996. 117. Invited Speaker, Neurology Grand Rounds, “Interferon beta therapy in MS”, Stanford Medical School, Palo Alto, CA, June 19, 1996. 118. Invited Speaker, Dinner Seminar on MS, Palo Alto, CA, June 19, 1996. 119. Invited Speaker, “MS: Clinical Issues and Decisions”, Lansdowne Conf. Ctr., Lansdowne, VA, June 21-23, 1996. 120. Invited Speaker, Dinner Seminar “MS”, Manhattan, NY, Aug 6, 1996. 121. Invited Speaker, Neurology Grand Rounds, “Post Infectious Syndromes” A. Einstein Med. Ctr., Bronx, NY Aug 14, 1996. 122. Invited Speaker, Dinner Seminar, “MS”, Des Moines, IA, September 9, 1996. 123. Invited Speaker, “interferon β Therapy in MS”, San Diego Neuroscience Society, San Diego, CA, September 12, 1996. 124. Invited Speaker, Neurology Grand Rounds, University of California, San Diego, CA, September 13, 1996. 125. Invited Speaker, “Diagnosis and Classification of MS”, MS Consortium Pre-Conf. Workshop, Atlanta, GA, Sept 26, 1996. 126. Invited Speaker, “Fatigue Management”, MS Consortium Annual Conference, Atlanta, GA, September 27, 1996. 50

127. Invited Speaker, “New Directions in the Management of MS”, York Hospital, York, PA, October 3, 1996. 128. Invited Speaker, “Phase III Study of Interferon beta1a” Symposium on Avonex, Stony Brook, NY October 3, 1996. 129. Invited Speaker, Dinner Seminar, “Treatment of MS”, Maitland, FL, October 16, 1996. 130. Invited Speaker, Medical Grand Rounds “MS”, Orlando Regional Medical Center, Orlando, FL, October 17, 1996. 131. Invited Speaker, Dinner Program on MS, Fort Lauderdale, FL, October 21, 1996. 132. Invited Speaker, Dinner Seminar “Treatment of MS”, Winston Salem, NC, October 24, 1996. 133. Invited Speaker, Neurology Grand Rounds, “New Directions in the Management of MS”, Bowman Gray School of Medicine, Winston-Salem, NC, October 25, 1996. 134. Keynote Speaker, Annual Meeting, Central North Carolina MS Chapter, “MS Update” Greensboro, NC, October 26, 1996. 135. Invited Speaker, Annual meeting, Colorado MS Chapter "MS Update", Denver, CO, October 29, 1996. 136. Invited Speaker, Neuroimmunology Symposium: “The Comprehensive Management of MS, Diagnosis and Classification of MS, Impact on Treatment Decisions”, University of Maryland, Baltimore, MD, November 8, 1996. 137. Keynote Speaker, “MS Update on Research and Treatment,” Annual Meeting of the Greater Carolinas Chapter, National MS Society, Charlotte, NC, November 16, 1996. 138. Invited Speaker, Dinner Seminar “New Directions in the Management of MS”, Athens, GA, November 19, 1996. 139. Invited Speaker, Dinner Seminar “Treatment of MS”, Albany, NY, November 20, 1996. 140. Invited Speaker, Neurology Grand Rounds, “MS Update”, Albany Medical Center, Albany, NY, November 21, 1996. 141. Keynote Speaker, Eastern North Carolina Chapter Annual Meeting, AMS Update, Raleigh, NC, November 23, 1996. 142. Invited Speaker, Neurology Grand Rounds, “Neurologic Lyme Disease”, Mt. Sinai School of Medicine, NYC, November 25, 1996. 143. Invited Speaker, Dinner Seminar “Treatment of MS”, Kansas City, KS, December 5, 1996. 144. Invited Speaker, Neurology Grand Rounds, “New Directions in the Management of MS”, Kansas University Medical Center, Kansas City, KS, December 6, 1996. 145. Keynote Speaker, Annual Meeting Georgia Chapter of National MS Society, “MS Update”, Atlanta, GA, December 7, 1996. 51

146. Invited Speaker, Dinner Seminar, “MS”, Teaneck NJ, December 18, 1996. 147. Featured Speaker, Northern New Jersey Gimbel MS Center, “Update on MS”, Teaneck, NJ, December 18, 1996. 148. Invited Speaker, Dinner Seminar Sponsored by the Medical College of Georgia/National MS Society, “Treatment of MS”, Augusta, GA, January 21, 1997. 149. Invited Speaker, Dept. Of Neurology, Medical College of Georgia, “New Directions in the Management of MS”, Augusta, GA, January 21, 1997. 150. Invited Speaker, Neurology Grand Rounds, “New Directions in the Management of MS”, University of Vermont/Fletcher-Allen Health Center, Burlington, VT, January 23, 1997. 151. Invited Speaker, Neurology Grand Rounds, Vanderbilt University Medical Center, “MS”, Nashville, TN, January 24, 1997. 152. Invited Speaker, Dinner Seminar, “MS”, Needham, MD, February 3, 1997. 153. Guest Speaker, Lahey Clinic, “New Directions in the Management of MS”, Needham, MA, February 4, 1997. 154. Invited Speaker, Neurology Grand Rounds, “Neurologic Lyme Disease”, University of Calgary, Alberta, Canada, February14, 1997. 155. Invited Speaker, Neurology Grand Rounds, “MS”, University of Texas HSC, San Antonio, TX, February 27, 1997. 156. Invited Speaker, Neurology Grand Rounds, “New Directions in the Management of Multiple Sclerosis” LSU Medical Center, Shreveport, LA, February 28, 1997. 157. Invited Speaker, Dinner Seminar, “MS”, Biloxi, MS, March 3, 1997. 158. Invited Speaker, Dinner Seminar, “MS”, Glen Cove, NY, March 4, 1997. 159. Invited Speaker, “Medical Management of the Patient with MS”, Symposium on MS and Quality of Life: The Search for New Directions, Columbia Presbyterian Medical Center, March 11, 1997. 160. Invited Speaker, Local Carolinas Chapter of the National MS Society, Charleston, SC, March 17, 1997. 161. Invited Speaker, Neurology Grand Rounds “MS”, Medical University of South Carolina, Charleston, SC, March 17, 1997. 162. Invited Speaker, “MS”, Local MS Chapter, Boston, MA, March 18, 1997. 163. Invited Speaker, Neurology Grand Rounds, “Lyme Disease”, Johns Hopkins Medical School, Baltimore, MD, March 20, 1997. 164. Invited Speaker, Neurology Grand Rounds, “MS”, University of Virginia Medical Center, Charlottesville, VA, March 21, 1997.

52

165. Invited Speaker, Conference on MS, “Issues in Diagnosis, Classification and Prognosis”, Atlanta, GA, March 21, 1997. 166. Invited Speaker, Dinner Seminar MS, Travis Air Force Base, Sacramento, CA, March 27, 1997. 167. Invited Speaker “MS”, Richland Hospital, Columbia, SC, April 2, 1997. 168. Invited Speaker, MS Treatment Options, Local Chapter of National MS Society, Columbia, SC, April 2, 1997. 169. Invited Speaker, Fairfield County Neurologic Association, “Treatment of MS”, Ridgefield, CT, April 3, 1997. 170. Invited Speaker, Medical Grand Rounds “MS”, Salem VA Medical Center, Salem, VA, April 8, 1997. 171. Invited Speaker, St. Joseph’s Hospital Conference on “Current Strategies for Management of the MS Patient”, Savannah, GA, April 23, 1997. 172. Invited Speaker, Alabama Chapter of the National MS Society, Birmingham, AL, April 24, 1997. 173. Invited Speaker, Delaware Valley Chapter of MS Society, “MS Update”, Philadelphia, PA, May 1, 1997. 174. Invited Speaker, Arizona MS Chapter 1997 Teleconference, “MS”, Phoenix, AZ, May 17, 1997. 175. Invited Speaker, Las Vegas MS Chapter 1997 Teleconference, “MS”, Las Vegas, NV, May 17, 1997. 176. Invited Speaker, Mississippi MS Chapter “MS”, Jackson, MS, May 19, 1997. 177. Invited Speaker, Iowa City Chapter of National MS Society, Iowa City, IA, May 22, 1997. 178. Invited Speaker, Neurology Grand Rounds, University of Iowa Medical School, “MS”, Iowa City, IA, May 23, 1997. 179. Invited Speaker, Dinner Program, “MS”, Waterbury, CT, May 28, 1997. 180. Invited Speaker, MS Symposium, Atlanta, GA, May 29, 1997. 181. Invited Speaker, Meeting on Management of MS in the Era of Immunotherapy, Oak Brook, IL, June 4, 1997. 182. Invited Speaker, Dinner-Conference on Design and Methodology of Clinical Trials in Neurological Diseases, New Jersey Neuroscience Institute, JFK Hospital, Edison, NJ, June 11, 1997. 183. Invited Speaker, Dinner Seminar, “MS”, Los Angeles, CA, June 16, 1997. 184. Invited Speaker, Neurology Grand Rounds “MS”, University of Southern California, Los Angeles, CA, June 17, 1997. 53

185. Invited Speaker, Dinner Seminar, “MS”, Pasadena, CA, June 17, 1997. 186. Invited Speaker, Neurology Grand Rounds “Lyme Disease”, Loma Linda University, Loma Linda, CA, June 18, 1997. 187. Invited Speaker, “MS” Dinner Symposium, Hyde Park, NY, June 19, 1997. 188. Invited Speaker, National Symposium: Distinctive Approaches Needed for Life-Time Care, “MS”, July 10-12, 1997. 189. Invited Speaker, Annual Meeting and Education Seminar of the Florida Society of Neurology, “MS”, Naples, FL, July 10-13, 1997. 190. Invited Speaker, Middletown MS Chapter, “MS”, Middletown, NY, July 15, 1997. 191. Invited Speaker, 21st Annual Virginia Beach Update in Neuroscience, “MS”, Virginia Beach, VA, July 16-19, 1997. 192. Invited Participant, Copaxone Core Consultants Meeting, Kansas City, MO, July 17-19, 1997. 193. Invited Speaker, “MS”, MSSA Chapter, Bellevue, WA, July 22, 1997. 194. Invited Speaker, “MS” MSSA Chapter, Seattle, WA, July 22, 1997. 195. Invited Speaker, Breakfast Seminar “MS”, Edmonds, WA, July 23, 1997. 196. Invited Speaker, MSAA Western Region Annual Conference 1997, “MS Update”, Helena MT, August 16, 1997. 197. Invited Speaker, 8th Annual Vermont Summer Conference, University of Vermont, College of Medicine, “MS” and workshop on “The Practical Neurologic Exam” Burlington, VT, August17-19, 1997. 198. Invited Speaker, 1997 Pathogenesis of Neuroimmunologic Diseases Course, “Neuroimmunology of Lyme Disease”, Woods Hole, MA, August 29, 1997. 199. Invited Speaker and Session Moderator, Preconference Workshop on Optimizing Care for Patients with Multiple Sclerosis, a Multidisciplinary Approach Consortium of Multiple Sclerosis Centers, “Diagnosis, Classifications, Prognosis”, and Conference Workshop “Fatigue in MS”, Calgary, Canada, Sept 4-7, 1997. 200. Invited Speaker, Grand Rounds Kalispell Regional Medical Center “MS”, Kalispell, MT, September 8, 1997. 201. Invited Speaker, MS Society of Montana “MS”, Kalispell, MT, September 8, 1997. 202. Invited Speaker “MS Treatment Options”, South Florida Chapter, National MS Society, North Dade, FL, September 11, 1997. 203. Invited Speaker, Dinner Seminar “MS Therapy”, North Dade, FL, September 11, 1997. 204. Invited Speaker, Kaiser Permanente Seminar on “MS”, Orange, CA, September 20, 1997. 54

205. Invited Speaker, Neurology Grand Rounds, “Lyme Disease,” University of Massachusetts Medical Center, Worcester, MA, Sept 22, 1997. 206. Invited Speaker, Dinner Seminar on MS, Panama City, FL, September 25, 1997. 207. Invited Speaker, “MS Treatment Options 1997", Symposium sponsored by the National MS Society Local Chapter, Cincinnati, OH, October 1, 1997. 208. Invited Speaker, “MS” Medical Grand Rounds, Christ Hospital, Cincinnati, OH, October 2, 1997. 209. Invited Speaker, “MS” Grand Rounds, Frankfurt Hospital, Philadelphia, PA, October 7, 1997. 210. Invited Speaker, “MS” St. Joseph’s Hospital and Georgia MS Chapter, Savannah, GA, October 9, 1997. 211. Invited Speaker, “Overview of MS”, Greenville Education Conference, sponsored by the National MS Society, October 11, 1997. 212. Invited Speaker, “MS”, Dinner Seminar, Wichita, KS, October 14, 1997. 213. Invited Speaker, Dinner Seminar on “MS”, Morris Plains, NJ, October 15, 1997. 214. Invited Speaker, “MS: Women’s Issues”, Multiple Sclerosis Update 1997, Houston Marriott Medical Center Hotel, Houston, TX, October 17, 1997. 215. Invited Speaker, “Treatment of MS”, MS Educational Update, Youngstown, OH, October 18, 1997. 216. Keynote Speaker, “Understanding Your MS Treatment Options”, 1997 National MS Society Vermont Chapter Annual Meeting, Burlington, VT, October 20, 1997. 217. Invited Speaker, “Measures for Assessing Disease Activity,” Conference in Management of MS in the Era of Immunotherapy, Houston, TX, October 22, 1997. 218. Invited Speaker, “Multiple Sclerosis”, Rhode Island Chapter of NMSS, Warwick, RI, October 23, 1997. 219. Keynote Speaker on “Multiple Sclerosis: Research and Treatment Options”, 1997 Annual Meeting & Research Night Gateway Chapter of the NMSS, St. Louis Annual Meeting, St. Louis, MO, October 24, 1997. 220. Invited Speaker, Dinner Program on “MS”, Springfield, MA, October 27, 1997. 221. Invited Speaker, “MS Update”, Alabama Chapter Annual Meeting, Birmingham, AL, October 30, 1997. 222. Invited Participant and Speaker, “Markers for Neurologic Involvement” Molecular Immunobiology of Lyme Disease- The Banbury Center Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, November 2-5, 1997. 223. Invited Speaker, “Dinner Seminar on MS”, Charlotte, NC, November 6, 1997. 55

224. Invited Speaker, MS Self Help Group Leader Retreat, Charlotte, NC, November 7, 1997. 225. Keynote Speaker, “MS Research and Treatment” Annual Meeting of the Central Carolinas MS Chapter, Charlotte, NC, November 8, 1997. 226. Invited Lecturer, “Lyme Disease”, Neurology Grand Rounds, New York Hospital Cornell Medical Center, New York, NY, November 12, 1997. 227. Invited Speaker, AMS Connection: A forum for Patients’ “Speaker Training Workshop”, sponsored by Berlex Laboratories, Dallas, TX, November 14-16, 1997. 228. Invited Speaker, “Update on MS Treatment”, Texas Neuroscience Institute, San Antonio, TX, November 21, 1997. 229. Invited Speaker, Grand Rounds “MS”, Deaconess Hospital, Evansville, IN, December 2, 1997. 230. Invited Speaker, Greater New Jersey MS Chapter Gimbel MS Center Holiday Symposium, “MS”, Holy Name Hospital, Teaneck, NJ, December 10, 1997. 231. Invited Speaker, MS Educational Resource Panel Meeting, “MS Classification”, Teva Marion Partners, Jacksonville, FL, December 13, 1997. 232. Invited Speaker, Neurology Grand Rounds, “MS” University of Washington, Seattle, WA, December 18, 1997. 233. Invited Speaker, Neuroscience Grand Rounds “MS”, Abington General Hospital, Abington, PA, January 12, 1998. 234. Keynote Speaker/Work Shop Coordinator Annual Meeting, Middle Tennessee MS Chapter, “MS Symptomatic Management”, “Care Giver Issues”, January 17, 1998. 235. Invited Speaker, Neurology Grand Rounds, “MS Update”, Hospital Notre-Dame, Montreal, Quebec, January 22, 1998. 236. Invited Speaker Neurology Grand Rounds, “MS Update”, “Lyme Disease” University of Sherbrooke, Quebec, Canada, January 23, 1998. 237. Invited Speaker Evansville MS Support Group, St. Mary’s Hospital, Evansville, IN, February 2, 1998. 238. Invited Speaker, Grand Rounds “MS”, Welborn Hospital, Evansville, IN, February 3, 1998. 239. Visiting Professor University of Arkansas, Little Rock, AR, February 12-13, 1998. 240. Invited Speaker, Neurology Grand Rounds “MS”, Medical College of Virginia Richmond, VA, March 5, 1998. 241. Invited Speaker, Grand Rounds “MS” St. Joseph’s Hospital, Denver, CO, March 6, 1998. 242. Invited Speaker, “MS Update”, Denver MS Society, Denver, CO, March 6, 1998. 243. Invited Speaker, Dinner Seminar “MS Treatment Options”, Minneapolis, MN, March 10, 1998. 56

244. Invited Speaker, Dinner Program on MS, Chicago, IL, March 12, 1998. 245. Invited Speaker, Neurology Grand Rounds, “MS”, University of Wisconsin at Madison, Madison, Wisconsin, WI, March 13, 1998. 246. Invited Speaker, San Diego Neurological Society, “MS Update”, San Diego, CA, March 19, 1998. 247. Invited Speaker, Neurology Grand Rounds, “MS Therapy”, University of California, San Diego, CA, March 20, 1998. 248. Invited Speaker, Dinner Seminar “MS”, Costa Mesa, CA, March 25, 1998. 249. Invited Speaker, National MS Society Local Chapter, Dinner Program “MS”, Sacramento, CA, March 26, 1998. 250. Invited Speaker, Neurology Grand Rounds, “Lyme Disease”, UC Davis, Sacramento, CA, March 27, 1998. 251. Invited Speaker, Patient Program “MS in the Next Millenium”, New York, NY, March 28, 1998. 252. Invited Speaker, “Symptomatic Management of MS”, Program on New Directions in the Management of MS, Lewis-Gale Medical Center, Roanoke, VA, April 4, 1998. 253. Invited Speaker, Neurology Grand Rounds, “Lyme Disease”, University British Columbia, Vancouver, BC, Canada, April 8, 1998. 254. Invited Speaker, Luncheon and Dinner Programs on MS, Las Vegas, NV, April 15, 1998. 255. Invited Speaker, Dinner Program “MS”, Tampa, FL, April 16, 1998. 256. Invited Speaker, Dinner Program on “MS”, Lansing, MI, April 17, 1998. 257. Keynote Speaker, Central Michigan MS Chapter, Symposium on MS, Lansing, MI, April 18, 1998. 258. Invited Speaker, Dinner Seminar on MS, St. James, NY, May 5, 1998. 259. Invited Speaker, 21st Century Neurology Conference, “MS”, Palm Beach Gardens, FL, May 14, 1998. 260. Invited Speaker, National Weekend Meeting, MS: Clinical Issues & Decisions, Chicago, IL, May 15-17, 1998. 261. Invited Speaker, Dinner Seminar “MS Update”, Dallas, Texas, May 28, 1998. 262. Keynote Speaker, “Current Treatments and Therapies in MS”, 1998 Health Care Symposium, Wisconsin Chapter National MS Society, Madison, WI, May 29, 1998. 263. Invited Speaker, Symposium on “Living with MS”, Potomat Hospital, Woodbridge, VA, June 20, 1998.

57

264. Invited Speaker, 1998 Family Weekend Kentucky MS Chapter “MS Therapies, Lexington, KY, June 27, 1998. 265. Invited Speaker, Dinner Seminar, “MS Update”, Lexington, KY, June 27, 1998. 266. Invited Speaker “management of MS in the Era of Immunotherapy”, Miami, FL, July 16, 1998. 267. Invited Speaker, MS Pathways Forum, “Therapy of MS”, Concord, CA, July 19, 1998. 268. Invited Speaker, Moving Forward Symposium, Northwest Ohio Chapter, National MS Society, Toledo, OH, July 25, 1998. 269. Invited Speaker, Weekend Conference on “Multiple Sclerosis: Clinical Issues & Decisions”, San Francisco, CA, July 31-August 2, 1998. 270. Invited Speaker, “A Patient Centered Therapeutic Framework for Multiple Sclerosis: An International Conference on Models of Care”, Dallas, TX, August 5-7, 1998. 271. Invited Speaker, Update on Multiple Sclerosis, sponsored by University of South Florida, Key West, FL, August 8 & 9, 1998. 272. Invited Speaker, Dinner Program on MS, Cleveland, OH, August 14, 1998. 273. Invited Speaker, Summer Educational Symposium on MS, Northeast Ohio Chapter, Cleveland, OH, August 15, 1998. 274. Invited Speaker, Dermatology Grand Rounds “Case Presentations and Discussion”, SUNY at Stony Brook, NY, September 3, 1998. 275. Invited Speaker, Dinner Seminar “MS”, Baton Rouge, LA, September 9, 1998. 276. Invited Speaker, “MS” Patient Program, Baton Rouge, LA, September 10, 1998. 277. Invited Speaker, “MS” Dinner Program, Milwaukee, WI, September 15, 1998. 278. Invited Speaker, “MS” Neurology Rounds, St. Mary’s Hospital, Madison, WI, September 16, 1998. 279. Invited Speaker, Kentucky Medical Association, “Case Discussions on MS”, Louisville, KY, September 23, 1998. 280. Invited Speaker, Kentucky Chapter of National MS Society, “MS”, Louisville, KY, September 23, 1998. 281. Invited Speaker, Patient Program “MS”, Athens Regional Medical Center, Athens, GA, September 26, 1998. 282. Invited Speaker, Neurology Grand Rounds “MS”, University of Oklahoma, Oklahoma City, OK, September 29, 1998. 283. Invited Speaker, Dinner Seminar “MS”, Bloomfield Hills, MI, October 2, 1998.

58

284. Keynote Speaker, Michigan Chapter National MS Society Annual Meeting and Teleconference, Ipsilanti, MI, October 3, 1998. 285. Invited Speaker, Workshop on “IFNβ-1b Treatment for MS”, Consortium of MS Center Meeting, Cleveland, OH, October 4, 1998. 286. Invited Speaker, Conference on “Women and MS: Fulfilling Possibilities”, Alabama Chapter, Birmingham, AL, October 10, 1998. 287. Invited Speaker, Neurology Grand Rounds “MS”, Toronto Western Division Hospital, Toronto, Canada, October 13, 1998. 288. Keynote Speaker, Annual Meeting of the Toronto Chapter MS Society of Canada, Toronto, Canada, October 13, 1998. 289. Invited Speaker, Symposium on the Transition from Relapsing to Progressive Multiple Sclerosis: Reasons Why & Clinical Implications, “Identifying Patient at High Risk for MS”, Dinner Program, Montreal, Canada, October 17, 1998. 290. Invited Speaker, Postgraduate Medicine Conference, “Lyme Disease & Chronic Fatigue Syndrome”, Columbia Presbyterian Medical Center, Manhattan, NY, October 17, 1998. 291. Invited Speaker, Dinner Seminar on “MS”, New York, NY, October 22, 1998. 292. Invited Speaker, Lone Star Chapter National MS Society Annual Meeting and Educational Conference, Houston, TX, October 24, 1998. 293. Invited Speaker, IBC’s International Conference “Therapeutic Issues in CNS Infection”, Cambridge, MA, October 26-27, 1998. 294. Invited Speaker, Dinner Seminar on “MS”, Fulton, PA, November 3, 1998. 295. Invited Speaker, Dinner Program on MS, Charlotte, NC, November 6, 1998. 296. Keynote address, Annual Meeting of the Mid Atlantic Chapter, NMSS, Charlotte, NC, November 6-7, 1998. 297. Invited Speaker, Neurology Grand Rounds, SUNY-Upstate, Syracuse, NY, November 11, 1998. 298. Invited Speaker, Syracuse Chapter, National MS Society, Syracuse, NY, November 11, 1998. 299. Invited Speaker, Annual Meeting of the Delaware NMSS Chapter, Wilmington, DE, November 14, 1998. 300. Invited Lecturer, “MS Into the Millennium: A Peek into the Future”, Hospital for Joint Diseases, New York, NY November 24, 1998. 301. Teleconference New York, NY MS Program, December 1, 1998. 302. Invited Speaker, Symposium Management of MS in the Era of Immunotherapy, Halifax, Nova Scotia, December 5, 1998. 59

303. Invited Speaker, Dinner Seminar on MS, Detroit, MI, December 8, 1998. 304. Invited Speaker, Dinner Seminar on MS, York, Maine December 16, 1998. 305. Invited Speaker, Grand Rounds, “Diagnosis of MS”, Maine Medical Center, Portland, ME December 17, 1999. 306. Teleconference, Questions and Answers on MS, January 13, 1999. 307. Invited Speaker, 19th Annual A.B. Baker Lecture, “MS at the Millennium”, Dept. of Neurology, University of Minnesota. 308. Teleconference, MS Treatment Options, Columbus, OH, February 1, 1999. 309. Consultant, TEVA Pharmaceuticals USA, Oral Copaxone Study, Philadelphia, PA February 2, 1999. 310. Invited Speaker, “MS” and “Lyme Disease”, University of Miami Neurologic Update 1999, Miami Beach, FL, February 3-6, 1999. 311. Invited Speaker, “MS Update”, Neurology Grand Rounds, UC Davis Medical Center, Sacramento, CA, February 11, 1999. 312. Invited Speaker, “MS”, Dinner Seminar, Sacramento, CA February 11, 1999. 313. Invited Speaker, “MS Update”, Bronson Gillmore Center, Kalamazoo, MI, February 16, 1999. 314. Invited Speaker, Dinner Seminar “MS” Salt Lake City, UT, February 19, 1999. 315. Invited Speaker, Utah State Chapter NMSS Neurology Diagnostic Seminar, Salt Lake City, UT, February 20, 1999. 316. Invited Speaker, New Development in the Treatment of MS, Martin Memorial Health Systems, Stuart, FL, February 24, 1999. 317. Invited Participant, Workgroup Meeting-Serodiagnosis of Lyme Disease, Centers for Disease Control and Prevention, Ft. Collins, CO, February 25-26, 1999. 318. Invited Speaker, Dinner Program on MS, Danville, PA March 25, 1998. 319. Invited Speaker, Neurology Grand Rounds “MS”, Geisinger Medical Center, Danville, PA, March 26, 1999. 320. Invited Speaker, MS Pathways Forum, Marina Del Rey, CA, February 27, 1999. 321. Invited Speaker, MS Support Group, Tucson, AZ, March 2, 1999. 322. Invited Speaker, “MS” Medical Staff Meeting of Carondelet St. Joseph’s Hospital, Tucson, AZ, March 2, 1999. 323. Invited Speaker, Dinner Program on “MS”, Tucson, AZ, March 2, 1999. 324. Invited Speaker, Hoag Hospital Grand Rounds “MS”, Newport Beach, CA, March 3, 1999. 60

325. Invited Speaker, Dinner Program on MS, Anaheim, CA, March 3, 1999. 326. Invited speaker, Dinner program on MS, USC, Los Angeles, CA, March 4, 1999. 327. Invited Speaker, Neurology Grand Rounds, King Drew Medical Center, Los Angeles, CA, March 4, 1999. 328. Invited Speaker, Dinner Program on MS, Long Beach, CA, March 4, 1999. 329. Invited Speaker, Neurology Grand Rounds, Harbor UCLA Medical Center, Carson, CA, March 5, 1999. 330. Invited Speaker, MS Educational Symposium, Appleton, WI, March 6, 1999. 331. Invited Speaker, Patient Program on “MS”, Worcester, MA, March 11, 1999. 332. Invited Speaker, Neurology Grand Rounds “Lyme Disease” St. Vincent’s Hospital, Worcester, MA, March 11, 1999. 333. Invited Speaker, Dinner Program on “MS”, Worcester, MA, March 11, 1999. 334. Invited Participant, Immunex Thought Leaders Neuroscience Advisory Meeting, Scottsdale, AZ, March 12-14, 1999. 335. Invited Speaker, Dinner Program on MS, Springfield, MA, March 16, 1999. 336. Invited Speaker, Patient Program, “MS”, Greenville, NC, March 18, 1999. 337. Invited Speaker, Neurology Grand Rounds, East Carolina University School of Medicine, Greenville, NC, March 19, 1999. 338. Invited Speaker, Northern Colorado Chapter of NMSS, MS Newly Diagnosed Seminar, Ft. Collins, CO, March 20, 1999. 339. Invited Speaker, Dinner Seminar on MS, Ft. Collins, CO, March 20, 1999. 340. Invited Speaker, Neurology Grand Rounds, Northwestern Medical School, “Hormones and the Immune System”, March 23, 1999. 341. Invited Speaker, Dinner Seminar on MS, Chicago, IL, March 23, 1999. 342. Invited Speaker, Neurology Grand Rounds on MS, Geisinger Medical Center, Danville, PA, March 26, 1999. 343. Invited Speaker, Indiana MS Chapter “MS”, Indianapolis, IN, April 7, 1999. 344. Invited Speaker, Southern New York Chapter NMSS “MS Management Update and Sexual Changes in MS” Beacon, NY, April 8, 1999. 345. Invited speaker, Dinner program on MS, Danville, PA, March 25, 1999. 346. Invited Speaker, New Perspectives on Multiple Sclerosis, Litchfield Park, AZ April 9-11, 1999. 61

347. Invited Speaker, Dinner Program on MS, Greensboro, NC, April 13, 1999. 348. Invited Speaker, Patient Program on MS, Greensboro, NC, April 14, 1999. 349. Invited Speaker, “MS Update” Fairfield County Neurological Society, Fairfield County, CT April 15, 1999. 350. Invited Speaker, Symposium on the immunopathogenesis and treatment of MS, Bethesda, MD, April 16, 1999. 351. Invited Speaker, Dinner Seminar, “MS update, Pittsburg, PA, April 27, 1999. 352. Invited Speaker, MS Management, University of Pittsburgh Medical Center, Pittsburgh, PA, April 28, 1999. 353. Invited Speaker, Dinner Program on MS, Columbus, OH, April 30, 1999. 354. Invited Speaker, Patient Program on MS, Columbus, OH, May 1, 1999. 355. Invited Speaker, Neurology Grand Rounds “MS Update”, University of Texas Medical School, Houston, TX, May 7, 1999. 356. Consultant, Teva Marion Partners, May 7, 1999. 357. Invited Speaker, Member Educational Conference, Huntington Hilton, May 8, 1999. 358. Invited Speaker, Dinner Program “MS”, Lucern Inn, Bangor, ME, May 14, 1999. 359. Invited Speaker, Northern Maine Symposium, Bangor, ME May 15, 1999. 360. Invited Speaker, Dinner Program on MS, Orlando, FL May 18, 1999. 361. Invited Speaker, Dinner Seminar on MS, Ft. Lauderdale, FL May 19, 1999. 362. Invited Speaker, “MS Update”, New Directions in the Management of Multiple Sclerosis, Long Island Chapter, Huntington, NY, June 14, 1999. 363. Invited Speaker, “MS, You, Family and Friends”, Long Island Chapter, NMSS Educational Program, June 15, 1999. 364. Invited Speaker, “MS Update”, MS Patient Program, Good Samaritan Hospital, Dayton, OH, June 19, 1999. 365. Invited Speaker, “MS” MS Patient Program, Long Island MS Chapter, Oceanside, NY, June 22, 1999. 366. Neurology Grand Rounds, “MS and Its Masquerades: Diagnostic Dilemmas”, SUNY at Stony Brook, Stony Brook, NY, July 6, 1999. 367. Invited Speaker, “MS Update”, Annual Meeting of the Florida Society of Neurology, Vero Beach, FL, July 8-11, 1999. 368. Invited Speaker, Current Review: Multiple Sclerosis, “MRI and MS”, “Clinical Neuroimmunology”, Orlando, FL, July 9-11, 1999. 62

369. Invited Speaker, “Family Weekend” Indiana Chapter, NMSS, Evansville, IN, July 24, 1999. 370. Invited Lecturer, “MS Treatment Options”, Dallas, TX, August 9, 1999. 371. Invited Lecturer, “New Directions in the Management of Multiple Sclerosis”, Dinner Seminar on MS, Fort Worth, TX, August 10, 1999. 372. Invited Lecturer, Neurology Grand Rounds “Multiple Sclerosis”, Baylor Medical Center, Dallas, TX, August 10, 1999. 373. Invited Speaker, “Lyme Disease”, Pathogenesis of Neuroimmunology Diseases Course, Marine Biological Laboratory, Woods Hole, MA, August 26, 1999. 374. Teleconference, NMSS Eastern North Carolina Chapter, Raleigh, NC, September 2, 1999. 375. Invited Speaker, Dinner Seminar on MS, Charleston, WV, September 7, 1999. 376. Invited Speaker, Neurology Grand Rounds, “MS Update”, Charleston, WV, September 8, 1999. 377. Invited Speaker, “MS”. Kehering Neuro Science Institute, Kehering, OH, September 8, 1999. 378. Invited Speaker, North Florida Chapter NMSS Research Symposium on MS, Jacksonville, FL, September 9, 1999. 379. Invited Speaker, “MS Update”, Second Annual Meeting of the Tri-City Neuroscience Group, Saginaw, MI, September 10,1999. 380. Invited Speaker, Education Day on MS, Augusta, GA September 11, 1999. 381. Invited Speaker, International Conference, “The Pathology of MS: Implications for Disease Management”, ECTRIMS/ACTRIMS, Basel, Switzerland, September 15-18, 1999. 382. Invited Speaker, Neurology Grand Rounds, Owensboro Mercy Medical Center, Owensboro, KY, September 20, 1999. 383. Invited Speaker, MS Chapter Meeting, “Therapeutic Options”, Owensboro Mercy Medical Center, Owensboro, KY, September 20, 1999. 384. Invited Speaker, Allied Healthcare Professionals Meeting, Mid Atlantic, Eastern North Carolina and Central North Carolina MS Chapters, Charlotte, NC, September 22, 1999. 385. Invited Speaker, Neurology Grand Rounds, University of Alberta Hospital, Edmonton, Alberta Canada, September 24, 1999. 386. Invited Speaker, Education Day, Iowa and Illinois MS Chapters, Davenport, IA, September 25, 1999. 387. Neurology Grand Rounds, “Chronic Meningitis”, SUNY at Stony Brook, Stony Brook, NY, October 5, 1999. 388. Invited Speaker, Dinner Seminar on MS, Jackson, MS, October 6, 1999. 63

389. Invited Speaker, Neurology Grand Rounds, University of Mississippi Medical School, University Medical Center, Jackson, MS, October 7, 1999. 390. Invited Participant, Progressive MS Consensus Roundtable, Four Seasons Olympic Hotel, Seattle, WA, October 9, 1999. 391. Invited Speaker, “Neuroimmunology”, XVIII International Symposium of the Fulton Society, Seattle, WA, October 10, 1999. 392. Keynote Speaker, “Interferon-beta treatment in Multiple Sclerosis”, Annual Meeting of the Finish Neurologic Society, Tampere, Finland, October 12, 1999. 393. Invited Participant, MS at the Millennium: Evolving Trends in Science and Therapeutics. An Expert Roundtable. Woodmark Hotel, Kirkland, WA, October 14, 1999. 394. Invited Speaker, “MS Update”, Rhode Island Neurological Association, Providence, RI, October 19, 1999. 395. Invited Speaker, Neurology Grand Rounds, “Lyme Disease”, Brown University School of Medicine, Rhode Island Hospital, Providence, RI, October 20, 1999. 396. Invited Speaker, “MS Update”, Local MS Patient Program, Greenville, SC, October 21, 1999. 397. Invited Speaker, Lunch Meeting on MS, Orangeburg, SC, October 22, 1999. 398. Keynote Speaker, “MS at the Millenium”, Mid-Atlantic Chapter of the NMSS, Charleston, NC, October 23, 1999. 399. Invited Speaker, “Neuroimmunology and Hormones: New Thoughts Regarding Multiple Sclerosis”, Symposium on Update on Women’s Health: Neurological Disease in Women, St. John’s Mercy Medical Center, November 3, 1999. 400. Teleconference, “MS, Stress & Holidays-SuperWoman Syndrome”, MS Pathways, November 4, 1999. 401. Keynote Speaker, “Gender Issues and MS: What Do We Know?”, Symposium on Women and MS: Fulfilling Possibilities”, Alabama Chapter of the NMSS, Mobile, AL, November 6, 1999. 402. Invited Speaker, “MS Update”, Michigan MS Chapter Patient Conference, Corner Stone College, Grand Rapids, MI, November 8, 1999. 403. Invited Speaker, Dinner Seminar on MS, Phoenix, AZ, December 2, 1999. 404. Invited Speaker, Neurology Grand Rounds, Barrow Neurological Institute, St. Joseph’s Hospital, Phoenix, AZ, December 3, 1999. 405. Invited Speaker, Neurology Grand Rounds, “Lyme Disease”, St. Louis University Medical Center, St. Louis, MO, December 9, 1999. 406. Invited Speaker, Neurology Grand Rounds, “MS Update”, Thomas Jefferson University, Philadelphia, PA, December 17, 1999. 64

407. Invited Speaker, Midwest MS Chapter, NMSS “MS”, Edison, NJ, January 15, 2000. 408. Invited Speaker, “MS update” Colorado Springs MS Chapter, Colorado Springs, CO, January 21, 2000. 409. Invited Speaker, Colorado NMSS Chapter “MS update”, Pueblo, CO, January 21, 2000. 410. Invited Speaker, Program on rehabilitation in MS, Colorado NMSS Chapter, Denver, CO, January 22, 2000. 411. Invited Speaker, Neurology Grand Rounds, “MS”, Albany Medical Center, Albany, NY, January 27, 2000. 412. Invited Speaker, “MS” Primary care conference, Sunrise Hospital, Las Vegas, NV, January 28, 2000. 413. Invited Speaker, MS support group, Las Vegas, NV, January 29, 2000. 414. Invited Speaker, Dinner seminar “MS”, Portsmouth, NH, January 31, 2000. 415. Invited Speaker, Grand Rounds, “MS”, Portsmouth Regional Hospital, Portsmouth, NH, February 1, 2000. 416. Invited Speaker, Dinner seminar MS, Lebanon, NH, February 10, 2000. 417. Invited Speaker, Neurology Grand Rounds, “MS”, Dartmouth-Hitchcock Medical School, Lebanon, NH, February 11, 2000. 418. Invited Speaker, Neurology Grand Rounds, “MS”, Holy Name Hospital, Teaneck, NJ, February 15, 2000. 419. Invited Speaker, Dinner seminar MS, Raleigh, NC, February 15, 2000. 420. Invited Speaker, Neurology Grand Rounds, “MS”, University of North Carolina Medical School, Chapel Hill, NC, February 16, 2000. 421. Invited Speaker, Dinner seminar on MS, Bedford, NH, February 17, 2000. 422. Invited Speaker, Dinner seminar on MS, Myrtle Beach, SC, February 25, 2000. 423. Invited Speaker, MID Carolinas chapter, NMSS “MS”, Myrtle Beach, SC, February 26, 2000. 424. Invited Speaker, 23rd annual gold coast conferences “MS”, Palm Beach, FL, February 2729, 2000. 425. Invited Speaker, Dinner seminar on MS, Cincinnati, OH, March 6, 2000. 426. Invited Speaker, Dinner program on MS, Wichita Falls, TX, March 7, 2000. 427. Invited Speaker, Patient program on MS, Wichita Falls, TX, March 7, 2000. 428. Invited Speaker, Neurology Grand Rounds “MS”, University of Vermont, Burlington, VT, March 9 2000. 65

429. Invited Speaker, patient program on MS, St. Joseph’s hospital, Savannah, GA, March 11 2000. 430. Invited Speaker, Grand Rounds, “MS update”, Abington Hospital, Abington, PA, March 13, 2000. 431. Invited Speaker on MS, Farmington, CT, March 15, 2000. 432. Invited Speaker, Neurology Grand Rounds, “MS update”, Hartford Hospital, Hartford, CT, March 16, 2000. 433. Invited Speaker, Dinner Seminar, “MS”, Merrillville, IN, March 17, 2000. 434. Invited Speaker, Indiana MS chapter, “MS”, Merrillville, IN, March 17, 2000. 435. Invited Speaker, Dinner Program on MS, Boston, MA, March 20, 2000. 436. Invited Speaker, Neurology Grand Rounds, “MS update”, Boston University School of Medicine, Boston, MA, March 21, 2000. 437. Invited Speaker, patient program on MS, Newton, MA, March 21, 2000. 438. Invited Speaker, Neurology Grand Rounds, “MS update”, Cedars-Sinai Medical Center, Los Angeles, CA, March 23, 2000. 439. Invited Speaker, Dinner Program “neuroimaging in MS”, Beverly Hills, CA, March 23, 2000. 440. Invited Speaker, MS patient program, Thousand Oaks, CA, March 24, 2000. 441. Invited Speaker, Neurology Grand Rounds, “Progressive MS ”, West Los Angeles VA Hospital, West Los Angeles, CA, March 24, 2000. 442. Invited Speaker, “Multiple Sclerosis and Lyme Disease Update”, Southern California Kaiser Permanente, Santa Monica, CA, March 25, 2000. 443. Invited Speaker, neurology conference “MS”, Good Samaritan Hospital, Portland, OR, March 28, 2000. 444. Invited Speaker, Oregon MS Chapter, “MS”, Portland, OR, March 28, 2000. 445. Invited Speaker, Breakfast meeting on MS, Tacoma, WA, March 29, 2000. 446. Invited Speaker, lunch meeting “MS”, Seattle, WA, March 29, 2000. 447. Invited Speaker, patient program “MS”, Shoreline, WA, March 29, 2000. 448. Invited Faculty, weekend meeting, MS: Clinical issues & decisions. Puerto Rico, March 31April 2, 2000. 449. Invited Speaker, Strategies for identification and characterization of unknown pathogens, Cold Spring Harbor, NY, April 2-5, 2000. 450. Invited Speaker, Grand Rounds, “MS ”, Carolina’s Medical Center, Charlotte, NC April 6, 2000. 66

451. Invited Faculty, National Weekend Conference for Nurses, Las Vegas, NE, April 7-9, 2000. 452. Invited Speaker, Neurology Grand Rounds, “Lyme disease”, Johns Hopkins Medical School, Baltimore, MD, April 20, 2000. 453. Invited Speaker, Iowa MS Chapter, “MS update”, Cedar Rapids, IA, May 8, 2000. 454. Invited Speaker, Breakfast meeting on MS, Cedar Rapids, IA, May 9, 2000. 455. Invited Speaker, Neurology Grand Rounds, “MS update”, University of Iowa, Iowa City, IA, May 9, 2000. 456. Invited Speaker, State conference on MS, Iowa MS Chapter, Des Moines, IA, May 9, 2000. 457. Invited Speaker, Grand Rounds, “MS”, Mercy Hospital Medical center, Des Moines, IA, May 10, 2000. 458. Invited Speaker, Neurology Grand Rounds, “MS update”, Mount Auburn Hospital, Cambridge, MA, May 11, 2000. 459. Invited Speaker, Neurology Grand Rounds, “MS update”, Massachusetts General Hospital, Boston, MA, May 11, 2000. 460. Invited Speaker, 3rd annual MS awareness day, Central Florida Chapter, Vero Beach, Orlando, Sarasota, FL, May 12-13, 2000. 461. Invited Speaker, NMSS Central PA Chapter, Scranton, PA, May 30, 2000. 462. Invited Speaker, visiting professor lecture series at Genesys Regional Medical Center, Grand Blanc, MI, May 31, 2000. 463. Invited Speaker, Michigan MS Chapter “MS”, Saginaw, MI, May 31, 2000. 464. Invited Speaker, Grand Rounds, Hurley Medical Center, Flint, MI, June 1, 2000. 465. Invited Speaker, Michigan MS Chapter “MS”, Pigeon, MI, June 1, 2000. 466. Invited Speaker, the eighth annual congress on women’s health & gender-based medicine, SC, June 3-6, 2000. 467. Invited Speaker, Dinner Seminar on MS, Westport CT, June 6, 2000. 468. Invited Speaker, Neurology Seminar series, “MS update: AMGEN, Thousands Oaks, CA, July 7, 2000. 469. Invited Speaker, Dinner Seminar on MS, Huntington, WV, August 1, 2000. 470. Invited Speaker, Dinner Seminar on MS, San Francisco, CA, August 3, 2000. 471. Invited Speaker, Patient Program on MS, Santa Clara, CA, August 3, 2000. 472. Visiting Professor, Dept. of Neurology, University of Michigan health system, August 8-9, 2000. 67

473. Invited Speaker, “MS” MS Chapter support group, Southfield, MI, August 9, 2000. 474. Invited Speaker, “MS”, Providence Hospital, Southfield, MI, August 10, 2000. 475. Invited Speaker, Medical grand rounds, “Lyme disease”, Stamford Hospital, Stamford CT, August 23, 2000. 476. Invited Speaker, Neurology grand rounds, “Lyme disease”, New York university school of Medicine, New York, NY, September 1, 2000. 477. Invited Speaker, Dinner Program “spasticity”, Lexington, KY September 12, 2000. 478. Invited Speaker, Northern Maine MS Chapter “MS, Bangor, ME, September 20, 2000. 479. Invited Speaker, lunch meeting, gender issues in MS”, Portland, OR, September 22, 2000. 480. Invited Speaker, Oregon chapter MS, “symposium on MS”, Portland, OR, September 23, 2000. 481. Invited Speaker, 1st annual meeting of the American academy of immunotherapy, Washington DC, September 23-24, 2000. 482. Invited Speaker, Neurology Grand rounds, “secondary progressive MS”, Royal University hospital, Saskatchewan, Canada, September 26, 2000. 483. Invited Speaker, Neurology Grand rounds, “Lyme disease”, Royal university hospital, Saskatchewan, Canada, September 27, 2000. 484. Invited Speaker, Lyme disease: diagnosis, neurologic complications & management and treatment of SPMS: an update of recent clinical trials, Ontario, Canada, September 27, 2000. 485. Invited Speaker, Lyme disease, Ontario, Canada, September 28, 2000. 486. Invited Speaker, National education conference: MS research -2000 and beyond sponsored by national MS society, Boston, MA, October 18, 2000. 487. Invited Speaker, neuroscience grand rounds, “Rule of inflammation in the pathophysiology of MS”, Cooper university medical center, Camden, NJ, October 2000. 488. Invited Speaker, 2000 nursing conference: “nursing care in MS: progressive disease”, White Plains, NY, October 27, 2000. 489. Invited Speaker, dinner program on “selecting therapy in RR MS”, Boston MA, November 8, 2000. 490. Invited Speaker, dinner program on “MS masqueraders”, Winnipeg, Canada, November 16, 2000. 491. Invited Speaker, neuroscience ground rounds “Lyme disease” Health Sciences center, Winnipeg, Manitoba, Canada, November 17, 2000. 492. Invited Speaker, conference on MS: Clinical issues & decisions, Carlsbad, CA, December 13, 2000. 68

493. Keynote speaker, annual meeting, Long Island MS chapter, Woodbury, NY, December 4, 2000. 494. Invited Speaker, luncheon meeting on MS, Waukesha, WI, December 5, 2000. 495. Invited Speaker, dinner program on MS, Chicago, IL, December 5, 2000. 496. Invited Consultant, Teva Marion partner 2001, organizational meeting, New York, NY, December 5-6, 2000. 497. Invited Speaker, Mid Atlantic MS chapter patient program, Ashville, NC, December 7, 2000. 498. Invited Speaker, dinner program on MS, Oakbrook, IL, December 8, 2000. 499. Invited Speaker, Philadelphia Neurologic Society, “Lyme Disease”, Philadelphia PA, January 10, 2001. 500. Invited Speaker, dinner program “gender issues in MS”, Portland, OR, January 15, 2001. 501. Consultant, FDA vaccine panel, Lymerix vaccine, Bethesda MD, January 31, 2001. 502. Invited Speaker, patient program on MS, Augusta, GA, February 1, 2001. 503. Visiting professor, Medical college of Georgia, “new perspectives on MS”, Augusta, GA, February 1, 2001. 504. Invited Speaker, dinner program on MS, Harrisburg, PA, February 6, 2001. 505. Consultant, Bristol-myeus-squibb, February 6, 2001. 506. Invited Speaker, MS educator/speaker meeting, Teva Marion partners, Banff, Alberta, Canada, February 8-11, 2001. 507. Invited Speaker, dinner program on MS, Nasuua, NH, February 27, 2001. 508. Invited Speaker, Women neurologists’ MS initiative, New Orleans, LA, March 2-4, 2001. 509. Invited Speaker, dinner program on MS, Cincinnati, OH, March 6, 2001. 510. Invited Speaker, dinner program on MS, Merrillville, IN, March 16, 2001. 511. Invited Speaker, annual education program of Indiana MS chapter “MS”, Merrillville, IN March 17, 2001. 512. Invited Speaker, “update in neurology – 2001” dept. of neurology university of Oklahoma health sciences center “MS”, Oklahoma City, OK, March 15-16, 2001. 513. Invited participant, Neurology and psychiatry geriatric education retreat, St. John, U.S.V.I. March 25-31, 2001. 514. Invited co-chair, multiple sclerosis practical guidelines summit, Mclean VA, March 30-April 1, 2001. 69

515. Invited Speaker, dinner program on MS, Fairfield county neurological society, Stamford CT, April 2, 2001. 516. Invited Speaker, neurology center of Fairfax MS patient program, McLean VA, April 7, 2001. 517. Invited Speaker, Mid Atlantic chapter NMSS conference on “managing your MS-what’s new?” Greenville, SC, April 26, 2001. 518. Invited co-chair, conference on “MS: clinical issues & decisions”, Leesburg, VA, April 2729, 2001. 519. Invited Speaker, Mid Atlantic MS Chapter “Managing MS” Kingsport, TN, May 3, 2001. 520. Invited Speaker, patient program on MS, Dayton, OH, May 5, 2001. 521. Invited Speaker, Pennsylvania MS chapter, patient program on MS, Camp Hill, PA, May 12, 2001. 522. Invited Speaker, Delaware MS chapter annual research meeting, Wilmington, DE, May 16, 2001. 523. Invited Speaker, Dinner program on MS, Cleveland, OH, May 24, 2001. 524. Invited Speaker, Dinner program on MS, Moncton, Canada, May 24, 2001. 525. Invited Speaker, Workshops on “MS Masqueraders”, “Gender Issues in MS, 15th annual meeting of CMSC, Fort Worth, TX, May 31, 2001. 526. Invited Speaker, CMSC, 15th annual meeting satellite symposium (chair) on “the cost of delaying therapy”, workshops on “gender issues in MS”, “diagnostic dilemmas in MS”, Fort Worth, TX, May 31- June 3, 2001. 527. Invited Speaker, Neurology grand rounds-university of Washington “update on MS”, Seattle, WA, June 7, 2001. 528. Invited Speaker, Dinner Program, “Update on MS”, Seattle, WA, June 7, 2001. 529. Invited Speaker, Neurology grand rounds-Providence hospital, “general MS update”, Yakima, WA, June 8, 2001. 530. Invited Speaker, “facing challenges in management of MS: making a difference in issues that count”, Seattle, WA, June 9, 2001. 531. Invited Speaker, Dinner Program on MS, Huntington, NY, June 18, 2001. 532. Invited Speaker, Dinner Program on MS, Chicago, IL, June 28, 2001. 533. Moderator, MS Regional Advisory Meeting, Montreal, Canada, June 29-July 1, 2001. 534. Consultant, MS Advisory Meeting, Bermuda, July 26-28, 2001. 535. Invited faculty, MS treatment symposium, “Point…Counterpoint”, New York City, NY, July 28, 2001. 70

536. Invited Speaker, course on Pathogenesis of Neuroimmunologic Diseases “Lyme disease”, Woods Hole, MA, August 12-24, 2001. 537. Invited Speaker, TEVA neuroscience regional advisory meeting, 1) Review of the comparative Trials: a validation of phase III results, 2) Immunopathogenesis of MS, Anchorage, Alaska, August 23-26, 2001. 538. Invited Speaker, Dinner Program on MS, Ithaca, NY, August 29, 2001. 539. Invited Speaker, MS Dinner program, US Open, Flushing, NY, September 5, 2001. 540. Invited Speaker, Dinner program on MS, Kansas City, KS, September 6, 2001. 541. Invited Speaker, Neurology Grand Rounds, “MS”, University of Kansas Medical School, Kansas City, KS, September 6, 2001. 542. Invited speaker, Satellite symposium on MS, ECTRIMS-annual meeting, Dublin, Ireland, Sept 12-15, 2001. 543. Keynote speaker, “Women against MS”, Jacksonville, FL, September 19, 2001. 544. Keynote speaker, “Women against MS”, Tallahassee, FL, September 20, 2001. 545. Invited speaker, Program on MS, Mobile, AL, September 20, 2001. 546. Invited speaker, MS Research Dinner, Long Island Chapter, Manhasset, NY, September 25, 2001. 547. Invited speaker, Satellite Symposium, Italian Congress of Neurology, “EVIDENCE study on MS”, Rimini, Italy, October 1, 2001. 548. Invited speaker, Dinner program on MS, Nashville TN, October 4, 2001. 549. Invited speaker, Neurology Grand Rounds, “MS update”, October 5, 2001. 550. Invited speaker, Neurology Grand Rounds, “MS update”, LIJ Medical Center, New Hyde Park, NY, October 10, 2001. 551. Invited speaker, Dr. Kenneth Johnson’s retirement symposium, “MS -- a clinical perspective”, Baltimore, MD, October 11&13, 2001. 552. Invited speaker, Managed Care Conference, “MS Disease Modifying Therapies; short & long-term benefits”, Dallas, TX, October 16, 2001. 553. Visiting professor, and Invited speaker, Neurology Grand Rounds, “MS update” UC Davis Medical School, Sacramento, CA, October 18, 2001. 554. Invited speaker, Clinical Advisory Committee, Northern California MS chapter, “Etiopathogenesis of MS”, Sacramento CA, October 18, 2001. 555. Moderator, Northwest Regional Advisory Meeting on MS, Sonoma CA, October 19-21, 2001. 556. Invited speaker, Dinner Program on MS, Vestal, NY, October 25, 2001. 71

557. Co-moderator, Northeast Regional Advisory Meeting on MS, Bermuda, October 26-28, 2001. 558. Invited speaker, “MS” 25th annual meeting of the Mexico congress of Neurology, Queretaro, Mexico, Nov 1, 2001. 559. Invited speaker, Dinner Program on MS, “Issues & controversies in treating relapsing MS”, Atlanta, GA, November 13, 2001. 560. Invited speaker, Grand Rounds, “MS” Worcester Medical Center, Worcester, MA, November 15, 2001. 561. Invited speaker, Town Hall Meeting “Beyond tomorrow: MS and your future”, Atlanta, GA, December 5, 2001. 562. Visiting professor and invited speaker, Neurology Grand Rounds, University Arkansas Medical School, Little Rock, AR, December 6, 2001. 563. Invited speaker, Neurology Grand Rounds, Albert Einstein College of Medicine, “CNS infections”, Bronx, NY, December 12, 2001. 564. Invited speaker, Neurology Grand Rounds, Cooper Union Medical Center, “Role of Apoptosis in MS”, Camden, NJ, December 14, 2001. 565. Invited participant, Roundtable Meeting, “Optimizing Immunomodulatory therapy for MS patients”, Miami, FL, December 14-16, 2001. 566. Invited speaker, Dinner Program on MS, Raleigh-Durham, NC, December 18, 2001. 567. Invited speaker, Neurology Grand Rounds, University of North Carolina School of Medicine, “MS update”, Chapel Hill, NC, December 19, 2001. 568. Invited speaker, Dinner Program on MS, Philadelphia, PA, January 4, 2002. 569. Invited speaker, the Neurological Association of NJ and The Academy of Medicine of NJ, “the Pathogenesis if MS”, West Orange, NJ, January 9, 2002. 570. Invited speaker, CME lecture series, “Secondary Progressive MS”, LSU School of Medicine, Shreveport, LA, January 10, 2002. 571. Invited speaker, Neurology Grand Rounds, “MS update”, LSU School of Medicine, Shreveport, LA, January 11, 2002. 572. Invited speaker, Dinner Program on MS, Berthoud, CO, January 11, 2002. 573. Invited speaker, Colorado Chapter, NMSS, “Moving Forward: A Seminar for People Newly Diagnosed with MS”, Denver, CO, January 12, 2002. 574. Visiting professor as London Neurosciences speaker, University of Western Ontario, “pathogenesis of MS”, London Ontario, Canada, January 15, 2002. 575. Invited speaker, regional meeting, “Lesion Evolution in MS”, Atlanta, GA, January 16, 2002. 72

576. Invited speaker, Neurology Grand Rounds, “MS update”, St. Louis University Medical School, ST Louis, MO, January 17, 2002. 577. Invited speaker, “Treatment of SP MS”, Dana Point, CA, January 25-27, 2002. 578. Visiting professor, dept. of Neurology, University of Cincinnati, “MS update”, Cincinnati, OH, February 5-6, 2002. 579. Invited speaker, “Practicum in Neurology-Controversies & Clinical Pearls” Key Largo, FL, February 7-10, 2002. 580. Professor, Neurology Grand Rounds, “CSF infections”, SUNY at Stony Brook, Stony Brook, NY, February 12, 2002. 581. Invited speaker, 2002 AAN Winter Conference, “Update on CSF Analysis”, Fort Lauderdale, FL, February 15-17, 2002. 582. Invited speaker, Dinner Program on MS, Orlando, FL, February 27, 2002. 583. Invited speaker, Neurology Grand Rounds, “Controversies in MS”, University of South Florida, Tampa, FL, February 28, 2002. 584. Invited speaker, CME update program, University of South Florida, Tampa, FL, February 28, 2002. 585. Invited speaker, Lunch Program, “Gender Issues in MS”, Harrisburg, PA, March 2, 2002. 586. Invited speaker, Dinner Program on MS, Oklahoma City, OK, March 8, 2002. 587. Keynote speaker, 2nd Annual Professional and Public Education Conference, “MS Differential Diagnosis”, “MS Research Update”, Tulsa, OK, March 9, 2002. 588. Invited speaker, NMSS, New York City Chapter, “MS research: a spectrum of New Treatments and Opportunities”, New York City, NY, March 10, 2002. 589. Invited speaker, Neurology Grand Rounds, University of Texas “MS update”, San Antonio, TX, March 14, 2002. 590. Moderator, Northeast, Mid-Atlantic, Mid-Eastern Regional Advisory Meeting, “Clinical Outcome Measures & Trials, Comparative Data and Long Term Data in the Era of Therapeutic Options”, “Cutting Edge Issues& Emerging Trends in MS Treatment”, Bonita Springs, FL, March 15-17, 2002. 591. Invited speaker, Long Island MS Society, Dinner Program on “MRI in MS”, Smithtown, NY, March 25, 2002. 592. Invited speaker, “Neurologic and Rheumatologic Perspectives in Immunotherapy.’ Washington, DC, March 22-24, 2002. 593. Invited speaker, Fairfield County Neurological Society, ”Neurologic Lyme Disease”, Westport, CT, March 26, 2002. 594. Invited speaker, Grand rounds, ”MS update”, St. Luke’s Hospital, Boise, ID, April 3, 2002. 73

595. Invited speaker, Grand rounds, ”MS update”, Mercy Hospital, Boise, ID, April 3, 2002. 596. Invited speaker, Patient Program, “Current Research in MS”, Boise, ID, April 3, 2002. 597. Invited speaker, Dinner/ Presentation on MS, St. Matthews (Louisville), KY, April 4, 2002. 598. Invited speaker, Dinner Program on MS, Lexington, KY, April 5, 2002. 599. Invited speaker, Dinner Program on MS, Westwood, CA, April 8, 2002. 600. Invited speaker, Neurology Grand rounds, USC School of Medicine, ”MS update”, Los Angeles, CA, April 9, 2002. 601. Invited speaker, Orange County Neurologic, “MS,” Society Dinner, Orange County, CA, April 9, 2002. 602. Invited speaker, “MS” Neurology Grand rounds, UC Irvine, Irvine, CA, April 10, 2002. 603. Invited speaker, Dinner Program on MS, Westwood, CA, April 10, 2002. 604. Invited speaker, Dinner Program on MS, Scotisdale, CA, April 11, 2002. 605. Invited speaker, MS local advisory meeting, Fort Wayne, IN, April 12, 2002. 606. Invited speaker, Patient Program on MS, “New Research In MS” Fort Wayne, IN, April 13, 2002. 607. Invited speaker, “CSF analysis for infectious and noninfectious disorders,” Neurology Grand rounds, SUNY @ Stony Brook, Stony Brook, NY, April 30, 2002. 608. Invited speaker, Seattle Town Meeting on SP MS, “Treatment of SP MS”, Seattle, WA, May 1, 2002. 609. Invited speaker, CME Dinner Program on MS, “Advances in MS: A Research Update” Minneapolis, MN, May 16, 2002. 610. Invited speaker, Grand Rounds, “MS Update”, Brookdale Hospital, Brooklyn, NY, May 20, 2002. 611. Invited speaker, Neurology Grand Rounds, “MS Update”, New York Hospital Queens, Flushing, NY, May 20, 2002. 612. Invited speaker, Lunch Program on MS, “MS Update: Utilization as MRI as diagnosis of MS”, Providence, RI, May 22, 2002. 613. Invited speaker, Dinner Program on MS, “MS Update: Utilization as MRI as diagnosis of MS”, Buffalo, NY, May 22, 2002. 614. Invited speaker, Satellite Symposium, 2nd International MS week, “Milestones in the first decade of intervention: effective treatment strategies in MS”, Chicago, IL, June 6, 2002. 615. Invited speaker, 2nd International MS week Multiple Sclerosis: A World View, Chicago, IL, June 5-9, 2002. 74

616. Invited speaker, Dinner Program “Neuro-protection strategies in MS”, Chicago, IL, CA, July 7, 2002. 617. Invited speaker, Neurology Grand Rounds, Evanston Hospital, “The Influence of Sex on MS”, Evanston, IL, July 8, 2002. 618. Invited speaker, Neurology Grand Rounds, West Virginia University, “Pathogenesis of MS”, Morgantown, WV, July 19, 2002. 619. Invited speaker, Dinner Program on MS, Pittsburgh, PA, July 19, 2002. 620. Invited speaker, MS Chapter patient program on MS, Pittsburgh, PA, July 20, 2002. 621. Invited speaker, Florida Society of Neurology Annual Meeting, “Advances in Neurology” “MS: What’s New?” Orlando, FL, July 19-20, 2002. 622. Invited speaker, Neurology Grand Rounds, University of North Texas, HSC @ Fort Worth, “MRI studies in MS”, Irving, TX, July 30, 2002. 623. Invited speaker, Weekend Conference, “MS 2002: bridging neurology research and clinical practice”, Prince Edward Island, Canada, August 2-5, 2002. 624. Invited speaker, Dinner Program, “Evidence Based Medicine: an update in the Neuroimmunomodulatory treatment for relapsing forms of MS”, Boston, MA, August 7, 2002. 625. Invited speaker, resident teaching lecture, Dept of Neurology SUNY upstate, Syracuse, NY, August 8, 2002. 626. Invited speaker, Dinner Program on MS, Syracuse, NY, August 8, 2002. 627. Invited speaker, Dinner Seminar on MS, Kansas City, MO, August 13, 2002. 628. Invited speaker, Central MS Chapter, Kansas City, MO, August 14, 2002. 629. Invited speaker, Austin Neurologic society “Multiple Sclerosis: what’s new?” Austin, TX, August 19, 2002. 630. Invited speaker, regional advisory meeting on MS, Anchorage, AK, August 22-25, 2002. 631. Invited speaker, Dinner Program on MS, Evansville, IN, September 6, 2002. 632. Invited speaker, Patient Program on MS, Tri County MS Society, Evansville, IN, September 7, 2002. 633. Invited speaker, Dinner Program on MS, Honolulu Hawaii. September 12, 2002. 634. Invited speaker, Medical grand rounds, the Queen’s medical center, Honolulu Hawaii. September 12, 2002. 635. Invited speaker, 4th annual education, Hawaii division NMSS, “MS symptom management”, Honolulu Hawaii. September 14, 2002. 636. Invited speaker, Dinner Program on MS, Latrobe, PA, September 27, 2002. 75

637. Invited speaker, Dinner Program on MS, Pittsburgh, PA, October 1, 2002. 638. Invited speaker, Dept. of OB-GYN, University of Pittsburgh School of Medicine, “MS for the Non-neurologist,” Pittsburgh, PA, October 1, 2002. 639. Keynote speaker, Women against MS, Allegheny District Chapter, NMSS, Pittsburgh, PA, October 1, 2002. 640. Invited speaker, Dinner Program on MS, Louisville, KY, October 4, 2002. 641. Invited speaker, Kentucky-Southeast Indiana Chapter, “Enhancing Quality of Life Hope for the Future,” Louisville, KY, October 5, 2002. 642. Invited speaker, The Consortium of MS Centers, “Overview of Disease Modifying Therapies in Progressive Multiple Sclerosis,” Birmingham, AL, October 5, 2002. 643. Invited speaker, MS Dinner Program, Great Neck, NY, October 7, 2002. 644. Invited speaker, Medical grand rounds, “the role of neuroimaging in MS”, LSU, LA, October 18, 2002. 645. Invited speaker, MS Dinner Program, LA, October 18, 2002. 646. Invited speaker, MS Lunch Program, Metairie, LA, October 19, 2002. 647. Invited speaker, Mid-Atlantic Regional Advisory Meeting, “Deciphering the date: making sense of immunomodulatory therapy”, Manhattan, NY, October 26-27, 2002. 648. Invited speaker, NMS Lunch Program, NJ, October 27, 2002. 649. Invited speaker, Patient Program on MS, Billings, MT, October 28, 2002. 650. Invited speaker, CME Dinner Program on MS, billings, MT, October 29, 2002. 651. Invited participant, Primary Progressive MS Roundtable, Houston, TX, November 1-3, 2002. 652. Keynote speaker, Colorado Chapter NMSS 43rd Annual Meeting, Denver, CO, November 4, 2002. 653. Invited speaker, Luncheon Program on MS, Denver, CO, November 5, 2002. 654. Invited speaker, Colorado NMSS Chapter Seminar for newly diagnosed MS, Denver, CO, November 5, 2002. 655. Invited speaker, MS Conference on MS, San Juan, PR, November 9, 2002. 656. Invited speaker, Neurology Grand Rounds, “CSF Analysis of Infectious and Noninfectious Disease”, the University Hospital for the Albert Einstein College of Medicine, Bronx, NY, November 13, 2002. 657. Invited speaker, Dinner Program on MS, Huston, TX, November 14, 2002.

76

658. Invited speaker, Neurology Grand Rounds, “Gender Issues in MS”, University of Texas of Medical School, Huston, TX, November 15, 2002. 659. Invited speaker, Mid-Atlantic Chapter Annual Meeting & Education Conference, Charlotte, NC, November 15, 2002. 660. Invited speaker, Dinner Program “Progressive MS”, Charleston, WV, November 19, 2002. 661. Invited speaker, Neurology Grand Rounds, Charleston area Medical center, Charleston, WV, November 20, 2002. 662. Invited speaker, Dinner Program on MS, Albany, NY, November 21, 2002. 663. Invited speaker, Clinical Neurology Update 2002, MS update, San Antonio, TX, November 21-23, 2002. 664. Invited speaker, Research update, LI MS Chapter Annual meeting, Huntington, NY, December 2, 2002. 665. Invited speaker, Neurology Grand Rounds, “MS update”, Dept. of Neurology, SUNY Stony Brook, School of Medicine, Stony Brook, NY, December 3, 2002. 666. Invited speaker, Dinner Program on MS, Burlington, VT, December 4, 2002. 667. Invited speaker, Dinner Program on MS, Hanover, NH, December 5, 2002. 668. Visiting professor, Neurology Grand Rounds, Dept. of Neurology, University of Vermont, College of Medicine, Burlington, VT, December 5, 2002. 669. Invited speaker, Dinner Program on MS, Albany, NY, December 10, 2002. 670. Invited speaker, Dinner Program on MS, Westchester, NY, December 11, 2002. 671. Invited speaker, Dinner Program on MS, Philadelphia, PA, December 12, 2002. 672. Invited speaker, Dinner Program on MS, Jackson, MS, December 17, 2002. 673. Visiting professor, Neurology Grand Rounds, Dept. of Neurology, University of Mississippi, school of medicine, Jackson, MS, December 18, 2002. 674. Invited speaker, Lunch Program on MS, Indianapolis, IN, December 22, 2002. 675. Invited speaker, Neurology Grand Rounds, NYU School of Medicine, “West Nile Virus”, New York City, NY, December 24, 2002. 676. Invited speaker, Philadelphia Neurological Society “MS topics”, Philadelphia, PA, January 14, 2003. 677. Visiting professor, Neurology Grand Rounds, University of Maryland School of Medicine, “Lyme Disease”, Baltimore, MD, January 15, 2003. 678. Invited speaker, Dinner Program on MS, The Woodlands, TX, February 4, 2003. 679. Invited speaker, Dinner Program on MS, Houston, TX, February 5, 2003. 77

680. Invited speaker, Dinner Program on MS, Austin, TX, February 11, 2003. 681. Invited speaker, Dinner Program on MS, San Antonio, TX, February 12, 2003. 682. Invited speaker, Dinner Program on MS, Detroit, MI, February 27, 2003. 683. Invited speaker, Philadelphia Neurological Society “MS topics”, Philadelphia, PA, January 14, 2003. 684. Visiting professor, Geisinger Medical Center, Danville, PA, February 25, 2003. 685. Visiting professor, Barrow Neurological Institute, Phoenix, AZ, March 6-7, 2003. 686. Moderator, Women Neurologists’ MS Advisory Meeting, Beverly Hills, CA, March 7-9, 2003. 687. Invited speaker, Grand Rounds, Flushing Hospital, Flushing, NY, March 11, 2003. 688. Invited speaker, San Diego Neurology Society, “MS Variants”, San Diego, CA, March 21, 2003. 689. Invited speaker, Neurology Grand Rounds, “MS: diagnostic issues,” University of California at San Diego, CA, March 21, 2003. 690. Invited speaker, University of Florida, Tampa, FL, March 22, 2003. 691. Invited speaker, Neurology Grand Rounds, Long Island College Hospital, Brooklyn, NY, May 8, 2003. 692. Invited speaker, “The Spectrum of Multiple Sclerosis,” San Diego, CA, May 30-31, 2003. 693. Invited speaker, 16th international scientific conference: state of the art of Tick-borne disorders. “Update on PPG for Neurologic Lyme Disease,” East Hartford, CT, June 7-8, 2003. 694. Invited speaker, Dinner Program on MS, Westport, CT, June 11, 2003. 695. Consultant, Pfizer Global Research & Development, Groton, CT, June 11, 2003. 696. Invited speaker, Dinner Program on MS, Salt Lake City, WO, June 13, 2003. 697. Invited speaker, Patient Program on MS, Salt Lake City, WO, June 14, 2003. 698. Invited speaker, Leadership Initiatives in MS, Berkeley, CA, June 22-23, 2003. 699. Invited speaker, Dinner Program on MS, Uncasville, CT, July 1, 2003. 700. Program on MS, Oklahoma City, OK, July 10, 2003 Invited speaker, Dinner. 701. Invited speaker, Dinner Program on MS, Fort Worth, TX, July 23, 2003. 702. Invited speaker, Dinner Program on MS, Dallas, TX, July 24, 2003. 703. Co-moderator, New England Regional Advisory Meeting, Boston MA, August 22-23, 2003. 78

704. Invited speaker, Dinner Program on MS, NYC, NY, August 25, 2003. 705. Invited speaker, grand rounds, “MS” ST Mary’s Hospital, Portland, ME, August 28, 2003. 706. Invited speaker, Maine chapter of the National MS Society, Portland, ME, August 29, 2003. 707. Invited speaker, Dinner Program on MS, Louisville, KY, September 2, 2003. 708. Invited speaker, Dinner Program on MS, Cincinnati, OH, September 3, 2003. 709. Visiting professor and grand rounds speaker. Dept of Neurology, University of Cincinnati, School of Medicine, September 3, 2003. 710. Invited speaker, plenary lecture, XVth Congress of the International Society of Neuropathology, “Lyme Disease”, Turin, Italy, September 14-18, 2003. 711. Invited speaker, Dinner Program on MS, Boston, MA, September 23, 2003. 712. Visiting professor and grand rounds speaker. Dept of neurology, University of Syracuse, School of Medicine, September 25, 2003. 713. Invited speaker, Dinner Program on MS, Syracuse, NY, September 26, 2003. 714. Invited speaker, Dinner Program on MS, Baltimore, MD, September 29, 2003. 715. Invited speaker, for MS Program Update, Johns Hopkins, Baltimore, MD, September 29, 2003. 716. Invited speaker, MS Center of Excellence EAST, “Inaugural Symposium”, Baltimore, MD, September 29, 2003. 717. Invited speaker, Dinner Program on MS, Washington D.C. September 30, 2003. 718. Invited speaker, Dinner Program on MS, East Rutherford, NJ, October 2, 2003. 719. Invited speaker, The 25th meeting of the Western Intermountain Neurological Organization, “MS Update,” University of Utah School of Medicine (CME), Salt Lake City, UT, October 3-4, 2003. 720. Invited speaker, Italian Neurological Society, 34th Annual meeting MS Symposium, Rome, Italy, Oct 14, 2003. 721. Invited speaker, Dinner program for patients on MS, Charleston, SC, October 16, 2003. 722. Invited speaker, Grand rounds “MS”, Charleston, SC, October 17, 2003. 723. Invited speaker, Patient program on “MS”, Mount Pleasant, SC, October 17, 2003. 724. Invited speaker, Patient program on “MS”, Savannah, GA, October 18, 2003. 725. Invited speaker, Dinner program on “MS Update,” Center Valley, PA, October 23, 2003. 726. Invited speaker, CME program “Practical Issues in MS,” Allentown, PA, October 23, 2003. 79

727. Invited speaker, Dinner program on “MS Update,” Pittsburgh, PA, November 4, 2003. 728. Invited speaker, Neurology Grand Rounds “MS”, University of Pittsburgh, School of Medicine, “Role of MRI in MS”, Pittsburgh, PA, November 5, 2003. 729. Invited participant, MS National Advisory Board Meeting, for GlaxoSmithKline, November 7-8, 2003. 730. Invited speaker, Leadership Initiatives in MS, Tempe, AZ, November 14-16, 2003. 731. Invited speaker, Neurology Grand rounds “CSF Analysis,” LIJ Medical Center, New Hyde Park, NY, December 17, 2003. 732. Invited speaker, Neurology Grand rounds, George Washington Medical School, Washington, D.C., January 6, 2004. 733. Consultant, Treatment algorithm article roundtable discussion meeting, Baltimore, MD, January 8-9, 2004. 734. Invited speaker, Northern New England Neuroimmunology Symposium: “Gender-related issues in MS,” Stowe, VT, January 9-11, 2004. 735. Invited speaker, MS Conference: “Benign/ Mild MS and CIS”, San Juan, Puerto Rico, February 6-8, 2004. 736. Invited speaker, Rehabilitation Associates, “MS diagnosis and treatment,” Fairfield, CT, February, 10 2004. 737. Invited speaker, Therapeutics Dinner Program, “MS update,” Long Beach, CA, March, 11 2004. 738. Invited speaker, Therapeutics Patient Program, “MS update,” Baldwin Park, CA, March, 11 2004. 739. Invited speaker, Therapeutics Grand Rounds Program, “MS update,” Los Angeles, CA, March, 12 2004. 740. Invited speaker, Neurology Grand Rounds Program, “Gender Issues in MS,” Chicago, IL, March, 26 2004. 741. Invited speaker, Dinner Meeting on MS, Merrillville, IN, March, 30, 2004. 742. Invited speaker, Dinner Program on MS, Boston, MA, March, 30, 2004. 743. Invited speaker, Dinner Program on MS, Hingham, MA, March, 31, 2004. 744. Invited speaker, Dinner Program on MS, Dayton, OH, April, 6, 2004. 745. Invited speaker, Neurology Grand Rounds Program, “MS topics,” Dayton, OH, April, 6, 2004. 746. Invited speaker, Dinner Program on MS, Columbus, OH, April 7, 2004. 747. Invited speaker, Lunch Program, “MS topics,” Columbus, OH, April, 7, 2004. 80

748. Invited speaker, Dinner Program on MS, WAMS Houston Group, Houston, TX, April 14, 2004. 749. Invited speaker, “MS update”, 30th annual family medicine update: Health Sciences Center, SUNY at Stony Brook, Stony Brook, NY, June, 2, 2004. 750. Invited speaker, “Evidence-based Medicine of MRI in the Management of MS”, Leadership Initiatives in MS, Banff, Alberta, Canada, June, 11-13, 2004. 751. Invited speaker, neurology grand rounds “Nervous System Infections, Part I”, SUNY Stony Brook, Medical School, Stony Brook, NY, July 6, 2004. 752. Invited speaker, neurology grand rounds “Nervous System Infections, Part II”, SUNY Stony Brook, Medical School, August 24, 2004. 753. Invited speaker, Multiple Sclerosis Strategic Advisory Meeting, Vienna, Austria, October 10, 2004. 754. Invited speaker, Conference on “Lyme & Other Tick-Borne Disease” Rye Town, NY, October 22, 2004. 755. Invited speaker, “MS update” at Institute for Basic research in Developmental Disabilities, Staten Island, NY, November 17, 2004. 756. Invited speaker, “Treatment Optimization In MS, a two-faced disease”, The 3rd TevaSanofi-aventis International Symposium on MS, November 19-20, 2004. 757. Moderator and invited speaker, “Advances in Neuroimmunologic Therapy 2004,” Columbia University, New York, NY, December 3-4, 2004. 758. Invited speaker, neurology grand rounds “Nervous System Infections, Part II” SUNY @ Stony Brook, Medical School, August 24, 2004. 759. Invited speaker, “MS update”, Baton-Rouge, IA, January 11, 2005. 760. Invited speaker, “MS update”, New Orleans, IA, January 12, 2005. 761. Invited speaker, “MS: What’s new?” Phoenix, AZ, January 27, 2005. 762. Invited speaker, neurology grand rounds “MS Update”, SUNY @ Stony Brook, Medical School, Stony Brook, NY, March 9, 2005. 763. Invited speaker, neurology grand rounds “Lyme Disease”, Duke University Medical Center, Durham, NC, March 23, 2005. 764. Invited speaker, neurology grand rounds “MS Update”, Cooper Medical Center, Garden NJ, May 13, 2005. 765. Invited speaker, neurology grand rounds “MS Update”, SUNY Stony Brook, Medical School, Stony Brook, NY, May 19, 2005. 766. Invited speaker, neurology grand rounds “Role of Neuroimmunology in MS”, USF, Tampa, FL, May 27, 2005. 81

767. Course director, “The Eighth Annual Review of Multiple Sclerosis,” Orlando, FL, May 28 & 29, 2005. 768. Invited speaker, Neurology Grand rounds “Lyme Disease,” Wayne State University, Detroit, IL, June 3, 2005. 769. Invited speaker, Neurology Grand rounds “CIS,” SUNY Stony Brook, Medical School, Stony Brook, NY, July 12, 2005. 770. Invited speaker, Neurology Grand Rounds “Lyme Disease,” SUNY Stony Brook, Medical School, Stony Brook, NY, July 26, 2005. 771. Invited speaker, Neurology Grand rounds “MS Masqueraders,” New York Presbyterian Hospital-Weill Cornell Medical center, New York, NY, August 29, 2005. 772. Invited speaker, “Short and long term efficacies of currently approved MS therapies,” ECTRIMS 2005, Thessaloniki, Greece, September 28, 2005. 773. Invited speaker, “IFNβ neutralizing antibodies,” ECTRIMS 2005, Thessaloniki, Greece, September 29, 2005. 774. Invited speaker, Neurology Grand rounds “MS Therapies,” SUNY @ Stony Brook, Medical School, Stony Brook, NY, November 22, 2005. 775. Invited speaker, Neurology Grand rounds “MS Update,” Stanford Hospital, Stanford, CT, December 2, 2005. 776. Invited speaker, Neurology Grand rounds “MS Update,” SUNY @ Stony Brook, Medical School, Stony Brook, NY, December 13, 2005. 777. Invited speaker, Neurology Grand rounds “MS Update,” The Charles Hospital, Cambridge MA, December 14, 2005. 778. Invited speaker, Pathology Grand rounds (CPC) “POPARTMUS Study,” SUNY Stony Brook, Medical School, Stony Brook, NY, January 18, 2006. 779. Invited speaker, Johns Hopkins Medical School, Consortium of Multiple Sclerosis Centers on the topic “Is it MS? Mimics and Variants,” NYC, NY, February 27, 2006. 780. Invited speaker, Preventative Medicine, “Experimental Clinical Research: MS,” SUNY Stony Brook, Medical School, Stony Brook, NY, February 27, 2006. 781. Invited speaker, “Tysabri,” SUNY Stony Brook, Medical School, Stony Brook, NY, March 7, 2006. 782. Invited speaker, neurology grand rounds “MS Update,” Stanford Hospital, Stanford, CT, March 22, 2006. 783. Invited speaker, “Menopausal Neurology: MS,” AAN 58th, San Diego, CA, April 2, 2006. 784. Invited speaker, “MS Update,” AAN 58th, San Diego, CA, April 7, 2006. 785. Invited speaker, “Immunosuppressive therapy in demyelinating disease: how I do it,” AAN 58th, San Diego, CA, April 8, 2006. 82

786. Invited speaker, Neurology Grand rounds ““MS Update,” University of South Carolina, SC, May 11, 2006. 787. Invited speaker, Neurology symposium “Early treatment rationale,” Dublin, Ireland, May 19, 2006. 788. Invited speaker, CME_MS “Management of suboptimal responders.” Phoenix, AZ, June 1, 2006. 789. Invited speaker, CME_MS “Clinical utility of neutralizing antibody testing in multiple sclerosis.” Phoenix, AZ, June 2, 2006. 790. Invited speaker, CME_MS “Treatment approaches in MS: Evidence based medicine and clinical trials.” Phoenix, AZ, June 2, 2006. 791. Invited speaker, CME_MS “Diagnostic dilemmas in MS.” Phoenix, AZ, June 3, 2006. 792. Invited speaker, Neurology Grand rounds “Overview of Acute and Chronic Meningitis,” SUNY Stony Brook, Medical School, Stony Brook, NY, July 7, 2006. 793. Invited Speaker, 22nd Congress of the European Committee for Treatment and Research in MS (ECTRIMS), “Treatment Algorithm,” Madrid, Spain, September 27-30, 2006. 794. Invited mentor, ANA Career Development Symposium, Chicago, IL, October 7, 2006. 795. Invited speaker, CME Conference, MS Update: A Focus on Women. Berkeley, CA, October 14, 2006. 796. Invited speaker, Connecticut Academy of Family Physicians (CAFP) 2006 Scientific Symposium, “MS”, Plantsville, CT, October 25-26, 2006. 797. Invited speaker, “MS Update,” New York Medical College, Valhalla, NY, November 8, 2006. 798. Invited speaker, “Update on Neuroimaging of MS,” New York City, NY, January 13, 2007. 799. Invited speaker, “MS Update,” Dept. of Medicine Grand rounds, Stony Brook Medical Center, Stony Brook, NY, January 31, 2007. 800. Invited speaker, Neurology Grand rounds, M“S Update” Stony Brook Medical Center, Stony Brook, NY, February 6, 2007. 801. Invited speaker, CME Conference, MS Update: “Difficult Problems in the Management of MS,” Atlanta, GA, February 24, 2007. 802. Invited speaker, “MS Clinical Trials,” Dept. of Preventive Medicine, Stony Brook Medical Center, Stony Brook, NY, March 5, 2007. 803. Invited speaker, “Current Therapy in Neurology 2007: Parkinson’s, Alzheimer’s, and Multiple Sclerosis Callosal Connection Corporation (CCC) August 24-25, 2007. 804. Invited Speaker, Alpers Lecture and Neurology Grand Rounds, “Lyme Disease: A Primer for Neurologists”, “MS Update”, Thomas Jefferson University, Philadelphia, PA June 19-20, 2008. 83

805. Invited Speaker, “Implications of Modern MS Trials”, University of Kansas Medical Center, Neurology/Neurosurgery Grand Rounds, August 1, 2008. 806. Invited Participant, “Future of Neurology Think Tank” What are the implications to the treatment of individuals? Sponsored by Merck Serono, Geneva, Switzerland, December 5, 2008. 807. Invited Speaker, Neurology Grand Rounds, NYU School of Medicine, “Update on CIS,” February 10, 2009. 808. Invited Speaker, “Review of Interesting Case Studies in MS”, Roundtable discussion, Long Island Multiple Sclerosis Nurses Society, Smithtown, NY (Sponsored by Teva) February 11, 2009. 809. Invited Speaker CME Program, “Early Treatment Trials in MS” Sponsored by USF Health, Charleston, SC, June 20-21, 2009. 810. Invited Speaker, CMSC Sponsored Symposium "MS in 2011: Examining the Evidence", Teaneck, NJ, May 4, 2011. 811. Invited Speaker and Faculty, Master MS Fellowship Program, Montreal, Canada, May 30June 1, 2011. 812. Invited Speaker, 25th Annual Meeting CMSC "What are the Therapeutic Options for Breakthrough Disease on DMT Now and in the Near Future?", "Disability Through the Stages of MS", "Real World Application of Treatment Options in MS: Navigating the Changing Waters", Montreal, Canada, June 1-4, 2011. 813. Invited Speaker, "Matching Therapy to MS Mechanisms: Unique Solutions for Patients", CME Symposium on "MS: Imaging, Immunology, Genetics, and Treatment Strategies Enhance Clinical Outcomes, Denver, CO, June 25, 2011. 814. Invited Speaker, NYS MS Consortium Annual Research Meeting, "Fingolimod", New York City, NY, September 9, 2011. 815. Invited Speaker, "Emerging Treatment Algorithms in MS", National Congress on "MS: Past, Present and Future", Hellenic Neurology Society, Thessaloniki Greece, September 23-24, 2011. 816. Invited Speaker, "Disability Outcome in MS", The 2nd Annual ISNVD Scientific Meeting, Orlando, FL, February 18-22, 2012. 817. Invited Speaker, Neurology Grand Rounds SUNY Downstate "MS and Pregnancy" in Brooklyn, NY, February 24, 2012. 818. Invited Speaker, "The Brain and Lyme Disease", Scientific Symposium Celebrating Guy McKhann, MD, Johns Hopkins School of Medicine, June 16, 2012. 819. Invited Speaker, "Freedom from MS Disease Activity: What does it mean and how do we achieve it?”, MS Experts Consensus Summit, Cleveland OH, September 20-22, 2012. 820. Invited Speaker/Panelist, Crossfire Forum for MS Healthcare Providers, Multiple Sclerosis Association of America, Philadelphia, PA, June 19, 2013. 84

821. Invited Panelist, "Staying Sharp: Ask the Experts", Dana Foundation & AARP, Melville, NY, June 8, 2013. 822. Invited Speaker, "Progressive MS", Neurology Grand Rounds, Beth Israel Medical Center, New York, NY, June 7, 2013. 823. Invited Speaker, Neurology Grand Rounds, School of Medicine Brown University, Providence, Rhode Island, September 18, 2013. 824. Invited Speaker, CME Program on “MS Clinical Update,” Arlington, TX, Nov 16, 2013. 825. Invited Speaker, Live Interactive Online CME Summit, Neuroseries LNE, “Strategies for Optimizing Function and QOL in MS,” New York City, NY, Nov 19, 2013. 826. Invited Speaker & Co-chair, Emerging MS Treatment National Advisory Board, “Current Approaches to Treating MS,” Baltimore, MD, Nov 21, 2013. 827. Invited Speaker, Aubagio Speaker Training Meeting, “Pregnancy,” Dallas, TX, November 23, 2013. 828. Faculty, VHA: Advances in Multiple Sclerosis Care, “Strategies for Appropriate Diagnosis and Improved Patient Outcomes,” Irving, TX December 18, 2013. 829. Advisor, Novartis Brain Volume Loss Advisory Board Meeting, Ft. Lauderdale, FL, January 24-25, 2014. 830. Consultant, Virtual Ad Board, “Tecfidera Switch Ad Board,” January 30, 2014. 831. Advisor, Plegridy Advisory Board, “Safety and Tolerability,” Atlanta, GA, January 31, 2014. 832. Faculty, Medscape Roundtable on MS, “Current Opinion on Monoclonal Antibody Therapies in Multiple Sclerosis,” New York, NY, February 28, 2014. 833. Consultant, Acorda Axon Advisory Board Meeting, Miami, FL, March 8, 2014. 834. Consultant, Core Consultants Advisory Board, Boston, MA, March 15, 2014. 835. Invited Speaker, San Diego Neurology Society, “Improving Management Strategies for Patients with Multiple Sclerosis: An Evaluation of Current Practice,” San Diego, CA, March 20, 2014. 836. Invited Speaker, Neuroscience Grand Rounds, “CSF: Insights into MS,” University of California San Diego, San Diego, CA, March 21, 2014. 837. Invited Speaker, California Neurology Society, “Improving Management Strategies for Patients with Multiple Sclerosis: An Evaluation of Current Practice,” Marina del Ray, CA, March 29, 2014. 838. Invited Speaker, MS Cure Fund, “New and Emerging MS Therapies,” Port Jefferson, NY, April 2, 2014. 839. Advisor, Genentech Advisory Board, “Anti-IL17 Development in Multiple Sclerosis National Advisory Board Meeting,” Washington, D.C., April 4, 2014. 85

840. Advisor, Genentech Advisory Board, “Ocrelizumab Evidence Gap Assessment and Phase 3B/4 Considerations,” Washington, D.C., April 5, 2014. 841. Invited Faculty, Teriflunomide Academy of Knowledge, “Teriflunomide for the Treatment of Relapsing MS: Efficacy Results,” Brussels, Belgium, April 11-12, 2014. 842. Invited Speaker, The Cure Panel Talk Show, “Multiple Sclerosis,” Stony Brook, NY, April 18, 2014. 843. Invited Speaker, HCPLive Peer Exchange, “Modifying the Course of Multiple Sclerosis: The Growing Treatment Armamentarium,” New York, NY, April 23, 2014. 844. Invited Speaker, Genzyme Corporate Therapeutic Update, “The Evolving Treatment Paradigm Individualizing MS Care,” Philadelphia, PA, April 29, 2014. 845. Invited Speaker, Neurological Issues in Pregnancy, “Multiple Sclerosis and Pregnancy: Update 2014,”Philadelphia, PA, April 30, 2014. 846. Invited Speaker, Neuroscience Conference, “Updates in Lyme Disease,” Stony Brook, NY, May 15, 2014. 847. Invited Faculty, Teriflunomide Academy of Knowledge, “Teriflunomide for the Treatment of Relapsing MS: Efficacy Results,” São Paolo, Brazil, May 16-17, 2014. 848. Invited Speaker, Key Opinion Leaders Panel, “Pills, Payers, and the Pharma Industry,” Atlanta, GA, May 20, 2014. 849. Invited Speaker, Genzyme Spanish Launch Meeting, “Experience: Efficacy and effectiveness with Teriflunomide,” Barcelona, Spain, May 23-24, 2014. 850. Invited Speaker, Fundamentals of MS Care Part 1, “Primary Progressive MS: Diagnosis, Clinical Course and Long-Term Management,” Dallas, TX, May 29, 2014. 851. Invited Speaker, Medscape Symposium: Case Challenges: Beta Interferons in MS, “The Challenge of Choice,” Dallas, TX, May 29, 2014. 852. Invited Speaker, Geisinger Multiple Sclerosis Symposium, “What we know about Multiple Sclerosis today: A comprehensive overview,” “Current and Upcoming Treatments,” Danville, PA, June 11, 2014. 853. Consultant, Biogen Idec MS Franchise Data Generation Advisory Board, New York, NY, June 20, 2014. 854. Consultant, AbbVie Global Medical Affairs Daclizumab Expert Panel, Chicago, IL, June 29, 2014. 855. Consultant, Genentech National Advisory Board, “OCR Monitoring Disease Progression in Multiple Sclerosis,” Chicago, IL, July 18, 2014. 856. Invited Speaker, Genzyme MS Leaders’ Summit 2014, “Disability Progression in MS,” “MS and Family Planning,” Melbourne, Australia, July 26-27, 2014. 857. Invited Speaker, MS Cure Fund, “Current Topics in MS,” Melville, NY, August 20, 2014. 86

858. Invited Speaker, Genzyme, “The Evolving Multiple Sclerosis Landscape: The Emerging Role of Aubagio in Managing Adults with Relapsing Remitting Multiple Sclerosis,” 2014 Joint ACTRIMS-ECTRIMS Meeting, Boston, MA, September 10, 2014. 859. Invited Speaker, Biogen Idec Corporate Therapeutic Update, “Satellite Symposium: Treatment Decisions at the Intersection of Trials and Practice,” 2014 Joint ACTRIMSECTRIMS Meeting, Boston, MA, September 12, 2014. 860. Invited Speaker, Shaw Science Partners, “Treating to target and beyond: Is improvement in functioning a realistic treatment goal in multiple sclerosis?,” 2014 Joint ACTRIMSECTRIMS Meeting, Boston, MA, September 12, 2014. 861. Invited Panelist, Medscape Education First Response, “The Transformation of MS Treatment – What is the Evidence from the Latest Clinical Studies?” 2014 Joint ACTRIMSECTRIMS Meeting, Boston, MA, September 13, 2014. 862. Invited Speaker, CMSA Chapter Meeting, “Patient-Centered Care for the Patient with Multiple Sclerosis: The Role of the Case Manager,” Boxborough, MA, October 2, 2014. 863. Invited Speaker, Colombian Association of Neurology, “Natural History of Multiple Sclerosis,” “Therapeutic Failure,” “How to Select a DMT,” Barranquilla, Colombia, October 17, 2014. 864. Invited Speaking Faculty Member, MS Forum: Steering Committee, “Diagnostic Modalities,” “Panel Discussion: Adherence to Therapy,” “Case Choice: Symptomatic Treatment,” New York, NY, October 18, 2014. 865. Consultant, Genzyme Advisory Board Meeting, “The Evolving Multiple Sclerosis Landscape 2014,” Cambridge, MA, September 10, 2014. 866. Invited Speaker, Living Well With MS Patient Education Program, “MS Research & Therapies Update,” East Setauket, NY, October 23, 2014. Invited Speaker, Stony Brook Neurosciences Institute, “Clinical CNS Infections,” Stony Brook, NY, October 24, 2014. 867. Invited Speaker, Stony Brook Neurosciences Institute, “Multiple Sclerosis,” Stony Brook, NY, October 29, 2014. 868. Presenting Faculty Member, The 10th Annual Johns Hopkins Multiple Sclerosis Symposium Series, “MS Overview and Diagnosis,” “Educational Breakout Session: Case Studies – Focus on early symptom identification and management,” New York, NY, November 1, 2014. 869. Invited Speaker, Teva Symposium at the Annual Meeting of the Mexican Academy of Neurology: Balance Between Experience and Innovation in the Treatment of Multiple Sclerosis, “Improving Convenience in the Treatment of MS,” “Definition and Diagnosis: Neuromyelitis Optica and/or Multiple Sclerosis?" Cancún, Mexico, November 3, 2014. 870. Invited Speaker, CMSA Chapter Meeting, “Patient-Centered Care for the Patient with Multiple Sclerosis: The Role of the Case Manager,” Milwaukee, WI, November 6, 2014. 871. Invited Speaker, Fall Managed Care Forum, “Recent Advances in the Treatment & Management of Multiple Sclerosis,” Las Vegas, NV, November 13, 2014. 87

872. Invited Speaking Faculty Member, MS Forum: Steering Committee, “Diagnostic Modalities,” “Panel Discussion: Adherence to Therapy,” “Case Choice: Symptomatic Treatment,” Chicago, IL, November 15, 2014. 873. Invited Speaking Faculty Member, MS Forum: Steering Committee, “Diagnostic Modalities,” “Panel Discussion: Adherence to Therapy,” “Case Choice: Symptomatic Treatment,” Washington, D.C., November 22, 2014. 874. Invited Speaker, MS Cure Fund, “Risks and Benefits When Considering Changing Therapies: How to Achieve Best Outcome from MS DMTs,” Melville, NY, December 4, 2014. 875. Invited Speaking Faculty Member, MS Forum: Steering Committee, “Diagnostic Modalities,” “Panel Discussion: Adherence to Therapy,” “Case Choice: Symptomatic Treatment,” Los Angeles, CA, December 6, 2014. 876. Invited Speaker, CME Program Sponsored by CMSC/SPIRE Learning, “Optimizing Multiple Sclerosis Management,” Pittsburgh, PA, December 13, 2014. 877. Invited Speaker, HCPLive, “Multiple Sclerosis: Advances in Our Understanding of the Disease and its Treatment,” Plainsboro, NJ, December 18, 2014. 878. Invited Speaker, Stony Brook Medicine Neurology Unit of the Clinical Medicine, “Introduction to Neurology,” Stony Brook, NY, January 8, 2015. 879. Invited Speaker, Stony Brook Medicine Neurology Unit of the Clinical Medicine, “Multiple Sclerosis,” Stony Brook, NY, January 9, 2015. 880. Invited Speaker, Southampton Hospital, “Neurologic Lyme Disease,” Southampton, NY, January 21, 2015. 881. Invited Speaker, Stony Brook Medicine Neurology Unit of the Clinical Medicine, “Dementia,” Stony Brook, NY, January 21, 2015. 882. Consultant, Novartis Pharmaceuticals Corporation, “Alemtuzumab Advisory Board Meeting,” Denver, CO, January 24, 2015. 883. Invited Speaker, CMSA Chapter Meeting, “Patient-Centered Care for the Patient with Multiple Sclerosis: The Role of the Case Manager,” Tulsa, OK, February 12, 2015. 884. Invited Speaker, Neurology/Neurosurgery Grand Rounds, “CNS Reserve and Health Maintenance,” Stony Brook, NY, February 27, 2015. 885. Consultant, Genzyme Advisory Board Meeting, “Women in MS,” Atlanta, GA, March 7, 2015. 886. Consultant, Genzyme Alemtuzumab Regional Benefit: Risk Medical Advisory Board Meeting, New York, NY, March 14, 2015. 887. Invited Speaker, Genzyme Aubagio Academy of Knowledge, “Evaluation of Efficacy,” Madrid, Spain, March 19-21, 2015.

88

888. Consultant, Global PLEGRIDY Post-launch Commercial Advisory Board, London, England, March 28, 2015. 889. Invited Speaker, CMSA Chapter Meeting, “Patient Centered Care for the Patient with Multiple Sclerosis: The Role of the Case Manager,” Melville, NY, April 8, 2015. 890. Consultant, Acorda’s AXON in MS Medical Advisory Board Meeting, Hollywood, FL, April 13, 2015. 891. Moderator, Medscape Neurology Video Media activity, “Controversies in MS: Part 1,” Washington, D.C., April 23, 2015. 892. Invited Faculty, Medscape Neurology Video Media activity, ““Virtual Encounters in Multiple Sclerosis: An Innovative Patient Simulation Program,” Washington, D.C., April 23, 2015. 893. Consultant, Novartis Advisory Board Dinner Meeting, Washington, D.C., April 24, 2015. 894. Invited Speaker, MS Cure Fund, “Risks and Benefits When Considering Changing Therapies: How to Achieve Best Outcome from MS DMTs,” New York, NY, April 29, 2015. 895. Invited Faculty, HCPLive, “Peer Exchange on Multiple Sclerosis,” New York, NY, May 1, 2015. 896. Consultant, Bayer Pharmaceuticals, MS Council Meeting, Houston, TX, May 2, 2015. 897. Invited Faculty, MS Leadership Summit, “Overview of Effective Symptom Management for MS,” New York, NY, May 9, 2015. 898. Consultant, Novartis, “Evaluating effectiveness of oral DMTs in the real-world setting,” Millbrae, CA, May 16, 2015. 899. Invited Speaker, Medical Learning Institute, Inc. CMSC Symposium: Understanding the Evolution of MS Care: Optimizing Therapeutic Decision Making, “General Principles,” “Current Progressive MS Trials,” “Cast 3 Transition to SPMS,” Indianapolis, IN, May 27, 2015. 900. Invited Speaker, Master MS Fellowship Program, “Neuromyelitis Optica,” “Clinical Trial Design and Analysis,” “Current Trials: Emerging Concepts in Treatment,” Indianapolis, IN, May 26, 2015. 901. Invited Speaker, CMSC: What Neurologists Need to Know About Infections Part I and II, “Lyme Disease and MS: Fact and Fiction,” “Vaccines and MS: Updates,” Indianapolis, IN, May 27, 2015. 902. Invited Speaker, CMSC: Fundamentals of MS Care Part I, “Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management,” Indianapolis, IN, May 28, 2015. 903. Invited Speaker, CMSC Symposia: Biomarkers in MS: The Role of CSF, “CSF in MS: Background,” “CSF: Lessons from Other Diseases,” “Proteomic Studies: Insights into MS,” Indianapolis, IN, May 28, 2015.

89

904. Invited Speaker, Potomac Center for Medical Education and Rockpointe, “Following the Evidence: A Practical, Case-Based Approach to Improving Quality of Life in MS Patients,” Indianapolis, IN, May 28, 2015.

905. Consultant, Genzyme Lemtrada MS Expert Advisory Board Meeting, Boston, MA, June 13, 2015. 906. Invited Faculty, Vindico Medical Education CME Webcast, “Deciding Factors: Answering the Questions of When, How, and Why When Individualizing Multiple Sclerosis Treatment,” June 18, 2015. 907. Consultant, Novartis MS Scholar Program Web Conferences, July 1-2, 2015. 908. Advisor, Genzyme MS Global Strategic Advisory Board Meeting, Cambridge, MA, July 2122, 2015. 909. Advisor, Novartis Opportunistic Infections Advisory Board Meeting, Morristown, NJ, August 15, 2015. 910. Panelist, Bay Street Theater Tick-Borne Disease Resource Center Panel Discussion, “Neurologic Lyme Disease,” Sag Harbor, NY, August 22, 2015. 911. Consultant, Biogen MS Disease Education Advisory Board, Minneapolis, MN, September 25, 2015. 912. Invited Speaker, MedLearning Group, “The 3D MS THRIVE Initiative: Clinical Management and Patient Outcomes in Multiple Sclerosis,” Dallas and Houston, TX, October 14-15, 2015. 913. Invited Faculty Speaker, Online Virtual CME Summit: Global Perspectives in Multiple Sclerosis Management from ECTRIMS 2015, “Controversy, Consensus, and Cases on Multiple Sclerosis from ECTRIMS 2015” New York, NY, October 16, 2015. 914. Invited Speaker, CME Medical Meeting Reporter of the 2015 ECTRIMS Meeting, “PostECTRIMS 2015 Review and Analysis: Scientific and Therapeutic Advances in the Treatment of Multiple Sclerosis,” New York, NY, October 16, 2015. 915. Invited Speaker, Novartis Grand Rounds, “Risk Mitigation Strategies in MS Therapies,” East Hanover, NJ, October 21, 2015. 916. Consultant, Bayer Neurology Virtual Advisory Board, October 21, 2015. 917. Invited Speaker, Multiple Sclerosis Monthly Reports: 2nd Annual Case-based Online Series, “Switching MS Medicines: What Do We Know, What Do We Do?” October 23, 2015. 918. Consultant, Genentech, “Ocrelizumab In MS - Phase III Efficacy And Safety Data Advisory Board,” San Francisco, CA, October 30, 2015. 919. Invited Speaker, Med Learning Group Multiple Sclerosis 3D Summit, “MS THRIVE: Facing Multiple Sclerosis in Practice - The Facts and Consensus on Clinical Management and Patient Outcomes,” Miami, FL, November 3, 2015. 90

920. Invited Speaker, MS Forum II: 2015 CME/CNE Meeting Series, “Imaging Modalities,” “Clinical and Practical Review of Disease Modifying Therapies,” “Optimizing Treatment Response in MS: Balancing Risk vs. Efficacy,” “Case Choice: Therapeutic Switching,” “Managing MS in Pregnancy,” Chicago, IL, November 7, 2015. 921. Invited Speaker, MedLearning Group, “The 3D MS THRIVE Initiative: Clinical Management and Patient Outcomes in Multiple Sclerosis,” West Palm Beach, November 11, 2015. 922. Invited Speaker, CME Outfitters, “Risky Business: Understanding and Attenuating Risk Associated with Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis,” Washington, D.C., December 9, 2015. 923. Invited Speaker, MS Forum II: 2015 CME/CNE Meeting Series, “Imaging Modalities,” “Clinical and Practical Review of Disease Modifying Therapies,” “Optimizing Treatment Response in MS: Balancing Risk vs. Efficacy,” “Case Choice: Therapeutic Switching,” “Managing MS in Pregnancy,” New York, NY, November 21, 2015. 924. Invited Speaker, MS Forum II: 2015 CME/CNE Meeting Series, “Imaging Modalities,” “Clinical and Practical Review of Disease Modifying Therapies,” “Optimizing Treatment Response in MS: Balancing Risk vs. Efficacy,” “Case Choice: Therapeutic Switching,” “Managing MS in Pregnancy,” Los Angeles, CA, December 5, 2015. 925. Invited Faculty, CME Outfitters, “Risky Business: Understanding and Attenuating Risk Associated with Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis,” Washington, D.C., December 9, 2015. 926. Invited Speaker, Stony Brook Medicine Physician Assistant Teaching Course, “Introduction to Neurology,” Stony Brook, NY, January 6, 2016. 927. Invited Speaker, Stony Brook Medicine Physician Assistant Teaching Course, “Multiple Sclerosis,” Stony Brook, NY, January 15, 2016. 928. Invited Speaker, Stony Brook Medicine Physician Assistant Teaching Course, “Dementia,” Stony Brook, NY, January 20, 2016. 929. Invited Speaker, Academic CME Advanced Curriculum for Multiple Sclerosis, “The Great MS Debate: How to Work Up a Case of MS,” “When to Switch Therapies,” New Orleans, LA, February 17, 2016. 930. Invited Speaker, Colombian Association of Neurology, “Biomarkers for MS Therapy,” “Early Induction Therapy: No,” “NMO Attack: Single Steroid Treatment Preferred to Plasma Exchange,” “NMOSD,” Calí, Colombia, February 25-27, 2016. 931. Invited Speaker, MS Grand Round Series, “Integrating New DMD Therapies into the MS Treatment Landscape,” Teaneck, NJ, March 22, 2016. 932. Invited Speaker, St. Charles Hospital, “Multiple Sclerosis,” Port Jefferson, NY, April 7, 2016. 933. Invited Speaker, MS Grand Round Series, “Integrating New DMD Therapies into the MS Treatment Landscape,” Petersburg, VA, April 14, 2016. 934. Invited Faculty, Medscape, “Treating to Target in MS: What is the Evidence?,” Vancouver, BC, April 19, 2016. 91

935. Invited Faculty, Medscape, “Perspectives on Key MS Data from the Annual Neurology Meeting,” Vancouver, BC, April 20, 2016. 936. Invited Faculty, Strategic Consultants International, “AAN Highlights Video Roundtable,” Vancouver, BC, April 20, 2016. 937. Invited Faculty, PlatformQ Healthy Education virtual symposium, “Clinical Insights on Multiple Sclerosis Management from AAN 2016,” New York, NY, April 26, 2106. 938. Invited Speaker, MS Grand Round Series, “Integrating New DMD Therapies into the MS Treatment Landscape,” Yonkers, NY, May 12, 2016. 939. Invited Speaker, Neuroscience Nursing Conference, “Movement Disorders for the NonNeurologist,” Stony Brook, NY, May 19, 2016.

THE INFORMATION PRESENTED ABOVE IS AN ACCURATE COMPILATION OF PROFESSIONAL BIOGRAPHICAL INFORMATION.

5-27-16 ________________________________ Signature

92

Date